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Abstract: 
Raman spectroscopy is an optical technique that can interrogate biological tissues. In 
doing so it gives us an understanding of the changes in the molecular structure that are 
associated with disease development. The Kerr gating technique uses a picosecond 
pulsed laser and fast temporal gating of inelastically (Raman) scattered light.  
The tissue samples used were taken following fully informed consent and ethics 
approval. Bladder samples were obtained by taking a biopsy during a TURBT or 
TURP, prostate samples were taken during TURP and the liver and kidney (pigs) 
were bought at a supermarket. The bladder and prostate samples were snap frozen in 
liquid nitrogen and stored in an -80°C freezer until required for experimentation. The 
liver and kidney tissue were used fresh. The constituent samples were bought from 
Sigma – Aldrich.  
Multivariate and least squares analysis were used to ascertain the biochemical basis of 
the differing pathologies within the bladder and the prostate gland, as well as to test 
diagnostic algorithms produced by a colleague in our group. Depth profiling through 
the bladder and prostate gland was shown to be feasible by utilizing the Kerr gating 
technique as was the suppression of fluorescence from dark tissue (liver and kidney). 
We have shown for the first time, that we can utilise Raman spectroscopy to 
determine the biochemical basis of pathologies of the bladder and the prostate gland. 
With the help of the Kerr gating technique we also obtained spectra from different 
depths through them. We also suppressed fluorescence and resonantly enhanced 
Raman spectra from dark tissue. These have major implications in terms of 
understanding pathogenesis and disease progression and also the potential to 
accurately assess depth of tumour invasion. 
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Actin     The contractile protein that makes up thin 
filaments in a muscle fibre (cell). 
Acute     Having rapid onset, severe symptoms, and a 
short course. 
Acute urinary retention  The painful inability to pass urine when your 
bladder is full.  
Adenocarcinoma   A malignant neoplasm of glandular or secretory 
epithelium. 
Adenosine Triphosphate  The universal energy-carrying molecule 
manufactured in all living cells as a means of 
capturing and storing energy. It consists of the 
purine base adenine and the five carbon sugar 
ribose, to which are added, in a linear array, 
three phosphate groups. 
Androgen    Substance producing or stimulating masculine 
characteristics, such as the male hormone 
testosterone. 
Basement membrane   Thin, extracellular layer consisting of a basal 
lamina secreted by epithelial cells and a reticular 
lamina secreted by connective tissue cells. 
Biopsy     The process of removing tissue or other material 
from the living body for examination, usually 
microscopic for diagnosis.  
 
 xxi
Brachytherapy    The ultrasound guided trans-perineal insertion of 
radioactive rods or seeds into the prostate. 
Calculus    A stone or insoluble mass of crystallized salts or 
other material, formed within the body. 
Carcinogenesis   Mechanisms of the causation of malignant 
neoplasms. 
Carcinoma    A malignant epithelial neoplasm. 
Carcinoma in situ   A malignant epithelial neoplasm that has not yet 
invaded through the original basement 
membrane; synonymous with intra-epithelial 
neoplasia. 
Castration    Removal of gonads, (testes or ovaries). 
Cell     The basic structural and functional unit of all 
organisms; the smallest structure capable of 
performing all the activities vital to life. 
Chronic    Persisting for a long period of time.   
Chronic urinary retention  The painless stretching of the bladder due to 
outlet obstruction, resulting in the inability to 
completely void urine. Occurs over a long 
period of time. 
Cyst     A cavity with an epithelial lining, containing 
fluid or other material. 
Cystectomy    The surgical removal of the bladder. 
 
 xxii
Cystitis inflammation of the bladder, whether used as a 
histologic, bacteriologic, or cystoscopic 
description, or a clinical syndrome that is 
usually accompanied by an abrupt onset of 
dysuria, increased frequency, urgency, and 
suprapubic pain. 
Cystoprostatectomy   The surgical removal of the bladder and the 
prostate gland. 
Detrusor muscle   Intermediate muscularis layer surrounding the 
mucosa of the urinary bladder. 
Differentiation   1. Embryological – process by which a tissue 
    develops special characteristics. 
2. Pathological – degree of morphological    
    resemblance of a neoplasm to its parent tissue. 
Disease    Abnormal state causing or capable of causing ill 
health. 
Down regulation   Phenomenon in which there is a decrease in the 
number of receptors in response to an excess of 
a hormone or neurotransmitter. 
Dysplasia    Change in the size, shape and organisation of 
cells due to chronic irritation or inflammation; 
may revert to normal if the stress is removed or 
progress to neoplasia.  
Dysuria    Pain on passing urine. 
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Elastic scattering   When monochromatic radiation passes through a 
substance it can be scattered or absorbed. Most 
of the scattered light is elastically scattered with 
the same frequency as incident light, so energy 
is conserved with the same number and type of 
particles in the initial and final state. 
Ejaculatory duct   A tube that transports sperm cells from the 
ductus (vas) deferens to the prostatic urethra. 
Epithelial tissue tissue composed of cells that line the cavities 
and surfaces of structures throughout the body. 
Many glands are also formed from epithelial 
tissue. Epithelium lines both the outside (skin) 
and the inside cavities and lumen of bodies 
False negative    The proportion of individuals with the disease 
that are classified as not having the disease.  
False positive    The proportion of individuals without the 
disease that are classified as having the disease. 
Gland     Single or group of specialised epithelial cell that 
secrete substances. 
Gold standard    The standard with which all other tests or 
procedures are compared. 
Haematoxylin and Eosin  The standard stains used in the histological 
processing of frozen and formalin fixed tissue 
for pathological analysis. 
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 Haematuria    Blood detected in the urine; can be either 
microscopic or macroscopic. 
Haematogenous   Via the blood vessels. 
Hesitancy    The inability to commence the floww of urine 
immediately. 
Histopathology   The study of microscopic structure of tissue 
used in the diagnosis of disease. 
Hyperplasia    Enlargement of an organ, or tissue within it, due 
to an increase in the number of cells. 
Incidence    The number of new cases diagnosed per 100,000 
persons / year. 
Inelastic scattering   When monochromatic radiation passes through a 
substance it can be scattered or absorbed Most 
of the scattered light is elastically scattered with 
the same frequency as that of incident light, but 
a small proportion of the incident light is 
inelastically scattered with the difference in 
energy changing the vibrationalstate of the 
molecule probed. Inelastic scattering is the 
process measured in Raman spectroscopy. 
Inflammation    Localised, protective response to tissue injury 
designed to destroy, dilute, or wall off the 
infecting agent or injured tissue; characterised 
 xxv
by redness, swelling, pain, heat and sometimes 
loss of function. 
Inter-observer variation  Disagreement between different observers. 
Intra-observer variation  Disagreement between the same observer. 
Intravenous urogram   The injection of a contrast agent into a vein that 
is excreted by the kidneys. Plain radiographs are 
then taken at specific times post injection and 
the contrast is seen within the urinary tract. In 
this way filling defects from tumours can be 
seen as can obstruction of a kidney. 
Intravesical    Within the bladder. 
Lymphoedema   A condition of localized fluid retention caused 
by a compromised lymphatic system. 
Macroscopic    Can be seen with the naked eye. 
Metastasis    The spread of cancer to the surrounding tissues, 
(local), or to other body sites, (distant). 
Microscopic    Can be seen with a microscope, but not with the 
naked eye. 
Morbidity    Diseased, pertaining to disease. 
Mortality rate    Number of deaths occurring per 100,000 persons 
per year. 
Neoplasia    Uncoordinated and abnormal tissue growth; new 
growth that does not respond to normal growth 
controls. 
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 Nephrostomy    The insertion of a tube into the calyceal system 
of the kidney through the back to relieve 
obstruction to the kidney i.e. ureteric 
obstruction. 
Nocturia    The need to pass urine during the night. 
Oestrogen    Female sex hormones produced by the ovaries 
concerned with the development and 
maintenance of female reproductive structures 
and secondary sex characteristics, fluid and 
electrolyte balance, and protein anabolism. In 
males it is produced by the peripheral 
conversion of testosterone and androstenedione. 
Orchidectomy       The surgical removal of one or both testes.  
Plasma     The extracellular fluid found in blood vessels; 
blood minus the formed elements. 
Prevalence    The number of cases of a disease present per 
00,000 persons at a given time. 
Prostadynia    Pain originating from the prostate gland. 
Prostatitis    Inflammation within the prostate gland. 
 
PSA density    The PSA level divided by the volume of the 
prostate gland. 
PSA velocity    The rate of change of serum PSA over a period 
of time. 
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 Radical Cystectomy   The surgical removal of the bladder, in it’s, 
entirety, in an attempt to cure bladder cancer. 
Radical Cystoprostatectomy  The surgical removal of the bladder and the 
prostate gland,  in it’s entirety, in an attempt to 
cure bladder cancer. 
Radical prostatectomy  The surgical removal of the prostate gland, in 
it’s entirety, in an attempt to cure prostate 
cancer. 
Radical external beam radiotherapy Giving radiation to an area in the body in an 
attempt to cure the patient of cancer. 
Radical treatment   The attempt to cure, usually cancer. 
Raman spectroscopy   An inelastic scattering technique, which exploits 
the frequency shift that occurs in incident light 
due to excitation of vibrational and rotational 
states in illuminated molecules. 
Regression The process of estimating a mean outcome in a 
population for any given value of the exposure 
variable, using a sample of exposures and 
outcomes. 
Regression equation An equation describing the relationship between 
a continuous exposure variable and the mean of 
a continuous variable. 
Residual    The volume of urine left in the bladder post 
micturition. 
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Retropubic prostatectomy. The surgical removal of the prostate nodules as 
an open procedure, usually leaving behind the 
prostatic capsule. 
Sensitivity The proportion of individuals with the disease 
that are classified as having the disease. 
Specificity    The proportion of individuals without the 
disease that are classified as not having the 
disease.  
Stroma     The tissue that forms the ground substance, 
foundation, or framework of an organ, as 
opposed to its functional parts, (parenchyma). 
Synergistic effect   A hormonal interaction in which the effects of 
two or more hormones acting together is greater 
or more extensive than the sum of each hormone 
acting alone. 
Tenesmus    The sensation for the need to have the bowels 
opened without there being any faeces within 
the rectum. 
Tissue     A group of similar cells and their intercellular 
substance joined together to perform a specific 
function.  
Transrectal ultrasonography  An ultrasound probe passed into the rectum to 
gain good views of the prostate gland. 
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Transurethral resection of bladder tumour  
The surgical removal of a bladder tumour by 
operating via the urethra. Therefore resulting in 
no cuts on the outside. 
Transurethral resection of prostate The surgical removal of part of the prostate 
gland by operating via the urethra. Therefore 
resulting in no cuts on the outside. 
Ureter     The tube that carries urine from the kidney to 
the bladder. 
Ureteric stent    Tubes passed through the ureter to relieve an 
obstruction and keep the ureter open. 
 
 
 
1. Introduction. 
 
1.1. Aims and Objectives. 
 
The main aim of this study is to determine whether near-infrared Raman Spectroscopy 
can be used to build robust spectral and biochemical diagnostic models to differentiate 
between benign and malignant disease of the bladder and the prostate gland in vitro. In 
doing so we hope to further our understanding of carcinogenesis within these tissues. 
 
Secondary objectives include, significantly increasing the sample size of the pilot 
bladder and prostate diagnostic models developed by my predecessor as well as 
determining whether near-infrared Raman Spectroscopy can be used for the real-time 
optical differentiation of benign and malignant disease of the bladder and the prostate 
gland in vivo.   
 
Raman Spectroscopy has already shown potential for the in vivo use of a probe in the 
oesophagus [Shim 2000], colon [Molckovsky 2003], cervix [Mahadevan-Jansen 1998b] 
and skin [Caspers 1998]. At present however there is no real time diagnostic tool to 
diagnose pathologies within the bladder or the prostate gland, without the need for 
biopsy. It is hoped that Raman Spectroscopy will be helpful with the in-situ diagnosis of 
tissue as well as assessing surgical margins following excision, therefore obviating the 
need for subjective histology. 
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1.2. Raman spectroscopy. 
 
1.2.1. Why Raman spectroscopy? 
 
There are many spectroscopic techniques that can be used in tissue diagnosis both in 
vitro and in vivo. The conventional means of diagnosis is by white light cystoscopy but 
biopsies are needed to enable a histopathological diagnosis. The following is used for 
the clinical diagnosis of urological tissues at present: fluorescence spectroscopy.  
Fourier transform infrared (FTIR) spectroscopy , optical coherence tomography and, 
Raman spectroscopy are used in research to distinguish between different pathologies in 
urological tissues.  
 
Fluorescence spectroscopy with the use of exogenous molecules such as 5-
aminolaevulinic acid (5-ALA) has been used clinically and in-vivo within the bladder. 
The administration of 5-ALA results in the accumulation of proto-porphyrin IX which 
is tumour specific and fluoresces. This can guide the biopsy of lesions within the 
bladder. It does have a high false positive rate and has so far only been used the bladder 
and not with the prostate [Baumgartner 1999]. Work in parallel by Grimbergen et al 
[2006] have shown that Raman spectroscopy could be performed on biopsies post 5-
ALA guided biopsy by subtracting the background fluorescence using a subtraction 
algorithm. The combination of the two in vivo may lead to a better method of obtaining 
optical biopsies. 
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Optical coherence tomography (OCT) is a cross sectional imaging technique that is 
similar to B-mode ultrasonography, however images are formed by detecting light 
reflected from subsurface tissue as opposed to sound waves. The light is reflected from 
the subsurface tissue microstructures [Yang 2004]. In vivo studies have been done in the 
bladder [Sergeev 1997] as well as in vitro in the prostate, urethra. ureter and bladder 
[Tearney 1997]. The latter showed an axial resolution of 16 microns which is better than 
any other available intraluminal imaging at present. The disadvantages with it however 
are that the images are subjective and artefact can be caused by peristalsis if in the 
ureter or movement of the bladder with respiration. 
 
FTIR spectroscopy could be used seperately or as an adjunct to Raman spectroscopy as 
they are both able to probe the molecular constituents of the tissue being measured by 
studying the interaction of light with the molecular vibrational states. 
The disadvantage of FTIR spectroscopy over Raman is that there is interference from 
water and therefore the tissue needs to de dry and would not be suitable for in-vivo 
work. As the research group’s final aim is to have an in-vivo probe for the diagnosis of 
urological pathologies, it was felt that FTIR spectroscopy was not appropriate for these 
experiments [Bhargava 2001, Gazi 2004].  
 
Raman has been demonstrated elsewhere to be highly specific, insensitive to water 
content of the tissue and compatible with fibre optic technologies. It was therefore felt 
that it would be suitable for the work in this thesis and future work of the group.  
As the objective of this thesis was to look at pathologies within the bladder and the 
prostate gland using the same spectroscopic method and the group was hoping to 
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progress to in-vivo diagnoses it was felt that Raman spectroscopy was the best modality 
for this.  
 
1.2.2.  An overview. 
 
In 1928, Chandrasekhara Venkata Raman first reported the Raman effect. This is a 
phenomenon whereby light is inelastically scattered. He initially observed that 
scattering from the sea gave it its colour independent of reflection or absorption of light 
from the sky, and later went on to focus sunlight onto a liquid. The scattered light was 
viewed via polarizers and filters so that it could be seen by the eye. These experiments 
culminated in a publication in Nature whereby he described ‘a new type of secondary 
radiation’ [Raman 1928]. Chandrasekhara Venkata Raman was later awarded a Nobel 
prize for his work (1930). 
 
Raman spectroscopy is an optical technique that analyses the way that incident light is 
inelastically scattered from a substance. It utilises the concept of the Raman effect, 
whereby energy is exchanged between light and matter.   
 
Light is an electromagnetic wave composed of both an electric field component and a 
magnetic field component. The electric and magnetic fields are both orthogonal to each 
other and orthogonal to the direction of propagation of the wave. A photon is a package 
of light. Therefore if the speed of light (c) is equal to the wavelength of light (λ) 
multiplied by its frequency (v), then the energy of a photon (E) is equal to Planks 
constant (h) multiplied by frequency, or Planks constant multiplied by (the speed of 
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light divided by the wavelength), as is shown below. The energy is inversely 
proportional to the wavelength. 
 
 
  c = λ v 
  E = h v            therefore       E = h (c/ λ) 
 
 
When a beam of light, is passed through a substance, the light will either be scattered or 
absorbed. This occurs even if the substance is cleaned to exclude any dust particles or 
other material. Two types of scattering are noted, the majority will be Rayleigh 
scattering, this is elastic scattering i.e. the scattered light has the same frequency as the 
incident light, and therefore has no energy change. The second type which occurs in a 
very small fraction of the photons is Raman scattering (in 1 in 10-7). This scattering is 
inelastic, i.e. the frequency of the scattered light is different to that of the incident light, 
and therefore there has been a gain or loss of energy.  This is shown in the simplified 
diagram below, (Fig 1.1). 
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 Fig 1.1: A simplified energy diagram illustrating Raman and Rayleigh scattering. 
Reproduced from Anderson (2000) 
http://carbon.cadenver:edu/public/chemistry/classes/chem4538/raman.htm 
 
 
Raman scattering can be Stokes whereby the scattered light frequency is less than that 
for the incident light or vice versa for Anti-Stokes. As light energy is proportional to 
frequency, the change in the scattered light frequency is equal to that of the molecular 
vibrations of the molecule. Figure 1.2 shows how a Raman spectrum may appear in its 
basic form. 
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 STOKES 
ANTI-STOKES 
RAYLEIGH Intensity 
(arb units) 
1130 830 530 
Wavenumber (cm-1) 
Fig 1.2: A diagram showing a Raman spectrum in its basic form. 
 Adapted from Anderson (2000). 
http://carbon.cadenver:edu/public/chemistry/classes/chem4538/raman.htm 
 
 
As you can see from the above diagram the Stokes line is more intense but both are 
equally displaced from the Rayleigh line. In view of this and the fact that Anti-Stokes is 
temperature dependent (because molecules have to already be in an excited state) and is 
less likely to occur when compared to Stokes then the Stokes spectrum is usually used. 
Not all molecules are able to be Raman active. Only those that show polarizability 
within the vibrational motion can be Raman active. The stretching and contraction of 
the bonds changes the interactions between the electrons and nuclei thereby changing 
the molecular polarizability. It is the interaction of the polarizability with the incident 
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light that creates an induced dipole moment in the molecule (change in the rotation of 
the molecule) and the light emitted by this contains the Raman scattering as on rotating 
the molecule may lose polarizability and retain some of the energy.  
   
The scattered light can be collected using a spectrometer. The position of the peaks is a 
function of the frequency change of the molecules, and the intensity of the peaks is 
proportional to the number of photons at each frequency.  
As each molecular species has its own unique set of vibrations, the Raman spectrum is 
inherently dependent on the architecture of the tissue. Unfortunately most tissues are 
extremely heterogenous and prior knowledge of the tissue structure is essential for the 
interpretation of the spectra. In this way Raman spectroscopy can provide qualitative 
and quantitative information on the tissue in question.  
 
 
1.2.3. Development of the instrumentation used in Raman spectroscopy. 
 
The principles of the Raman effect and Raman spectroscopy have remained relatively 
unchanged since its discovery. However there have been a number of technological 
advances that have enabled its application to medical diagnostics.  
For Raman spectroscopy to be of practical use in medical diagnostics, a Raman system 
must combine a high intensity monochromatic light source, with a high resolution 
wavelength dispersive element and a highly sensitive detector. This is needed in view of 
Raman scattering being a small proportion of the light scattered as was discussed above. 
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The initial breakthrough came when in 1960 Maiman invented an amplified light source 
that was monochromatic. This was to become known as a LASER (light amplification 
by stimulated emission of radiation). A LASER is not only monochromatic i.e. it had 
the same wavelength but it was also coherent therefore the light travelled in the same 
direction enabling focusing. 
The first lasers used as the excitation source however were visible. These unfortunately 
caused a lot of fluorescence when used on biological tissues. The fluorescence had the 
effect of drowning out the Raman signal so that it could not be seen. Therefore initial 
studies had to be confined to biological tissues that had minimal fluorescence such as 
the lens of the eye [Yu 1975] and gallstones [Ishida 1987]. 
Then came the development of filters. These filtered out the laser wavelength prior to 
detection, therefore enabling the use of single grating systems. Previously it was 
necessary to use triple grating systems to remove the entire laser light, however, this 
also reduced the amount of Raman scattering light that reached the detector. Improved 
grating technology has improved things further. Gratings work like a prism and disperse 
the light so that it can be measured by the detector. We use a holographic grating with 
300 lines per millimetre.  
The development of NIR (near infrared) lasers enabled its use to advance Raman 
spectroscopy in biological tissues. The advantage of infrared light (800nm) over visible 
light (300nm) is that it has a longer wavelength and decreased frequency therefore 
making it less energetic. In this way fluorophores within the tissue tend not to get 
excited. It is the fluorophores that are responsible for the fluorescence seen when using 
the visible light. 
 9
Initially the detectors that were used were indium-gallium-arsenide (InGaAs) detectors. 
These detectors were able to pick up the Raman signal and were sensitive to the infrared 
region of the spectra, however due to the low energy of the infrared excitation light, the 
detectors required long acquisition times to be able to obtain a spectrum. These 
acquisition times were up to several hours long therefore making the possibility of in 
vivo acquisition not applicable [Alfano 1991, Wang 1993]. With the advent of charged 
coupled device (CCD) detectors acquisition times have been reduced to practical levels 
[Baraga 1992]. The other advantage of these detectors is that they are array detectors 
and therefore can measure more than one wavelength. In this way it can measure more 
of the spectrum at one time. This NIR excitation light source produces a stronger 
Raman signal in biological tissues than the infrared region, but still has little in the way 
of fluorescence when compared to visible light [Manoharan 1994].  
Not only were the acquisition times improved by the use of CCD detectors but also by 
the advent of holographic notch filters. Initially a triple monochromator was used to 
remove the Rayleigh scattering but this tended to remove 95% of the light and therefore 
longer acquisition times were needed to obtain a good Raman signal. In using a 
holographic notch filter, a single monochromator can be used and therefore less light is 
lost. This allows a higher throughput of light and Raman signal therefore enabling 
acquisition times to be reduced. 
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1.3. Kerr gated Raman spectroscopy. 
 
Raman spectroscopy is thought to have the potential for minimally invasive detection of 
malignancies and pre-malignancies within the bladder and the prostate gland. A 
potential problem with this is the inability to obtain spectra from beneath the surface. 
This is needed to ascertain whether there has been any local extension of the disease in 
the case of the bladder, or to find a focus of adenocarcinoma in an otherwise benign 
prostate gland. 
 
A possible way to overcome this is by temporal gating techniques such as picosecond 
Kerr gating. The Kerr gating technique uses excitation with a picosecond pulsed laser in 
combination with a fast temporal gating of instantaneous Raman scattered light. The 
scattered light is collected at various time delays following the laser pulse. 
The ability of depth probing using Raman was determined by two stages: 
1. The laser photons have to be able to migrate to a given depth within the tissue. 
2. The Raman photons that have been produced have to migrate back to the 
surface. 
In this way Raman spectra from differing depths within the tissue will emerge at 
different times thereby making their separation feasible [Matousek 2005]. 
There have been studies utilising the Kerr gating technique to improve upon Raman 
spectra obtained from bone interiors [Morris 2004] as well as test experiments 
demonstrating the depth resolving power of the Raman Kerr gating concept on 
artificially prepared samples [Matousek 2005]. 
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 In an attempt to further our understanding of the heterogeneity of tissue structure the 
basic cell morphology will be discussed, using an epithelial cell as an example. The two 
tissues that make up the majority of the urologists workload – the prostate gland and the 
urinary bladder will then be looked at and finally the anatomy and histology of the 
normal prostate gland and urinary bladder as well as the main pathologies within these 
tissues will be discussed.  
In this way the information within the Raman spectra from each of the pathologies 
studied will be interpreted with greater accuracy. 
Other spectroscopic techniques used for tissue analysis and diagnostics will be 
discussed in chapter 4. 
 
    
1.4. Cell morphology. 
 
 
The cell is the basic, living, structural and functional unit in the body, and it is at the 
cellular level that disease processes originate. It is here that activities essential to life 
occur as well as changes determining the cell structure.  
There are well over 200 different types of cell identified within the body thus far, yet 
despite this they possess many common features (Fig 1.3). There are three main 
components to the cell – the plasma membrane, the cytosol and the organelles. 
Inclusions are also a component of cells but they tend to be temporary. They consist of 
lysosomes and peroxisomes, these act to store and secrete the products of the cell, and 
are metabolically inactive. 
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Fig 1.3: The sectional view of a generalised animal cell. 
Reproduced from Principles of Anatomy and Physiology, 8th edition [Tortora 1996]. 
 
The first of the three main components of the cell to be considered is the plasma 
membrane (Fig 1.4). This is a thin membrane approximately 8.5-10 nm thick that 
surrounds the cell separating it from the extracellular material. It functions both as a 
barrier and a transport medium that regulates the passage of substances in and out of the 
cell. The plasma membrane is composed of a phospholipid bilayer, with integral and 
peripheral proteins embedded in it. The membrane forms a bilayer as the phospholipids 
are amphipathic – they have a hydrophilic phosphate head and a hydrophobic fatty acid 
tail.    
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Fig 1.4: The sectional view of a plasma membrane. 
Reproduced from Principles of Anatomy and Physiology, 8th edition [Tortora 1996]. 
 
The next major component of the cell is the cytosol. This is the intracellular fluid in 
which organelles and inclusions are suspended, and solutes are dissolved. It is a 
transparent, viscous, gel-like fluid that consists of 75 – 90% water [Tortora 1996]. It is 
within this fluid that complex metabolic reactions occur, by receiving raw materials 
from the extracellular fluid.  
The cytosol contains a series of microtubules, microfilaments and intermediate 
filaments known as the cytoskeleton. Microfilaments and microtubules consist of the 
proteins, actin and tubulin respectively. The cytoskeleton functions to hold the cellular 
shape, as well as to carry out co-ordinated cellular movements. It aids phagocytosis and 
the movement of organelles and chemicals within the cell itself.  
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The last major component of cells is made up of organelles. Organelles are small 
compartments in which highly specialised reactions can occur. Different cells will have 
differing numbers and types of organelles present within them depending on their 
function. The organelles are as follows; the nucleus, ribosomes, endoplasmic reticulum, 
golgi complex, and mitochondria. 
The largest organelle is the nucleus (Fig 1.5). This is spherical in shape, and is 
surrounded by the nuclear envelope – a phospholipid bilayer such as the plasma 
membrane. It contains the chromosomes where most of the genetic material is found. 
This genetic material controls cell structure as well as many of the cellular activities 
within the cell. These are made up of deoxyribonucleic acid (DNA), and histones. The 
nucleus also contains nucleoli, which are clusters of DNA, ribonucleic acid (RNA) and 
protein. Nucleoli are the sites at which ribosomes are synthesised. 
Ribosomes are small granules that contain ribosomal RNA (rRNA), and ribosomal 
proteins. They are primarily involved in the synthesis of proteins. These proteins can be 
used within the cell or be destined for export out of the cell. 
 
Fig 1.5: Scanning electron micrograph of a nucleus (7800x). 
Reproduced from Principles of Anatomy and Physiology, 8th edition [Tortora 1996]. 
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Endoplasmic reticulum is continuous with the nuclear envelope, being made up of a 
number of cisterns, (membrane – enclosed channels). There are two main types – 
smooth and rough, or agranular and granular. The smooth or agranular endoplasmic 
reticulum has no ribosomes on it and is the site of steroid, fatty acid and phospholipid 
synthesis. Rough or granular endoplasmic reticulum is studded with ribosomes and is 
the site of protein synthesis (Fig 1.6). It also acts as a temporary storage area for the 
newly synthesised molecules. 
 
 
Fig 1.6: Scanning electron micrograph of endoplasmic reticulum, ribosomes 
and mitochondria (60,000x). 
Reproduced from Principles of Anatomy and Physiology, 8th edition [Tortora 1996]. 
 
 
The golgi complex also consists of cisternae, and functions to package up the products 
of the cell and delivers them to the cell membrane (Fig 1.7). 
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 Fig 1.7: Scanning electron micrograph of a Golgi complex (20,000x). 
Reproduced from Principles of Anatomy and Physiology, 8th edition [Tortora 1996]. 
 
The mitochondria are the main sites for the generation of adenosine tri-phosphate 
(ATP), via oxidative phosphorylation (Fig 1.6). ATP is needed for all chemical 
reactions to occur, therefore an active cell will have a large number of mitochondria 
with a high rate of ATP production. Mitochondria also have the ability to self- replicate 
in response to an increase in ATP demand, if the cell divides or becomes more active. 
As you can appreciate from the above, the cell is very complex, with many constituents. 
Each of these will potentially be able to give Raman peaks on a spectrum, of which 
some will be stronger than others. 
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1.5. The Prostate Gland. 
 
Recently the prostate gland has been mentioned a lot in the media. This is because the 
vast majority of men will suffer with symptoms related to disease of the prostate gland 
at some point in their lives.  
The main concern however is of prostate cancer. As many as 40% of men aged between 
60 and 70 years, have microscopic foci of well differentiated adenocarcinoma of the 
prostate gland (CaP). 27,000 men were diagnosed in the year 2000 in England and 
Wales with prostate cancer [Cancer research UK 2004]. It is the second leading cause of 
cancer related death in men in Western Europe and North America [Kurth 1998, Cancer 
research UK 2004], and the leading cause of cancer related death in the United States 
[Tortora 1996]. It is also a major cause of morbidity and health care related costs. 3-5% 
of men will die of CaP and 10% of men diagnosed with CaP will develop clinical 
disease [Kurth 1998]. The diagnosis of CaP is dependent on an abnormal digital rectal 
examination (DRE), and / or a raised level of serum prostate specific antigen (PSA). A 
finding of either of these in men will lead onto transrectal ultrasonography (TRUS), and 
biopsy (Fig 1.8). The biopsies tend to be sextant sampling with targeting if a lesion is 
suspected on TRUS. Unfortunately the biopsies have a high number of false negatives, 
and therefore a cancer can remain undiagnosed. These false negative results are mainly 
due to sampling error (in that the CaP may be present as a small focus within the 
prostate gland and the biopsy may have missed this) [Kurth 2000]. It has been shown 
that even if a man has two sets of negative biopsies with a persistently raised PSA, he 
has a 10% risk of having a cancer found on the third biopsy [Kurth 2000]. 
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Fig 1.8: Transrectal ultrasound scan and biopsy. Reproduced with the kind permission 
of Health Press. 
 
Also the biopsies are reviewed by the histo-pathologists (Fig 1.9). The samples are very 
small and the process is subjective, an error can occur in the diagnosing, as well as the 
grading of CaP. The sensitivity of TRUS for prostate cancer varies from 33 –83%, and 
the specificity varies from 97-100%. [Campbell 2002] 
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 Fig 1.9: A needle biopsy showing CaP prepared at the Gloucestershire Royal hospital. 
 
 
The ideal would be to diagnose CaP with a PSA in the range of 2.5-10 ng/ml, as this 
would increase the chances of cure with radical treatment. The reality, given the low 
specificity of both the PSA, and the TRUS and biopsy, is that many of the cancers are 
diagnosed when a cure is not possible.   
The prostate gland and its pathologies will be discussed in more depth in chapter 2. 
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1.6. The Urinary Bladder. 
 
There has been a lot of research work done on the bladder in the past, with the aim to 
provide a specific and sensitive means of distinguishing between the pathologies 
associated with the bladder. The most important pathology is as expected cancer.  
 
The incidence of bladder cancer in the UK is 8% in men and 3% in women. It is the 
fourth most common cancer in men and the eighth in women. Each year there are 9000 
cases diagnosed in men and 3600 diagnosed in women in the UK but although the 
figures are high there has been a reduction in the age standardised incidence since the 
1980’s. It is thought that the reason for this is the reduction in smoking and the banning 
of aromatic amines in the 1980’s. Both of these are known risk factors for the 
development of bladder cancer [Meyer 2003]. 
 
Ninety percent of bladder cancers are transitional cell carcinomas of the bladder, and the 
majority of these are superficial. They tend to be found in the over 65 year olds. 
The standard method for the diagnosis of bladder cancer is by means of a cystoscopy 
and biopsy, which ordinarily involves a general anaesthetic. Once diagnosed patients 
are staged by means of the TNM (tumour-nodes-metastases), classification and entered 
into a surveillance scheme, if no further treatment is required. The surveillance program 
involves 6 monthly – yearly cystoscopies for at least 10 years. 
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The gold standard, non-invasive test is urine cytology. This is stained with a 
Papanicolaou stain and has 95% specificity. However the test is only 40 – 60% sensitive 
(the sensitivity increases with the grade of the tumour). This is because of the 
significant inter and intra-observer variability, as well as the fact that urine cytology is 
altered by UTI, bladder instrumentation, indwelling catheters, radiotherapy and 
intravesical chemotherapy. 
 
Unfortunately some of the bladder tumours, especially carcinoma in situ and flat 
superficial tumours can look just like cystitis, or normal bladder.  In view of this a test 
that has a greater sensitivity and specificity than urine cytology is urgently needed, so 
that patients won’t have to undergo unnecessary anaesthetic procedures. 
The bladder and its pathologies will be discussed in more depth in chapter 3. 
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2. The Prostate Gland. 
 
2.1. Anatomy of the Prostate Gland. 
 
The prostate gland is a chestnut shaped gland approximately 4 cm in diameter. It lies 
within the true pelvis, between the bladder neck and the urogenital diaphragm, it 
surrounds the bladder neck and the proximal urethra in the male (Fig 2.1). It is anterior 
to the rectum and posterior to the inferior aspect of the symphysis pubis [Young 1998]. 
The prostate gland weighs approximately 20g but increases in size and weight with age 
[Berry 1984].  
 
 
Fig 2.1: Anatomy of the male lower urinary tract.  
  Reproduced from Grant’s Atlas of Anatomy, 10th edition [Agur 1999]. 
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It is separated into lobes by the urethra and the ejaculatory ducts. There are five in total, 
two lateral lobes – these are palpable on DRE and are marked by a midline groove 
posteriorly, a middle lobe – this lies between the urethra and the ejaculatory ducts, an 
anterior lobe – this is enclosed by the urethra, and a posterior lobe – this lies behind the 
ejaculatory ducts. Tisell and Salander have postulated that there are actually six lobes, 
two each of the lateral, dorsal and median lobes [Young 1998]. In practice however, this 
has little application to prostatic pathology. Mc Neal’s model has now replaced the 
concept of lobes with that of zones, and this is more widely used [Mc Neal 1988]. The 
prostate is divided into three zones, the transition zone- this accounts for 5% of the 
prostatic volume and is located around the proximal urethra as two lateral lobes, the 
central zone- this accounts for 25% of the prostatic volume and is located around the 
ejaculatory ducts from apex to prostatic base, and the peripheral zone- this accounts for 
70% of the prostatic volume and is located around the other zones and the distal urethra. 
 
The prostate gland is said to have a capsule, however this is not a true capsule but a 
condensation of fibromuscular stroma. It covers the majority of the prostate gland, but 
not at the bladder neck, here the prostatic stroma blends into the smooth muscle of the 
bladder neck. 
 
The prostate gland receives its blood supply from the internal iliac artery via the inferior 
vesical and middle rectal branches. The prostatic veins drain into the prostatic plexus 
that surrounds the gland and then drains into the internal iliac veins. There is an 
extensive venous network in both the capsule and peri-capsular connective tissue of the 
prostate. The lymphatic drainage of the prostate gland is to the internal iliac nodes 
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mainly, via intra and peri-prostatic lymphatics. Some however do drain directly into the 
external iliac and sacral lymph nodes. The prostate gland has a rich nerve supply located 
in the neurovascular bundles that are situated on the supero-lateral borders of the 
prostate [Young 1998]. 
 
 
2.2. Histo-pathology of the Prostate Gland. 
 
The prostate gland consists of both stromal and glandular elements as shown in Fig 2.2. 
It is surrounded by a fibro-elastic capsule, (a pseudocapsule), that is made up of 
numerous smooth muscle fibres. This capsule extends fibres into the stroma of the 
prostate gland, in doing so the gland is separated into approximately 50 poorly defined 
lobules. The glandular tissue has three groups of glands that are arranged around the 
urethra. These are compound tubulo-acinar glands, and they drain into either the distal 
urethra via long ducts (main glands), into the urethral sinuses via short ducts 
(submucosal glands), or directly into the urethra (mucosal / peri-urethral glands). The 
ducts are lined with transitional epithelium near their entry points into the urethra. The 
glandular epithelium has a pseudostratified columnar form, with the majority of cells 
being either tall cuboidal or columnar. Their nuclei are uniform and located basally, 
they also have abundant apical cytoplasm that tends to be pale and granular, rarely 
being vacuolar. The cell type depends on the degree of activity of the prostate gland and 
the androgenic stimulation to the prostate. The epithelial cells produce the prostatic 
secretions. 
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 Fig 2.2: Histology of the normal prostate gland. Prostatic acini are interspersed   
     between striated muscle prepared at Gloucestershire Royal Hospital. 
 
There is zonal variation to the normal histology of the prostate gland. The transitional 
and peripheral zones both contain glands that have simple, rounded contours, with some 
gentle undulation of the luminal borders. The central zone however contains glands that 
are larger and tend to be arranged in lobules around central ducts. Also the epithelial 
cells of the central zone tend to be more granular than those of the other zones. The 
stroma in the peripheral zone is randomly arranged with smooth muscle bundles that are 
loosely woven, whereas that of the transitional zone interlaces with the smooth muscle 
bundles and is more compact. The central zone however has a less abundant stroma 
with compact smooth muscle fibres [Young 1998]. 
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2.3. The Function of the Prostate Gland. 
 
The function of the prostate gland is to produce a secretion that mixes with the semen 
and contributes approximately 25% of the volume of semen. The secretion consists of a 
mildly acidic fluid with a pH of approximately 6.5. This fluid contains zinc, citrate 
(which provides ATP to the sperm), acid phosphatase, PSA, prostate binding protein, 
hormones, growth factors, pepsinogen, fibrinolysin (liquefies coagulated semen after 
deposition in the female genital tract) [Burkitt 1993], lysozyme, amylase, and 
hyaluronidase [Zaneveld 1981, Tortora 1996]. The function of the secretion is therefore 
to contribute to the motility and viability of the sperm, as well as provide a medium for 
the transport of sperm [Tortora 1996, Foley 2002].  The prostatic fluid also acts to affect 
the female reproductive tract and prevent the activation of the female immune response 
to the foreign sperm antigens [Foley 2002].   
 
 
2.4. PSA (Prostate specific antigen). 
 
PSA is a component of the prostatic secretion (seminal fluid) that is present in high 
concentrations. It is produced by epithelial cells lining the prostatic ducts and acini and 
secreted directly into the lumen of the prostatic ducts [Eble 2004, Goldfarb 1986].  It 
has a half-life of 2.2-3.2 days. PSA is a protein that is responsible for the liquefaction of 
seminal fluid, and is not produced until puberty [Goldfarb 1986]. It is also present in the 
serum of male patients in much lower concentrations, and this concentration is 
dependent on age, race and prostate volume. In some diseases of the prostate gland, the 
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concentration of PSA within the serum can be markedly raised. CaP is one of these 
diseases and in view of this, it is utilised as a serum marker for both detecting CaP and 
monitoring CaP. The problem with using PSA as a marker for CaP is that although it is 
highly sensitive, it is not very specific. Therefore many men undergo unnecessary 
invasive procedures to rule out CaP.  
 
A number of studies have shown that measuring the ratio of free to total PSA in the 
serum can reduce the number of unnecessary biopsies, as there is a difference between 
the ratio in patients with CaP as compared to those with Benign prostatic hyperplasia 
(BPH) [Eble 2004, Catalona 1998]. The ratio < 15% is suggestive of cancer, >25% is 
suggestive of BPH, and 15-25 is unknown [Campbell 2002]. This can be utilised as the 
majority of serum PSA is bound to antiproteases, but up to a third may be present as 
free PSA [Stenman 1991]. It is felt that the level is useful in patients with a PSA of 
between 4 and 10ng/ml [Campbell 2002]. 
 
Prostate density is the serum PSA level divided by the volume of the prostate gland. 
Therefore by measuring prostate density with the aid of TRUS, you can distinguish 
between the prostate gland with a raised PSA secondary to CaP, and that due to BPH. A 
PSA density of >0.15 has been proposed as a cut off threshold for undertaking biopsies 
[Campbell 2002]. 
 
 
Another means of avoiding unnecessary invasive procedures is to look at the PSA 
velocity. This is the rate of change of serum PSA over a period of time. Those patients 
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with CaP will have a higher PSA velocity than those with normal prostate glands or 
BPH. There have been studies suggesting that the PSA velocity improves the pickup of 
men with CaP and borderline PSA levels, but this does result in multiple serum PSA 
measurements over a minimum of 18 months [Smith 1994]. It is felt that a rise of 
>0.75ng/ml in a year is a cause for concern for prostate cancer [Campbell 2002]. 
 
 The other diseases in which the serum PSA can be raised are: BPH, prostatitis, acute 
urinary retention (AUR), and urinary tract infection (UTI). The PSA will also be raised 
with recent urethral instrumentation, catheterisation, prostatic biopsy and DRE. The 
PSA level in the serum can also be affected by certain operations as well as by 
medications the patient is taking. The operations are transurethral resection of prostate 
(TURP), radical prostatectomy, radiotherapy to the prostate gland and orchidectomy. 
The medications are Finasteride and gonadatrophin releasing hormone agonists. 
Finasteride has been shown to reduce the group mean PSA levels by approximately 
50% however individual serum PSA responses are highly variable. As serum PSA is 
used in the detection of CaP it is suggested that a baseline PSA level is taken prior to 
commencing patients on Finasteride [Campbell 2002]. 
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2.5. Diseases of the Prostate Gland. 
 
2.5.1. Benign prostatic hyperplasia. 
 
Benign prostatic hyperplasia (BPH), is a very common disease of the prostate gland. It 
is present in approximately 20% of males by the age of 40 years [Kumar 1997] and 
approximately 70% of men aged 70 – 80 years are affected by BPH and suffer with 
variable symptoms [Underwood 1996]. BPH is however very rare under the age of 30 
years [Berry 1984].  
Garraway (1991) has shown with prevalence studies in one community of men aged 
between 40 and 79 years that ‘the prevalence rate of BPH, defined as enlargement of the 
prostate gland of equivalent weight greater than 20 g in the presence of symptoms of 
urinary dysfunction and/or a urinary peak flow rate less than 15 ml/s and without 
evidence of malignancy, was 253 (95% CI 221-285) per 1000 men in the community, 
rising from 138 per 1000 men aged 40-49 years to 430 per 1000 men aged 60-69 years’.  
There are racial differences as well in the prevalence of BPH in that it is low in 
Orientals in China, Hong Kong and Japan [World Health Organisation 1985], and also 
low in some African countries such as Sudan [Young 1998], but higher in the American 
black population [Moore 1943].  
 
The aetiology of BPH is thought to be related to an imbalance in the hormones, but the 
exact mechanism is uncertain. It is thought that androgens and oestrogens play a 
synergistic role in its development. It is known that BPH will not develop in males 
castrated prior to puberty, and therefore an intact testis is necessary for its development 
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[Kumar 1997]. Oestrogen increases the expression of dihydroxytestosterone (DHT), 
receptors on the parenchymal cells within the prostate gland. Therefore the effects of 
DHT are enhanced. DHT is an androgen derived from testosterone through the actions 
of 5 α- reductase, and is the major hormonal stimulus for glandular and stromal 
proliferation. The oestrogen in males is produced by the peripheral conversion of 
testosterone and androstenedione [Young 1998]. 
 
Morphologically the hyperplastic process involves the lateral lobes and the peri-urethral 
glands / the transitional zone. Macroscopically, the prostate is enlarged and weights 
greater than 200g have been reported. The cut surface of the gland shows multiple 
nodules that are yellow in colour, and cysts that are well circumscribed (Fig 2.3). 
 
 
Fig 2.3: The cut section of a prostate gland showing the variable solid and cystic nodules 
associated with BPH. 
Reproduced from the Atlas of Tumor Pathology, Tumours of the Prostate Gland, 
Seminal Vesicles, Male Urethra, and Penis, 3rd series [Young 1998]. 
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 Microscopically, there is hyperplasia of the glandular and / or stromal components of 
the prostate gland. The hyperplastic glands have a lining of tall epithelial cells that are 
columnar in nature (Fig 2.4). They resemble the glands of the normal prostate but have 
little or no secretory activity. There is a peripheral layer of flattened basal cells, and the 
overcrowding can result in papillary infoldings. Proliferating stromal elements are 
always present between the glands and differ from that of the normal prostate. The 
stroma in BPH has more smooth muscle and there is an absence of elastic tissue. Also 
there are often areas of squamous metaplasia within the prostatic ducts adjacent to areas 
of necrosis, but BPH is not a pre malignant condition. Corpora amylacea are also 
present, but less so than in a normal prostate gland. These are deposits of proteinaceous 
secretory material within the acini that may have phosphates and oxalates deposited 
around them to form prostatic calculi. 
  
 
Fig 2.4: A needle biopsy showing the hyperplastic glands of varying size and shape, associated 
with BPH prepared at Gloucestershire Royal Hospital. 
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 The clinical presentation of BPH varies, and some men although they have the disease 
will not suffer with any of the symptoms associated with it. As the peri-urethral glands / 
transitional zone are commonly affected then the presentation tends to be of lower 
urinary tract obstruction. The symptoms associated with this consist of hesitancy, poor / 
reduced urinary flow, post micturition dribbling (PMD), nocturia, and haematuria may 
occur. In severe cases there is incomplete emptying of the bladder that leads to stagnant 
residual urine. This predisposes the patient to cystitis and UTI’s. In longstanding BPH 
this results in bladder dilatation, hypertrophy and trabeculation, with the potential for 
further complications with hydroureter, hydronephrosis and pylenephritis [Young 
1998]. 
The signs tend to be of an enlarged prostate gland on DRE that is firm but rubbery to 
touch. Patients may suffer with chronic urinary retention (CUR), which is painless, or 
go into acute urinary retention (AUR), which is painful. 
 
Treatment of BPH can be either medical or surgical. Medical treatment is by means of 
α- blockers- these act to relax the prostate gland and therefore open up the urethra, 
relieving the obstruction. They do this by specifically blocking the smooth muscle α1- 
adrenoceptors of the prostate and bladder. 5 α- reductase inhibitors can also be used - 
these down regulate the DHT receptors and help halt the hyperplasia and shrink the 
prostate gland to an extent (approximately 18%). The 5 α- reductase inhibitors block the 
enzyme that converts testosterone to the more active DHT. Surgical treatment is either 
by ablation or enucleation of the prostate gland or by open or endoscopic methods. 
These all act to open up the urethra by making a channel through the prostate gland. 
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2.5.2. Prostatitis. 
 
Prostatitis is the inflammation of the prostate gland that can be either acute or chronic in 
nature. It is rarer than BPH or CaP, but is responsible for more urology clinic visits. It 
tends to affect younger men between the ages of 25 and 55 years, and can have a 
significant impact on their quality of life [Foley 2002]. 
 
The aetiology of prostatitis can be any cause of an increase in inflammatory cells within 
the prostatic parenchyma, and depends on the type of prostatitis. There are four main 
groups for the classification of prostatitis, as are shown below (the National Institutes 
for Health Classification) [Foley 2002]: 
 
1) Acute bacterial prostatitis 
2) Chronic bacterial prostatitis 
3)      a.     Chronic prostatitis / pelvic pain syndrome ‘inflammatory’ 
b.    Chronic prostatitis / pelvic pain syndrome ‘non-inflammatory’ 
4) Asymptomatic inflammatory prostatitis 
 
Each of these has differing aetiologies and prevalence. 
 
Acute bacterial prostatitis is rare and is caused by bacteria, whereby the spread of 
infection can be via the prostatic ducts secondary to urethritis or cystitis, 
haematogenous, or via the lymphatics. Typical bacteria include, Escherichia Coli (80%), 
Proteus spp, Klebsiella spp and Serratia spp. 
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 Chronic bacterial prostatitis accounts for only 5 – 10% of cases of prostatitis, and the 
aetiology is the same as that for acute bacterial prostatitis. The infection however, is 
thought to persist due to prostatic calculi, or the bacteria have an exo-polysaccharide 
coat that is poorly penetrated by either antibiotics or the host’s defences. 
 
Chronic non-bacterial prostatitis, ‘inflammatory’ is the most common form of 
prostatitis. It is thought to be caused by either, an autoimmune response to host prostatic 
proteins, or a chemical cell mediated inflammatory immune response to refluxed urine. 
 
Chronic non-bacterial prostatitis, ‘non-inflammatory’ is a difficult diagnosis to make, 
and the aetiology is unknown. However there does appear to be a strong psychological 
factor and videourodynamics suggest a neurological or neuromuscular cause [Foley 
2002].  
 
Morphologically the groups differ. The acute prostatitis is microscopically characterised 
by a neutrophilic infiltrate, congestion and stromal oedema (Fig 2.5). Without treatment 
the glandular epithelium is destroyed and micro-abscesses are formed. The chronic 
prostatitis however shows a variable amount of lymphoid infiltrate and glandular injury. 
There is stromal fibrosis, plasma cell and acinar atrophy. There must be evidence of 
tissue destruction and proliferation of fibroblasts, along side other inflammatory cells 
for a diagnosis of chronic prostatitis. The presence or absence of bacteria separates the 
second and third groups in terms of classification.   
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 Fig 2.5: A histological section showing the inflammatory atypia and the amphophilia of the 
cytoplasm in prostatitis prepared at Gloucestershire Royal Hospital. 
 
 
 
The clinical presentation of prostatitis can vary, however symptoms include; dysuria, 
urinary frequency, lower back pain, poorly localised pelvic pain and prostadynia. As 
well as symptoms of fever and feeling generally unwell. Signs include a tender prostate 
gland that may be enlarged, and the presence of a urinary tract infection. 
 
Diagnosis is made via clinical examination and the classic Meares and Stamey 4 glass 
technique. This was first described in 1968 by Meares and Stamey and remains the gold 
standard test used to distinguish between urethral, prostate and bladder infections in 
men with chronic prostatitis. It consists of the following 4 samples -    
 
VB1 (voided bladder 1) -  the first 10 ml of urine representing the urethral 
specimen. 
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VB2 (voided bladder 2) - similar to a midstream urine collection and 
represents the bladder urine.  
EPS (expressed prostatic secretions) – collected directly in a container during 
   prostatic massage. 
 VB3 (voided bladder 3) - the first 10 ml of urine voided after prostatic 
massage, includes any EPS trapped in the prostatic 
urethra. 
 
The three urine specimens are centrifuged for 5 minutes and then the sediment is 
examined under high power for leukocytes macrophages, oval fat bodies, erythrocytes, 
bacteria, and fungal hyphae. A wet mount of a drop of EPS is examined under a 
coverslip in a similar manner. All four specimens are also cultured [Campbell 2002]. 
 
Treatment of prostatitis will depend on its cause. Acute bacterial prostatitis is usually 
easily treatable with a long course of high dose antibiotics, i.e. ciprofloxacin 500mg 
twice a day for four to six weeks. The other types of prostatitis tend to be refractory to 
treatment, although antibiotics are tried. Other treatments that can be tried include, 
allopurinol- thought to lower urinary urate levels therefore reducing inflammation when 
reflux occurs, repeated prostatic massage or regular ejaculation- thought to encourage 
emptying of the prostatic ducts therefore reducing congestion, and non-steroidal anti-
inflammatory drugs may ease the pain. 
For the rest of the thesis the histological diagnosis of acute prostatitis will be referred to 
as opposed to the clinical diagnosis of prostatitis,  as the details of individual patients’ 
symptoms were unknown. 
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2.5.3. Prostatic intra-epithelial neoplasia. 
 
Prostatic intra-epithelia neoplasia (PIN), can either be low or high grade, with high 
grade PIN (HGPIN), being thought to be a pre-malignant condition. Figure 2.6 shows 
the increasing cytological atypia corresponding to the different grade of PIN. It has a 
high predictive value as a marker for CaP, and in a Norwegian prospective study of 
HGPIN over 8 years, it was found to have a 38% progression rate to CaP [Harvei 1998]. 
There is a lot of controversy over the association of PSA and HGPIN, in that some feel 
that the rise in PSA found with HGPIN is due to the CaP that has not been found yet 
[Alexander1996] whereas others feel that HGPIN itself will raise the PSA level of a 
patient [Brawer 1994].  
 
Fig 2.6: A schematic diagram showing the increasing cytological atypia 
corresponding to the different grades of PIN. 
Reproduced from Pathology of the Prostate  [Bostwick 1998].  
The incidence of high grade PIN, in prostate biopsies has been shown to be between 0.7 
and 20%, and it increases with age. It is thought to predate CaP by more than 5 years, 
thereby reinforcing the idea that it is a pre-malignant condition [Kovi 1988]. HGPIN 
like CaP tends to be found in the peripheral zone, with only 5 % being seen in the 
transitional zone [Gaudin 1997].  
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The morphology of PIN is a continuum between benign and dysplasia. Microscopically 
HGPIN is a cellular proliferation within medium to large glands, with cytological 
atypia. It tends to be multifocal and is characterised by large prominent nucleoli that are 
hyperchromatic. There are an increase number of mitoses and there is a partial loss of 
the basal layer. There may also be occasional foci of luminal bridging therefore giving it 
a cribiform appearance. This is one of the four major architectural patterns described. 
The others are tufted- whereby stratified groups of secretory cells protrude into the 
lumen of the glands (Fig 2.7), micropapillary- this has slender filiform structures, and 
flat- this is the least common type that is characterised by an absence of significant 
stratification [Young 1998, Eble 2004]. 
 
The follow up of HGPIN found at prostatic biopsy is controversial, some feel that the 
biopsy has missed the CaP, whereas others feel that there is a high risk of it progressing 
over the years into CaP. It has been shown that the mean incidence of CaP on re-biopsy 
following a diagnosis of HGPIN is 30% whereas that following a diagnosis of BPH or 
low grade PIN is 20% [Eble 2004]. 
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 Fig 2.7: A needle biopsy showing the tufted and micropapillary patterns of HGPIN prepared at 
Gloucestershire Royal Hospital. 
 
 
Bostwick et al (1992) suggested biannual prostatic biopsies should be taken until the 
CaP was found. The consensus tends to be of close follow up with PSA testing and 
DRE biannually, and if there is a significant rise in the PSA or the DRE is suspicious 
then a repeat biopsy should be recommended. Although many urologists tend to re-
biopsy at between 0 – 6 months irrespective of PSA or DRE [Eble 2004]. 
 
 
2.5.4. Adenocarcinoma of the Prostate gland. 
 
Adenocarcinoma of the prostate gland (CaP), is the most frequently diagnosed non-
cutaneous cancer affecting Western men, and is the second most common cause of 
cancer related death in Western men [Foley 2002, Kurth 1998]. It represents 95% of the 
cancers affecting the prostate gland, with the other 5% being made up of the following; 
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transitional cell carcinoma, neuroendocrine carcinoma, sarcoma and lymphoma [Foley 
2002]. 
The incidence of CaP increases with age, and as the life expectancy of the population 
increases so does the prevalence of CaP. In the year 2000, 27,149 men in the UK were 
newly diagnosed with CaP and in the year 2002 there were 9,937 deaths in the UK from 
CaP. The 1997 the incidence rate for England and Wales was shown to be 34 per 
100,000 population and the crude rate in the UK in 2000 was 95.3 per 100,000 
population [Cancer research UK 2004]. 
However a diagnosis of CaP is not the death sentence, as the following Figures that 
were illustrated in Mims [Foley 2002] suggest: 
 
 There is a 30% lifetime risk of microscopic prostate cancer in a Western male. 
 There is a 10% lifetime risk of clinical disease. 
 There is a 3% lifetime risk of death from CaP. 
 
There is a marked difference between the incidence of CaP at autopsy as compared to 
the clinical manifestation of the disease [Sheldon 1980]. The prevalence of CaP at 
autopsy can be as high as 80% in the over 90 year olds [Bostwick 1992]. Many authors 
feel that these latent tumours are actually ones that behave in a benign fashion and 
therefore don’t manifest themselves clinically [Dhom 1983, Flanders 1984, Franks 
1956]. With the advent of PSA and TRUS and biopsy we are picking up more cases of 
CaP, some of which may never have manifested themselves clinically. 
There is a lot of geographical variation in both the incidence rates and the mortality 
rates of CaP. For example China has the lowest mortality rates at 1 per 100.000 
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population, when compared to other parts of the world, and Switzerland has one of the 
highest at 25 per 100.000 population, whereas the USA has the highest incident rate at 
104 per 100,000 population. This is thought to be secondary to screening [Boring 1992, 
Eble 2004, Cancer research UK 2004].  
There is variation within the UK, with the 2000 crude rates of new cases being highest 
in Wales at 114.5 (86.5) per 100,000 population and lowest in Northern Ireland at 66 
(67.5) per 100,000 population, (the Figures in brackets are for the European age 
standardised new case rate) [Cancer research UK 2004]. There has even been shown to 
be variation within England, with the 1997 incidence rates being higher in the South of 
England as compared to the North [Crow 2004]. 
 
The aetiology of CaP is unknown, but it is thought to be secondary to the hormonal 
changes that occur with advancing age. There is a decrease in the androgen levels due to 
the involution of the peripheral zone where the majority of tumours arise [Underwood 
1996]. To verify this, it is well known that an orchidectomy can inhibit the growth of 
many tumours, as can the administration of oestrogens. Also patients who were 
castrated prior to puberty do not develop prostate cancer. There is thought to be genetic 
and racial influences as well, in that there is a well documented familial association, 
with 10% of CaP having a familial component, and by having a first degree relative 
with the disease you have a 2-3 fold increase in risk. If the relative is young this further 
increases the risk of developing CaP, with an estimated 45% of cases under the age of 
55 years having a predisposing gene responsible [Cancer research UK 2004]. There are 
also significant geographical differences in the incidence of CaP suggesting that risk is 
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affected by ethnicity [Kumar 1997, Young 1998, Foley 2002, Cancer research UK 
2004].  
Other factors that have been related to CaP in some studies are a high fat diet, vitamin A 
and D deficiency, although data from the European prospective investigation into cancer 
and nutrition showed no association [Cancer research UK 2004]. Exposure to chemicals 
in the rubber, textile, fertilizer and atomic energy industries have also been implicated 
in certain studies [Young 1998]. 
 
As was previously discussed HGPIN and CaP are thought to be associated. It is present 
in biopsy samples near CaP, and is thought to be a pre-malignant condition, with a high 
predictive value as a marker [Mc Neal 1986]. A diagnosis of HGPIN should therefore 
alert you to the possibility of either a missed tumour, or the potential for its progression 
to CaP. 
 
Macroscopically the tumours tend to be firm with a yellow or yellowy – orange 
colouration and also show mutifocality in approximately 85% of tumours (Fig 2.8) 
[Eble 2004]. Approximately 50% of radical prostatectomy specimens were found to 
have multifocal CaP, although a lot of these were very small [Eble 2004, Young 1998]. 
They tend to arise more predominantly in the peripheral zone (75%) (Fig 2.9), with 
approximately 15% originating in the transitional zone and 10% in the central zone [Mc 
Neal 1968, 1969, Eble 2004].  
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 Fig 2.8: A cut section of the prostate gland showing multiple tan- yellow nodules of CaP. 
Reproduced from the Atlas of Tumor Pathology, Tumours of the Prostate Gland, 
Seminal Vesicles, Male Urethra, and Penis, 3rd series [Young 1998]. 
 
 
Microscopically they are, as the name implies, adenocarcinomas with a varying degree 
of differentiation. Those tumours that are well differentiated show a glandular 
arrangement that infiltrates the adjacent stroma. The glands are not encircled by 
collagen or stromal cells but lie next to each other. The glands are lined with a single 
layer of cuboidal cells, which have irregular nucleoli with a high nuclear to cytoplasm 
ratio. There is no basal layer seen and the glandular cells have varying degrees of 
anaplasia. As differentiation progresses the cells resemble their original structure less 
and less. Although many histological grading systems have been proposed, the one 
widely used by pathologists is the Gleason grading system [Eble 2004, Cancer research 
UK 2004, Kumar 1997].  
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 Fig 2.9: A whole mount section of the prostate gland showing a carcinoma in the left peripheral 
zone. 
Reproduced from the Atlas of Tumor Pathology, Tumours of the Prostate Gland, 
Seminal Vesicles, Male Urethra, and Penis, 3rd series [Young 1998]. 
 
 
Fig 2.10: A histology section from the prostate gland showing prominent fusion of epithelial 
elements, seen in CaP (Gleason 4a) prepared at Gloucestershire Royal Hospital. 
 
 
The Gleason grading system for CaP correlates well to its prognosis. The Gleason grade 
is a grade between 1 and 5 that is given to specific histological appearances. Figure 2.10 
shows an example of a Gleason 4a adenocarcinoma of the prostate gland and Fig 2.11 
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shows the histological appearences of the other grades. The Gleason score is utilised by 
the pathologists and urologists to help with the determination of the prognosis of CaP. It 
is the sum of the first and second most common grades seen within the tumour. The 
score can be anywhere between 2 and 10 (e.g. 4+3 = 7), where a score between 2 and 4 
show a well differentiated tumour, 5 and 7 a moderately differentiated tumour and 
between 8 and 10 show a poorly differentiated tumour [Foley 2002]. 
 
 
 
Fig 2.11: Histological grades of CaP as schematically depicted by Dr D. F. Gleason, (left). 
Description of the Gleason grades (right). 
Reproduced from the Atlas of Tumor Pathology, Tumours of the Prostate Gland, 
Seminal Vesicles, Male Urethra, and Penis, 3rd series [Young 1998]. 
 
The staging of CaP is done by means of clinical and pathological findings. The system 
that is widely used by Urologists is the TNM (tumour-nodes-metastases) system. This is 
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a system that looks at the size and site of the tumour (T), whether the local regional 
lymph nodes are involved (L), and whether there are any distant metastases (M). The 
2002 edition of the TNM classification for CaP is shown below. 
 
T – Primary tumour: 
Tx Primary tumour can’t be assessed. 
T0 No evidence of primary tumour. 
Tis In situ cancer (PIN). 
 
T1 Clinically inapparent tumour not palpable or visible by imaging. 
 T1a Tumour found in < 5% of tissue resected at TURP. 
 T1b Tumour found in > 5% of tissue resected at TURP. 
 T1c Tumour identified by a needle biopsy. 
 
T2 Tumour confined within the prostate. 
 T2a Tumour involves less than half of one lobe. 
 T2b Tumour involves more than half of one lobe. 
 T2c Tumour involves both lobes. 
 
T3 Tumour extends through the prostatic capsule. 
 T3a Extracapsular extension (unilateral or bilateral). 
 T3b Tumour invades the seminal vesicle(s). 
T4 Tumour is fixed or invades adjacent structures other than the seminal vesicles, 
i.e. bladder neck, external sphincter, rectum, levator muscles or the pelvic wall. 
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 N – Regional lymph nodes: 
Nx Regional lymph nodes can’t be assessed. 
N0 No regional lymph node metastases. 
N1 Regional lymph node metastases. 
 
 
M – Distant metastases: 
Mx Distant metastases can’t be assessed. 
M0 No distant metastases. 
M1 Distant metastases. 
 M1a Spread to non- regional lymph nodes. 
 M1b Spread to bone(s). 
 M1c Spread to other site(s). 
[Foley 2002, Eble 2004] 
 
Both the grade and the stage of the tumour are important in guiding the treatment of 
CaP, as well as in determining the prognosis. 
 
The mode of spread of CaP can be: 
 
Direct – this occurs both within the gland (urethra, bladder neck and stromal 
invasion), and to extracapsular structures such as the seminal vesicles. The rectal 
wall is rarely involved. 
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 Lymphatic spread – These provide a good route for dissemination. Initially the 
sacral and iliac nodes are involved and later the para-aortic nodes. 
 
Haematogenous – Invasion of the blood vessels results in distant metastases. 
This is commonly to the bone(s), lungs and liver. The bones commonly involved 
are the proximal femurs, pelvis and the lumbo-sacral spine. 
 
The clinical presentation of CaP can range from being asymptomatic and an incidental 
finding, to being because of either obstruction or symptoms of metastases. The 
incidental finding of CaP tends to be in patients who have either had a raised PSA level 
or an abnormal DRE that prompted a TRUS and biopsy, or patients who have 
undergone a TURP for BPH and the CaP has been found in the resection chips. 
Symptomatic patients can complain of a variety of symptoms. These include the 
following: 
 
 Obstructive bladder symptoms due to the compression of the urethra by the 
tumour. These symptoms consist of hesitancy, decreased flow, intermittent 
stream, incomplete voiding and post micturition dribbling. 
 
Irritative bladder symptoms due to either an obstruction of the outflow or 
invasion of  the trigone or pelvic nerves. These symptoms consist of dysuria, 
urgency and nocturia. 
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If the tumour invades the urethra, nerves sphincters or seminal vesicles then 
you may get the following symptoms; haematuria, suprapubic pain, perineal 
pain, impotence incontinence or haematospermia. 
 
Ureteric obstruction by the tumour can result in loin pain and renal failure. 
 
If the tumour invades the rectum then you may get tenesmus or rectal 
bleeding. 
 
Metastatic symptoms can be due to spread to the bones (bone pain, 
pathological fractures or spinal cord compression), spread to the lymph nodes, 
(enlarged nodes leading to lymphoedema), or general symptoms of metastases,  
(weight loss and lethargy). 
[Eble 2004, Cancer research UK 2004, Foley 2002] 
 
The treatment of CaP is very controversial and is determined by the grade and stage of 
the disease, as well as the age of the patient. 
 
 
Localised disease. 
 
Patients with a low grade and stage disease or localised disease, may be offered curative 
treatment or active monitoring. Active monitoring is where the patient undergoes 
regular review in terms of DRE and PSA testing. This is because well-differentiated 
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tumours have a disease specific survival of 87% over 10 years [Foley 2002, Eble 2004, 
Cancer research UK 2004]. Curative treatment involves one of the following; radical 
prostatectomy, radical external beam radiotherapy, or brachytherapy. Hormone therapy 
may be used with all of these treatments and there have been many papers looking at the 
effectiveness of this [Schulman 1997, Soloway 1997, Klotz 1997, Candas 1997]. 
Adenocarcinoma of the prostate has been shown to be androgen dependent and hormone 
therapy acts to medically castrate the patient and halt or slow the tumours progression. 
This effect however is not permanent and clinical progression will eventually occur 
[Huggins 1941]. 
 
Locally advanced disease. 
 
Patients with locally advanced disease (there is extracapsular spread but no evidence of 
metastasis to regional lymph nodes or distant sites) will be offered treatment to try and 
halt or slow the progression of the CaP. This is either by external beam radiotherapy 
with or without adjuvant hormonal therapy, or hormonal therapy alone. Bolla et al 
(2002) showed that there was both a disease free and overall survival advantage in those 
patients who were given hormone therapy during radiotherapy treatment and following 
treatment 3 years. In patients who are up staged following a radical prostatectomy it has 
been shown that not only does adjuvant anti-androgen therapy (medically or surgically) 
confer a survival advantage but also adjuvant radiotherapy has been shown to improve 
PSA relapse free survival in those patients at high risk of local recurrence [Eble 2004, 
Cancer research UK 2004].  
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Metastatic disease. 
 
Patients with metastatic disease tend to be treated either palliatively or by halting or 
slowing the disease progression. This is by means of hormonal therapy. Hormonal 
therapy acts on the principle that 70 – 80% of tumours respond to androgen ablation 
[Campbell 2002].  This ablation can be either by bilateral subcapsular orchidectomy, 
antiandrogens or gonadotrophin releasing hormone analogues. Second line therapies are 
used when the tumour becomes hormone resistant (HRPC). This normally occurs 
between 18 and 36 months with an overall mean survival of 30 months and with 80% of 
patients achieving symptomatic relief [Cancer research UK 2004]. The second line 
therapies can include oestrogens and anti-oestrogens which act on the principle that 
oestrogen receptors may be unregulated in HRPC. Diethylstilboestrol has been shown to 
have a response rate of 43% [Smith 1998]  
Recently there have been two randomised controlled phase III trials (TAX327 and 
SWOG) that have effectively shown that HRPC is chemotherapy sensitive. These trials 
have shown that overall and disease free survival times were significantly longer (2 / 3 
months) when patients were given docetaxal – a taxane They also showed that patients 
quality of life was improved. Taxanes are cytotoxic drugs that polymerize tubulin into 
stable microtubules, leading to cell death due to mitotic arrest [Tannock 2004, Petrylak 
2004]. 
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Other treatments employed in CaP are for the symptoms associated with it.  
 
Obstruction and urinary retention can be treated by a channel TURP. Ureteric 
obstruction and renal failure can be treated by nephrostomy or ureteric stents. 
Spinal cord compression is treated by steroids, external beam radiotherapy to the 
lesion or by surgical decompression.  
Bone pain is also treated by external beam radiotherapy or intravenous strontium 
radioisotope. Also by giving bisphosphonates the osteoclast activity can be inhibited 
which may help. Any fractures that occur are treated by surgical fixation with external 
beam radiotherapy to the fracture site.  
Patients may also become anaemic requiring either blood transfusions or 
supplementation with iron and vitamins. 
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3. The normal Urinary bladder. 
 
3.1. Anatomy of the bladder. 
 
The bladder is a hollow organ that is found deep in the pelvic cavity (Fig 3.1). It lies 
posterior to the symphysis pubis and anterior to the rectum in males, and in females it is 
anterior to the vagina and inferior to the uterus [Murphy 1993, Tortora 1996, 
Underwood 1996]. The bladder is a mobile organ that is held in place by peritoneal 
folds, and is covered by peritoneum only over the superior surface of the bladder. 
The bladder forms as a result of different embryological events, which accounts for its 
shape and portions. There is the trigone, which is on the base of the bladder. This as the 
name suggests is a triangular area, which at its two posterior corners receives the ureters 
from the kidneys. The anterior corner opens into the internal urethral orifice or the 
bladder neck. The posterior walls, dome and lateral walls of the bladder are formed 
from mesenchyme, and the anterior wall and portions of the lateral walls are formed 
when the infraumbilical portion of the abdominal wall closes [Meyer 2003]. 
The shape of the bladder varies depending on how much urine is within it. The female 
bladder will hold less than the male bladder, as the uterus is just superior to it. The 
average capacity of the bladder is between 500-800ml of urine, although most people 
will normally void when there is between 200 and 400ml within the bladder. 
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Fig 3.1: Anatomy of the female lower urinary tract.  
   Reproduced from Grant’s Atlas of Anatomy, 10th edition [Agur 1999]. 
 
The blood supply to the bladder is in the form of superior, middle and inferior vesical 
arteries, these are branches of the anterior trunk of the hypogastric artery. Small 
branches to the bladder also come from the obturator artery and the inferior gluteal 
artery, as well as from uterine and vaginal arteries in women. 
The venous drainage of the bladder is via a plexus that ultimately drains into the 
hypogastric vein. 
The nerve supply to bladder is from fine medullated fibres from the third and fourth 
sacral nerves, and non-medullated fibres from the hypogastric plexus. These are 
connected with ganglia in the outer and submucous coats and are finally distributed to 
the muscular layer and epithelial lining. 
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3.2. Histo-pathology of the bladder. 
 
Macroscopically the bladder is made up of three main layers. The innermost layer or the 
deepest layer is the mucosa, next is the muscularis and the outermost layer is the 
adventitia.  
The mucosa is made up of transitional epithelium lying on a layer known as the lamina 
propria. Transitional epithelium, also known as urothelium, is made up of transitional 
cells, so named as their shape changes as you go through its layers (Fig 3.2). It is 
approximately 7-8 cells thick and can be divided into 3 zones – basal, intermediate and 
superficial. The cells in the basal and intermediate zones are small and uniform with 
very well defined borders. The cytoplasm within these cells is rich in glycogen. The 
cells in the superficial layer are much more specialised. These cells have larger nuclei 
although the nuclear to cytoplasm ratios are low. The cells also secrete mucin and act to 
maintain the integrity of the mucosa during the constant changes in the bladder’s shape 
as it fills and expels urine. The mucin also acts to prevent urine transport. 
The lamina propria is made up of loose connective tissue which carries a network of 
blood vessels to the epithelium. 
The muscularis layer consists of a muscle known as the detrusor muscle. This consists 
of three layers of smooth muscle bundles – an inner and outer longitudinal layer and a 
middle circular layer. These layers aid the ability for the change in shape that occurs 
during filling and expelling of urine, and also ensures complete voiding of urine on 
contraction. 
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 Fig 3.2: A histological section showing normal urothelium prepared at Gloucestershire Royal 
Hospital. 
  
There is an internal urethral sphincter that is composed from the layer of circular 
muscle; this relaxes as the bladder contracts so that urine can be expelled. 
The adventitia is the most superficial layer of the bladder. It is made up of areolar 
connective tissue that is continuous with the superficial layer of the ureters, and is only 
present on the posterior and inferior surfaces of the bladder. The dome or superior 
superficial surface of the bladder is made up of a layer of peritoneum known as serosa. 
[Tortora 1996, Kumar 1997].  
 
3.3. The Function of the Bladder. 
 
The bladder is designed to store and expel urine that is produced by the kidneys. 
Micturition occurs secondary to a combination of voluntary and involuntary activities. 
When a bladder is full, or at micturating capacity, the stretch receptors present in the 
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bladder wall transmit impulses to the spinal cord. These impulses commence the 
micturition reflex as well as initiating the conscious desire to void. The reflex is 
controlled by the parasympathetic nervous system and causes contraction of the detrusor 
muscle and relaxation of the internal urethral sphincter. 
Micturition is not able to occur however until the external urethral sphincter that is 
made up of skeletal muscle is relaxed. The relaxation of this sphincter is controlled 
voluntarily. Therefore although the micturition reflex is involuntary, micturition can be 
controlled and stopped due to cerebral cortical control of the external urethral sphincter 
[Tortora 1996]. 
 
3.4. Investigations for diseases of the bladder. 
 
The main investigations for the diseases of the bladder covered by this thesis are urine 
microscopy looking for organisms, cystoscopy and biopsy, and urine cytology. The 
latter two are subject to inter and intra – observer variation. 
 
3.4.1 Cystoscopy. 
 
Cystoscopy involves passing either a rigid or flexible scope into the bladder via the 
urethra, filling the bladder full of saline or glycine and having a look around the bladder 
using white light. Any abnormal areas can then be biopsied and sent for histology.  
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It can however be very difficult to distinguish between areas of cystitis and malignancy. 
De Dominicis et al showed that the sensitivity and specificity of white light cystoscopy 
was 18% and 82% respectively. They also showed that by instilling 5-aminolevulinic 
acid into the bladder an hour before cystoscopy and using a blue light to detect areas of 
fluorescence (photodynamic diagnosis) the sensitivity of cystoscopy could be increased 
to 87%. The specificity does decrease to 63% however, due to inflammatory or 
hyperplastic tissue also fluorescing. 
 
3.4.2 Urine cytology. 
 
 
The gold standard, non-invasive test for urothelial tumours (found anywhere in the 
urinary tract that is lined with urothelium) is urine cytology. This is stained with a 
Papanicolaou stain and has 95% specificity. However the test is only 40 – 60% sensitive 
(the sensitivity increases with the grade of the tumour). This is because of the 
significant inter- and intra-observer variability, as well as the fact that urine cytology is 
altered by UTI, bladder instrumentation, indwelling catheters, radiotherapy and 
intravesical chemotherapy.  
It is ideal to obtain the urine sample from the first morning voided sample. 
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3.5. Diseases of the Bladder. 
 
3.5.1. Cystitis. 
 
Cystitis is the inflammation of the bladder.  
The commonest cause of cystitis is infective, and the majority of causative pathogens 
are the Gram negative facultative anaerobes usually present in the bowel flora.  
The majority of patients suffering with infective cystitis are women, with 30% of 
women between the ages of 20 and 40 having at least one episode and 12% of men 
between the ages of 14 and 61 reporting symptoms of kidney, bladder or urine infection. 
85% of women in the community-acquired setting have cystitis secondary to 
Escherichia coli, 5-10% are caused by other Gram negative Enterobacteriacae including 
Proteus spp. and Klebsiella spp. Gram positive organisms such as Staphylococcus 
saprophyticus occur in 10-30% of women. Infection is much commoner in women, and 
this is thought to be due to the length of the female urethra which is short. The male 
urethra on the other hand is much longer and is thought to help to prevent bacterial 
colonisation. 
 
The means by which the majority of bacteria reach the urinary tract is by the ascending 
route, although infection can also occur haematogenously. Bacteria tend to be normal 
flora within the bowel and they ascend from the bowel, into the vagina and then up 
through the urethra, into the bladder. It is within the bladder that they then adhere to the 
urothelial surface, this is done by the bacterial adhesins produced by the bacterial pili 
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interacting with receptors on the urothelial surface. The bacteria then have to overcome 
host defences such as urinary flow to be able to colonise and cause cystitis. 
 
The macroscopic features are of an erythematous oedematous mucosa with hyperaemia 
at cystoscopy. Pyuria may also be noted, and there may be debris within the bladder. 
Microscopically there is an inflammatory infiltrate with neutrophils; this is 
characteristically in the submucosal layers. If the cystitis is chronic then the infiltrate 
also contains fibroblasts and mononuclear cells (Fig 3.3). 
 
 
 
Fig 3.3: A histological section showing cystitis prepared at Gloucestershire Royal Hospital. 
   
 
 
The presentation of cystitis can be asymptomatic but the majority of cases suffer with 
any or all of the following; frequency, urgency, urge incontinence, dysuria, haematuria, 
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pungent urine, malaise and suprapubic pain. It is diagnosed by urine culture where it 
tests positive for blood leucocytes and nitrites, and definitively contains > 105 bacteria 
per ml of urine. [Campbell 2002] 
 
Treatment of cystitis secondary to simple infection involves antibiotics aimed at the 
offending pathogen and treatment of any other cause i.e. bladder stones, bladder neck 
stenosis. Patients also need to be advised on prevention. This involves the following; 
drinking plenty of fluid, avoiding dehydration, ensuring that the bladder empties 
properly, voiding post sexual intercourse, showering rather than having baths and 
wiping front to back with moist tissue. 
 
3.5.2. Bladder Cancer. 
 
Transitional cell carcinoma (TCC), of the bladder is the commonest form of cancer 
arising in the bladder. It accounts for 90% of all bladder tumours [Anderson 1996, 
Campbell 2002]. Other carcinomas of the bladder make up 10% of tumours within the 
bladder and consist of squamous cell carcinomas, mixed carcinomas, adenocarcinomas, 
sarcomas and poorly differentiated carcinomas. 
The incidence of bladder cancer has reduced since the 1980s and it is now the fourth 
and eighth most common cancer in men and women respectively, in the UK, with 9000 
men and 3600 women diagnosed each year [Meyer 2003]. In the United States, bladder 
cancer accounts for 4% of all male cancers and 2% of all female cancers [Anderson 
1996]. As you can see from these Figures there is a greater incidence in men and this is 
thought to be due to its aetiology. 
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Another encouraging statistic is that the population based survival rates have increased 
from 40% in the 1970s to greater than 60% in the early 2000s [Cancer research UK 
2004]. Unusually men have higher survival rates than women both in the UK and in 
Europe. The UK mortality statistics for 2001/2002 show that 4% and 2% of cancer 
related deaths in men and women respectively are due to bladder cancer [Meyer 2003, 
Cancer research UK 2004]. 
There is also geographical variation in bladder cancer types and mortality. For example 
the highest incidence of squamous cell carcinomas of the bladder are found in areas that 
are endemic for Schistosoma haematobium and it is also the commonest cause of cancer 
related death in these areas, whereas the highest incidence of transitional cell 
carcinomas are found in Western Europe, North America and Australia [Murphy 1993, 
Eble 2004, Anderson 1996]. 
 
The aetiology of bladder cancer is multifocal, and many toxins are now well recognised. 
Cigarette smoking and occupational exposure to aromatic amines are the most 
important. There is now a list of industrial occupations that have an increased risk of 
developing bladder cancer, these are as follows: 
 
 Manufacture of rubber or rubber products. 
 Manufacture of cable. 
 Manufacture of dyestuffs. 
 Manufacture of organic chemicals. 
 Gas works and coke ovens. 
 Rodent extermination. 
 63
 Sewage works. 
 Manufacture of firelighters or patent fuels. 
 Laboratory work. 
 
The toxic chemicals responsible are the metabolic products of α‐ and β‐naphthylamine, 
benzidine, and 4-aminodiphenyl. Other toxins associated with bladder cancer are 
cigarette smoke, phenacetin containing analgesics, cyclophosphamide and 
chlornaphazin. Pelvic radiation and trauma to the urothelium are also known risk factors 
for bladder cancer. 
The occupational cancers do tend to occur at an earlier age than those tumours that 
appear to be spontaneous, but there is thought to be a latent period of 15 – 20 years post 
initial exposure. 
 
Smoking tobacco is the major risk factor in the development of bladder cancer, with the 
estimated risk being attributed to tobacco being 66% and 30% for men and women 
respectively [Eble 2004]. This risk increase with the duration of smoking so that the risk 
increases from a 2 fold increase to a 6 fold increase for those who have smoked for 
more than 60 years. The risk also increase with the number of cigarettes smoked per day 
with a maximum of 40 or more cigarettes. Unusually some studies have shown that 
there is a higher risk in women for the equivalent level of exposure [Eble 2004]. 
Recurrent infection is also a risk factor for developing bladder cancer but it tends to be 
squamous cell carcinoma as with infection by Schistosoma haematobium. 
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As TCC is the commonest form of bladder cancer I am going to refer only to this in the 
following sections. 
 
Macroscopically TCC of the bladder can be uni- or multifocal, they can be finely or 
coarsely fronded, papillary, sessile, nodular, solid or ulcerative. Adjacent areas may be 
normal, erythematous or may have associated CIS present. They can occur anywhere 
within the bladder, but they do have a predilection for the trigone, around the ureteric 
orifices and the posterolateral walls [Murphy 1993 Eble 2004, Anderson 1996]. 
 
Microscopically they are, as the name implies, transitional cell carcinomas with a 
varying degree of differentiation. TCC is divided into three grades depending on this 
degree of differentiation. 
 
Grade 1 or well differentiated tumours have densely packed, evenly distributed, 
uniform cells with indistinct borders and little or no cytoplasm. The nuclei are enlarged, 
slightly pleomorphic and have irregular borders. There is also an increase in mitoses. 
They are noticeably transitional cell in origin but have an increase in the number of 
layers (Fig 3.4). 
 
Grade 2 or intermediately differentiated tumours are also able to be recognised as being 
of transitional cell origin, but they have even more layers of cells with a more 
pronounced hyperchromicity and increase in mitotic activity than those cells in the 
grade 1 tumours.  
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Grade 3 or poorly differentiated tumours are not recognisable as being transitional cell 
in origin. The cells tend to cluster and their borders may be sharply defined or indistinct. 
Nuclei are markedly pleomorphic and mitoses are common and may be abnormal (Fig 
3.5). Calcification has also been noted in tumours that are poorly differentiated. 
[Murphy 1993, Eble 2004, Anderson 1996]. 
 
Fig 3.4: A histological section showing grade 1 TCC of the bladder prepared at Gloucestershire 
Royal Hospital. 
 
 
Fig 3.5: A histological section showing grade 3 TCC of the bladder prepared at Gloucestershire 
Royal Hospital. 
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The staging of TCC is done by means of clinical and pathological findings. The system 
that is widely used by Urologists is the TNM (tumour-nodes-metastases) system. This is 
a system that looks at the size and site of the tumour (T), whether the local regional 
lymph nodes are involved (L), and whether there are any distant metastases (M). The 
2002 edition of the TNM classification for bladder transitional cell carcinoma is shown 
below. 
 
T – Primary tumour: 
 
Tx Primary tumour can’t be assessed. 
T0 No evidence of primary tumour. 
Ta Non invasive papillary carcinoma 
Tis Carcinoma in situ  
T1 Tumour invades subepithelial connective tissue. 
T2 Tumour invades muscle. 
 T2a Tumour invades superficial muscle (inner half). 
 T2b Tumour invades deep muscle (outer half). 
T3 Tumour invades perivesical tissue. 
 T3a Microscopically. 
 T3b Macroscopically. 
T4 Tumour invades adjacent structures, i.e. prostate, uterus, vagina, pelvic wall, 
abdominal wall. 
 T4a Tumour invades prostate, or uterus, or vagina. 
 T4b Tumour invades pelvic wall or the abdominal wall. 
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N – Regional lymph nodes: 
 
Nx Regional lymph nodes can’t be assessed. 
N0 No regional lymph node metastases. 
N1 Single lymph node < 2cm. 
N2 Single lymph node 2 - 5cm or multiple lymph nodes < 5cm. 
N3 Lymph node > 5cm. 
 
M – Distant metastases: 
 
Mx Distant metastases can’t be assessed. 
M0 No distant metastases. 
M1 Distant metastases. 
[Hermanek 1997, Sobin 2002]. 
 
Diagrammatic representation of the T part of the TNM classification is shown on the 
following page in Fig 3.6. 
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Fig 3.6: Diagrammatic representation of the T part of the TNM classification, modified from 
TNM classification of malignant tumours: Urinary bladder, 6th ed. [Sobin 2002] 
 
Both the grade and the stage of tumour are important in guiding the treatment of TCC, 
as well as in determining the prognosis. 
The mode of spread of TCC of the bladder can be: 
 
Direct – this occurs via invasion of the muscular wall of the bladder. It can be to 
the prostatic urethra, distal ureters and the prostatic ducts. In advanced disease it 
can also involve the pelvic wall, tethering the bladder to it. 
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Lymphatic spread – These provide a good route for dissemination. Initially the 
sacral and iliac nodes are involved and later the para-aortic nodes. 
 
Haematogenous – Invasion of the blood vessels results in distant metastases. 
This is commonly to the lungs, liver and then to the bone(s), in order of 
declining frequency. Other recorded sites include the adrenals, heart, brain and 
kidney. 
[Murphy 1993, Anderson 1996]. 
 
The presentation of TCC and other forms of bladder cancer is the same. Patients may be 
asymptomatic and the tumour can be an incidental finding. Otherwise patients may have 
microscopic or macroscopic haematuria, especially if the tumour is epithelial, 85% of 
patients present with painless haematuria [Eble 2004]. With extensive haematuria the 
patient may present with anaemia of unknown cause or in clot retention.  
Some patients will experience dysuria, frequency or suprapubic pain depending on the 
site of the tumour. Patients may also present with a mass or symptoms of metastases, 
such as general lethargy and weight loss, or enlarged nodes leading to lymphoedema. 
If the tumour blocks one or both of the ureters then obstruction may occur resulting in 
loin pain and renal failure.  
 
The definitive treatment of TCC will depend on the grade and stage of the disease and 
the age of the patient.  
The mainstay for diagnosis and establishing the grade and stage of TCC is cystoscopy 
(Fig 3.7) and biopsy / transurethral resection of bladder tumour (TURBT). Patients will 
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also have undergone an intravenous urogram (IVU) and/or an ultrasound scan (USS) of 
the abdomen and pelvis, however these are not good for staging the disease. USS has a 
high false negative rate with less than 70% accuracy for staging. This is due to both 
patient factors i.e. obesity and tumour factors i.e. site of tumour. Magnetic resonance 
imaging (MRI) is the modality of choice for assessing the primary tumour and searching 
for metastases however it still only reaches 83% accuracy for staging. Computerised 
tomography CT can also be used where MRI is not available and tends to be used in a 
lot of centres due to its ease of accessibility and cost. CT however only has a 55% 
accuracy for bladder tumours due to their size (small tumours are hard to visualise on 
CT) and an understaging of lymph node metastases in 40-70% [Eble 2004, Campbell 
2002]. 
 
 
 
Fig 3.7: An example of a small papillary tumour found at white light cystoscopy. 
Reproduced from the Fluorescence diagnosis of bladder tumour using 5 
Aminolevulinic Acid – fundamentals and results [Baumgartner 1999]. 
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Assuming the patient is able to undergo any form of treatment and has no medical 
reasons preventing any of the treatment options. The definitive treatment for the 
different stages of TCC are as follows: 
 
 
Superficial tumours (Ta/T1): Single  TURBT/Cystodiathermy/Laser 
(Follow up with cystoscopy  Multifocal As above with adjuvant 
at intervals determined by    chemotherapy – Intravesical  
history and pattern of recurrence).    BCG or Mitomycin C. 
     Recurrence As for multifocal 
T2 tumours:      TURBT → Radiotherapy/ 
cystectomy. 
T3 tumours:    Controversial. Possibilities include; 
radiotherapy, chemotherapy, 
cystectomy and radiotherapy, 
cystectomy alone with either an 
ileal conduit or a neo-bladder. 
T4 tumours:    T4a  Cystectomy. 
     T4b  Palliative radiotherapy.  
 
The cystectomies are cystoprostatectomy or cystectomy and hysterectomy. 
 
Superficial bladder cancer (Ta / T1) as can be seen above is treated differently to 
invasive bladder cancer (T2 – T4). The superficial tumours can be managed 
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endoscopically and with intravesical therapy. Parmar et al (1989) postulated the notion 
of risk stratification to help to assess the risk of recurrence in these tumours as it has 
been shown that 70-88% of superficial tumours will recur following treatment 
endoscopically [Sobin 2002].  
Superficial tumours are separated into 3 groups depending on the number of tumours at 
presentation and the presence of recurrent tumour at the first check cystoscopy. Group 1 
is a single tumour with no recurrence at first check and Group 3 is multiple tumours 
with recurrence at first check. Group 3 are at a high risk for recurrences and therefore 
require more frequent cystoscopies and further intravesical treatment whereas group 1 is 
very low risk and can go straight to annual check cystoscopies. Stromal invasion (T1) 
and the grade of the tumour are not good indicators of recurrence but are good 
indicators of progression with grade 1 / 2 and Ta disease having a lower risk of 
progression than grade3 T1 disease. 
Invasive bladder cancer is a different entity in that it is aggressive and therefore requires 
aggressive treatment modalities to prevent and treat metastatic disease. Treatment will 
depend on the individual patient and is in the form of either cystectomy with urinary 
diversion or formation of a neo-bladder or radiotherapy. Both have similar overall 5 
year survival rates of 40 – 60% although a Cochrane report suggested that cystectomy 
conferred an overall survival benefit [Shelley 2002]. In select patients neo- adjuvant and 
adjuvant chemotherapy can be considered with either cystectomy or radiotherapy. It is 
used as up to 50% of patients with muscle invasive disease may develop metastases as 
they already had micrometastatic disease [Sternberg 2002]. 
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3.5.2.1 Carcinoma in situ. 
 
Carcinoma in situ (CIS) is defined as a flat, non-invasive urothelial lesion composed of 
cells with significant anaplasia. Lesions often termed as severe dysplasia are also 
included in this definition [Murphy 1993], these involve cellular maturation toward the 
surface and can be difficult to distinguish from mild or moderate dysplasia, or atypical 
hyperplasia in morphologic terms. Richards et al showed that there is significant inter 
and intra-observer error between pathologists when diagnosing degrees of dysplasia and 
CIS [Richards 1991]. 
CIS can be found adjacent to a tumour within the bladder or in a bladder with no 
evidence of bladder tumour, and is thought to be a premalignant condition. Droller et al 
(2000) found that CIS could be associated with a high risk of progression in the context 
of a concomitant or prior neoplasm. However when diagnosed as a primary or unifocal 
lesion it could represent a non-progressive lesion or even one that had terminally de-
differentiated rather than one that may progress.  
 
The aetiology and true prevalence of CIS is unknown. However Cheng et al have shown 
that urothelial dysplasia is believed to be the putative precursor of CIS [Cheng 1999]. 
Patients diagnosed with CIS tend to be in their fifth to sixth decade of life, and the 
incidence of primary CIS is thought to count for less than 1 – 3% of urothelial 
neoplasms. CIS is however seen in between 45 and 65% of invasive neoplasms and 7 – 
15% of papillary neoplasms [Eble 2004]. 
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The clinical features vary from patients being asymptomatic to those suffering with any 
or all of the following; dysuria, frequency, urgency and/or haematuria. 
Morphologically CIS of the bladder on cystoscopic examination can look normal, and it 
is not picked up until random biopsying is undertaken [Richards 1991]. Alternatively it 
can appear as defined, a flat lesion that may be erythematous. It tends to be multifocal 
involving areas other than the bladder base. 
 
Microscopically CIS (Fig 3.8) is characterised by some or all of the following: 
 An increase in the number of cell layers. 
 Crowding of the nuclei. 
 Loss of the regular arrangement and polarity of the cells. 
 Hyperchromatic nuclei. 
 Increased mitotic activity. 
 Presence of mitoses above the basal layer of cells. 
 Lack of cohesion of the superficial layers of cells, which may desquamate into 
the lumen of the bladder [Andersons 1996, Eble 2004]. 
 
The presentation of CIS can be of irritative symptoms, e.g. dysuria, frequency and 
suprapubic pain, or haematuria, or some patients may be asymptomatic.  
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Fig 3.8: A histological section showing CIS undermining adjacent urothelium.  
Reproduced from Campbell’s urology 8th edition [Campbell 2002]. 
 
 
Treatment of CIS when confined to the urinary bladder is currently treated with local 
ablation and instillation of intravesical immunotherapy such as bacillus Calmette-
Guerin (BCG) [Herr 1986, Campbell 2002] this is due to the presumed aggressive 
nature of the disease. 30% of patients do not respond to BCG, but 53% of these will 
respond to a second course. Also 30% of responders will relapse at 5 years [Campbell 
2002]. 
Photodynamic therapy has also been suggested to treat CIS, however as yet it has not 
gained much acceptance throughout the urological community [Kriegmair 1994]. 
Patients are closely followed up and if invasion or progression is found on repeat 
biopsy, then radical treatment in the form of a radical cystoprostatectomy / cystectomy 
is advocated [Cheng 1999, Herr 1989]. 
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 4. Biomedical applications of Raman spectroscopy: A critical 
review of the literature. 
 
Raman spectroscopy is rapidly becoming popular in the field of research due not only to 
its potential ability to provide real time diagnosis of tissue in vivo, but also due to the 
evolution of lasers and detectors/spectrometers. It wasn’t until the late 1980s / early 
1990s that Raman spectroscopy really took off in terms of looking at biological tissues. 
This was because it wasn’t until this time that the Raman spectra obtained from tissue 
were of adequate quality to allow the identification of the different components within 
them. 
 
In this chapter the latest literature on the biomedical applications of Raman 
spectroscopy will be discussed as a discussion on the development and evolution of 
Raman spectroscopy and its instrumentation was had in chapter 1. 
 
 
4.1 Raman spectroscopy of the prostate gland and bladder  
 
There has been little in the way of literature looking at the use of Raman spectroscopy 
in the bladder and prostate that hasn’t originated from our own group.  
 
There has been no previous work done on the prostate gland except that done by our 
group. Crow et al (2003a, 2003b, 2004) showed that we were not only able to 
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distinguish between different pathologies within the prostate gland in vitro but also 
between different grades of adenocarcinoma of the prostate. However the sample size 
for each pathology was small and I have substantially improved upon this in my thesis.  
 
Recent work on the bladder by De Jong et al (2002, 2003) looked at the identification of 
bladder wall layers and the changes in the molecular composition of bladder muscle 
caused by outlet obstruction. Both of these papers looked at spectra taken from the 
bladders of guinea pigs. They showed that Raman spectroscopy could be used to 
identify different layers of the bladder in vitro and also that the urothelium had a high 
fatty acid concentration on comparison with oleic acid showing peaks at 1081,1261, 
1299, 1439 and 1659 cm-1. The group showed that the lamina propria and muscle layer 
spectra also compared well to the spectra of their major constituents (collagen and actin 
respectively). They used a Visionex Gaser 10 forward viewing fibreoptic probe to 
obtain spectra from the bladders of guinea pigs during urodynamic studies and were 
able to estimate the proportion that each layer attributed to the overall spectrum. The 
authors showed by means of mapping that there was a difference between the normal 
and damaged bladder in that there appeared to be clusters of glycogen within the 
damaged tissue. The authors hope that they will be able to determine the degree of 
damage to the bladder wall (in vivo) secondary to bladder outflow obstruction without 
the need to take biopsies. 
 
Prior to this, some work was performed by Feld et al (1995) looking at spectra from 
bladder samples. They showed that there was an increase in nucleic acid and a decrease 
in lipid contributions to the spectra from bladder cancer samples as opposed to normal 
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bladder sample spectra. The authors however do not seem to have taken this work any 
further. 
 
The most recent work done on the bladder was by our group. Crow et al (2003a, 
2004)[Stone 2002] showed that we were not only able to distinguish between different 
pathologies within the bladder in vitro but also to stage and grade the transitional cell 
carcinoma of the bladder. However the sample size for each pathology was small and 
cross validation testing was the best that could be achieved. Greater numbers would 
allow more vigorous testing.  
 
 
4.2 Raman spectroscopy of other tissues. 
 
Early work on the biomedical applications of Raman spectroscopy were confined to 
analysis of urinary calculi [Daudon 1983, Sudlow 1991,Hong 1992] and calcification of 
the aorta [Klug 1992]. As instrumentation and techniques improved groups started 
looking at the ability of Raman spectroscopy to differentiate between normal and 
malignant tissue. There have been many authors over the years who, have looked at the 
progress made in this field resulting in some very comprehensive review articles 
[Hanlon 2000, Mahadevan-Jansen 1996, Manoharan 1996]. The main aspects of work 
done in other tissues will be highlighted focusing on those dealing with the 
spectroscopic analysis of pre malignant and malignant tissue, and those tissues where 
the majority of work has been done. 
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4.2.1. The gastrointestinal tract. 
 
There have been several studies looking at the use of Raman spectroscopy in the 
oesophagus. Most recently Stone et al (2002) has shown that by measuring spectra from 
eight pathological groups of oesophageal samples and constructing a diagnostic 
algorithm they were able to achieve between 73 and 100% sensitivity and specificity for 
the correct classification of each spectrum. This was the first study to spectrally separate 
so many pathological groups therefore indicating the ability of Raman spectroscopy to 
classify pathologies as well as simply detecting disease. 
Georgakoudi et al (2001) showed that by combining fluorescence, reflectance and light-
scattering spectroscopy they were able to improve upon the sensitivity and specificity of 
using just one of the techniques. Their numbers however were very small having only 
looked at 16 patients with known Barrett’s oesophagus and there is the need for 
complex software with the ability to analyse all three types of spectroscopic 
information. This makes its use as a real time diagnostic tool more complicated. 
Barr et al (1998) reviewed different optical spectroscopic techniques in the early 
diagnosis of gastrointestinal malignancy and they concluded that Raman spectroscopy 
had the potential for the diagnosis of malignancy in the gastrointestinal tract, but that 
there were still a number of technical problems such as the fibre probes generating a 
Raman signal, to overcome before in vivo measurements become routine. 
Work is ongoing in this field to develop an in vivo probe. Initial work done by Shim et 
al (2000) showed that their probe was able to sample to an estimated depth of 500μm 
thereby enabling the detection of early stage lesions. There was no detectable increase 
in temperature when ex vivo experiments were done and they concluded that the near 
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infrared light was non-mutagenic. They were the first to use an in vivo fibre optic probe 
down an endoscope during a routine endoscopy. They are planning to take this further 
with a multi-centre clinical trial to further assess the probes ability to detect and 
diagnose disease thereby enabling its use in both surgical and therapeutic guidance. 
 
 
4.2.2. Gynaecological tissue. 
 
There has been a lot of work done over the years on cervical pre malignancies. Like the 
oesophagus, cervical malignancy has an intermediary condition between normal and 
cancer. This is known as cervical intraepithelial neoplasia. The incidence of this is 
rising and women over the age of 20 years are screened for this.  
Mahadevan – Jansen et al (1998a) investigated the potential of Raman spectroscopy to 
differentiate between different pathologies within the cervix. They used two 
pathologists gaining a consensus opinion on the histology. They found that they were 
able to get a sensitivity of 100% and specificity of 73% with the Raman system as 
compared to histology when differentiating between intraepithelial lesions and non- 
intraepithelial lesions. They suggest that Raman spectroscopy is potentially superior to 
colposcopy and cytology and also observed that peaks at 1246 and 1656 cm-1 were also 
found in other epithelial tissues (colon and bladder). They did point out that their in 
vitro system was not applicable for in vivo use due to the long integration times. 
Mahadevan- Jansen et al (1995, 1998b, 2002) also compared Raman with fluorescence 
and looked at an in vivo probe for detecting cervical malignancy. They showed the 
following advantages that Raman spectroscopy had over fluorescence – they achieved 
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better sensitivity and specificity when differentiating intraepithelial lesions from normal 
tissue, and also enabled further differentiation of the pathologies. The in vivo probe 
consisted of a portable system with a diode 785nm, 80mW laser. They showed that by 
using the probe they were able to achieve sensitivities and specificities similar to that of 
colposcopy, which unfortunately did not mimic the in vitro results, which were much 
better than colposcopy. The authors felt that this may be due to the probe geometry and 
interference from sunlight. They did however show that the use of Raman spectroscopy 
in vivo had potential in the diagnosis of cervical dysplasia, the pre malignant condition. 
More recently Mahadevan – Jansen et al have looked at the different sources of intra 
and inter-patient variability such as menopausal status, smoking history, overall patient 
diagnosis and the application of acetic acid. They looked at 35 patients undergoing a 
hysterectomy for reasons other than cervical disease. A portable spectroscopy system 
was used with a 785nm diode laser and fibre optic probe to obtain the spectra from the 
patients prior to their hysterectomy. They found that the intra-patient variability due to 
different locations on the cervix was negligible however there was greater variability 
due to inter – patient variation such as menopausal status. The authors demonstrated a 
difference in the intensity at 1324cm-1 which has also been shown to be one of the key 
difference between cervical dysplasia and normal ectocervix. Therefore they concluded 
that future studies were needed to separate classification algorithms depending on 
menopausal status. They also clarified the optimum integration time of 5 seconds by 
analysing the signal to noise ratio of different times. This also minimised probe 
movement during spectra acquisition that could lead to user error. The authors also 
found that although there was no statistical difference between the spectral difference 
before and after application of acetic acid, the difference is enhanced between normal 
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and diseased tissue. Therefore the authors inferred that the application of acetic acid 
would actually be advantageous in the detection of dyplasia [Robichaux-Viehoever (to 
be published)]. 
Utzinger et al (2001) also looked at the in vivo detection of cervical pre malignant 
conditions. They used a diode 789nm laser coupled to a fibre optic delivery and 
collection probe. They also found that they had trouble with long integration times and 
interference from the lighting in the room. However they did conclude that it was a 
promising technique that needed to evolve. 
Ovarian tissue has also been looked at with Raman spectroscopy, this is because ovarian 
tumours are rarely detected early on, as the main means of detection is a pelvic 
examination and a finding of an enlarged ovary. Lieber et al (2002) revealed that there 
were a number of significant Raman peaks that were observed only in some 
pathologies, but there sample size was very small having only looked at nine samples. 
They found that the following peaks were seen in the non- normal tissue; 1250, 1282, 
1364, 1543, 1594 and 1634cm-1. The authors were hoping to go onto in vivo testing with 
the completion of this study and the development of the probe. 
 
 
4.2.2. Breast tissue. 
 
There have been several studies in the literature that have looked at the diagnosis of 
breast cancer by using Raman spectroscopy. Alfano et al (1991) utilised near infrared 
Fourier transform Raman spectroscopy in medicine to obtain spectra from normal breast 
tissue and benign and malignant breast tumours. The authors showed that there were 
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four distinct peaks seen in normal tissue (1078, 1300, 1445, and 1651cm-1), and these 
differed in malignant tissue in terms of the intensity ratios between wavenumber 1445 
and 1651cm-1, and loss of the peaks at 1078 and 1300cm-1. They concluded that the 
spectral measurements could be used as a diagnostic tool however the sample numbers 
were small and needed increasing.  
Frank et al (1994) noted that near infrared wavelengths in the 691 – 832nm range yield 
high signal to noise ratio spectra with moderate power. The peaks noted were 
predominately from lipid and carotenoids, but that the carotenoid peaks at 1006, 1157, 
and 1525cm-1 wavenumbers were only picked up at laser wavelengths of 488nm where 
they were enhanced. They also noted that of the major lipid peaks in normal breast 
tissue, oleic acid appeared to be the major component. The group were also able to 
show that there was no qualitative difference between normal breast tissue taken from 
breasts that were being re-contoured and normal breast tissue adjacent to a cancer. 
Frank et al (1995) went on to show that at 784nm, sample to sample and patient to 
patient variations in normal breast tissue was less than 5% for the ratios between the 
major peaks. The authors also showed a difference between the spectra obtained from 
normal tissue, fibrocystic (benign) tissue and infiltrating ductal carcinoma were 
different. They noted the absence of the carotenoid peaks due to the lack of 
enhancement at 784nm, and also showed that by using a fibre optic needle they could 
obtain spectra from tissue and still get a difference between the pathologies. Using a 
wavelength of 784nm however did require long integration times, therefore 
necessitating further evolution of the probe prior to its use as an in vivo probe. 
Manoharan et al (1998) were able to distinguish spectral differences between even more 
pathologies within breast tissue. They looked at normal fatty tissue, normal glandular 
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tissue, fibrocystic disease, adenosis, carcinoma in situ and infiltrating ductal carcinoma, 
although they then grouped them into pairs resulting in three groups; normal, benign 
and malignant. The authors compared Raman spectroscopy and fluorescence photon 
migration imaging, concluding that Raman spectroscopy was better for the 
histochemical analysis of the breast lesions. It was felt that the sample numbers were 
too small to be able to distinguish between all the pathologies and a larger database was 
planned for the future. 
More recently Shafer – Peltier et al (2002) have taken things in the breast a step further. 
They looked at the contributions of fat, collagen, cell nucleus, cytoplasm, cholesterol-
like, Beta carotene and calcium hydroxyapatite, to the spectra from different pathologies 
in the breast. In this way they were able to not only show that there were spectral 
differences between the pathologies but also to give a morphological understanding to 
the spectra obtained. 
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5. Materials and Methodology. 
 
5.1. Constituents. 
 
The aim of measuring constituents was to assess the biochemical properties of each of 
the pathologies within the bladder and the prostate gland. In this way it was hoped that I 
would be able to quantify the differences between the pathologies. 
 
This thesis was limited to those constituents that were thought to be in sufficient 
concentrations in the tissue for the Raman spectrometer to be able to measure, ie gross 
molecules that change with pathology as opposed to subtle genetic changes such as p53. 
After consultation with available literature and discussions with pathologists in 
Gloucestershire Royal Hospital and Bristol Royal Infirmary the following constituents 
were picked. They were thought to be representative of different areas within a cell and 
this was confirmed by the literature [Shafer-Peltier 2002]. Unfortunately we are unable 
to completely validate the exact composition of tissue which is heterogenous. Berger et 
al [1996, 1997, 1999] have shown however that Raman spectroscopy can accurately 
determine concentration measurements of aqueous biological analytes and blood 
glucose. DNA is representative of the cell nucleus as the other constituents of the 
nucleus (ribosomes, RNA) have previously been shown to have a minor effect on the 
spectrum from the nucleus [Shafer-Peltier 2002]. Actin is thought to be representative 
of the cell cytoplasm and β-carotene is thought to be decreased in malignant tissue 
[Hata 2000, Toniolo 2001, Czeczuga-Seminiuk 2003]. Cholesterol is representative of 
necrosis [Shafer-Peltier 2002], choline is thought to be abundant in malignant tissue 
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[Anon 2003] and collagen is representative of the extracellular matrix / basement 
membrane. Glycogen is reduced in rapidly dividing cells such as malignant tissue, and 
only mature cells store glycogen. Lycopene is thought to be decreased in malignant 
tissue and oleic acid is thought to be abundant in urothelium. 
PSA is known to be produced by the prostate gland and triolein is representative of 
triglicerode lipids. 
 
Given the above directed approach, the following constituents were purchased from 
Sigma – Aldrich; 
Actin-    from bovine muscle, (A3653). 
β-carotene-   type 1, synthetic, approx 95%, (C9750). 
Cholesterol-   sigma grade, 99%+, (C8667). 
Choline-   base, approx 50% (w/w) aqueous solution, 
(C9154). 
 Collagen-   type 1, from human placenta, acid soluble, 
(C7774). 
type 3, from human placenta, acid soluble, 
(C4407). 
type 4, from human placenta, acid soluble, 
(C7521). 
 DNA-    from human placenta, (D7011). 
Glycogen-   from bovine liver, (G0885). 
Lycopene- from tomato, (L9879). 
Oleic Acid-   water soluble, (O1257). 
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Prostate Specific Antigen- from human seminal fluid, minimum 95%, 
(P3338). 
 Triolein (C18:1,(cis)-9)-  sigma grade, approx 95%, (T7140). 
  
 
5.2. Tissue collection. 
 
The experiments carried out that form the basis of the research were all undertaken at 
either the Gloucestershire Royal Hospital or at the Rutherford Appleton Laboratories. 
Local ethics committee approval was obtained for the collection of tissue [Appendix 1] 
and patients were given an information leaflet and asked to sign a consent form if they 
agreed for us to take some samples [Appendix 2]. 
 
 
5.2.1. Collection of prostate tissue. 
 
The aim of tissue collection from the prostate was to obtain samples from the following 
pathologies; Gleason grade 1 – 5 adenocarcinoma, HGPIN, prostatitis, and benign 
prostatic hyperplasia. Due to the variety of pathologies needed the prostate tissue was 
collected from patients undergoing routine TURP using a resectoscope, (Stortz 27040 
DH). Figure 5.1 shows a sample of prostate being taken during a standard TURP. The 
irrigating fluid during the TURP procedure was glycine. Once removed from the patient 
the sample was placed on a piece of acetate paper to facilitate its handling and 
preparation.  
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Once the tissue had been placed on the acetate paper it was placed into a 2.0ml cryovial, 
(Corning Incorporated) and dropped into liquid nitrogen, thereby snap freezing the 
tissue. The tissue was then stored at -80°C. 
 
 
 
Fig 5.1: Sample of prostate taken during a TURP. 
  Reproduced with kind permission from Health Press. 
 
5.2.2. Collection of bladder tissue. 
 
The aim of tissue collection from the bladder was to obtain samples from the following 
pathologies; Grades 1 – 3 TCC, CIS, Cystitis, and normal urothelium. Due to the variety 
of pathologies needed the bladder tissue was collected from patients undergoing routine 
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TURP, TURBT, and cystoscopy procedures, using either a resectoscope, (Stortz 27040 
DH), or cold cup biopsy forceps. The normal urolthelium was taken from the TURP and 
cystoscopy procedures to avoid any potential field changes that may be found in a 
bladder undergoing TURBT.  
 
Figure 5.2 shows a sample of TCC being taken using the resectoscope. The irrigating 
fluid during the procedure was glycine. Once removed from the patient the sample was 
orientated on to a piece of acetate paper to facilitate its handling and preparation. The 
orientation of the sample on to the acetate paper is crucial to the cutting of the sample 
using a cryotome. This is shown in Figure 5.3 and as you can see, is orientated so that 
the slices taken for H&E staining include both urothelium and muscle, otherwise the 
urothelium may potentially have been stripped. 
 
 
Fig 5.2: Resection of a sample of TCC using a resectoscope. 
  Reproduced with kind permission from Health Press. 
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Once the tissue had been placed on the acetate paper it was placed into a 2.0ml cryovial, 
(Corning Incorporated) and dropped into liquid nitrogen, thereby snap freezing the 
tissue. The tissue was then stored at -80°C. 
 
Acetate Paper 
Urothelium 
Muscle 
 
Fig 5.3: Orientation of the bladder tissue on the acetate paper. 
 
 
5.2.3. Snap freezing tissue. 
 
The rationale behind snap freezing the tissue in liquid nitrogen is as follows; 
1. There is no contamination to the tissue from formalin or other chemicals that 
may be used to fix the tissue. 
2. Tissue fixation halts metabolism and stabilises tissue structure but also produces 
chemical changes that will alter the spectra obtained [Bancroft 1996]. 
3. Slow freezing can distort and damage to tissue due to ice crystal artefact. 
4. Snap freezing gives us an in vitro model that is as close as possible to in vivo 
spectroscopy. 
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5.3. Histopathological process and analysis. 
 
5.3.1. The prostate tissue. 
 
The prostate tissue was cut into histological sections using a cryotome. The top layer 
was discarded to level out the sample, and then a 7μm section was cut for H&E 
staining, and placed on to a histology slide (Snowcoat X-tra, Surgipath). The next 
section cut was 30 μm and this was placed on a calcium fluoride slide which was stored 
at -80°C. Another 7μm section was cut for H&E staining below this so that the 
histology could be accurately identified. The remainder of the tissue was placed back 
into the cryovial and stored at -80°C. 
The use of the acetate paper made it possible for the tissue to be adhered to the 
cryotome chuck without the use of cutting agents. Therefore potential chemical 
contamination of the tissue was avoided.  
 
The H&E slides were viewed by a consultant histopathologist and the pathology in the 
sample was identified. As the prostate tissue is heterogenous, there was often more than 
one pathology present on the slide, therefore each of these needed to be accurately 
identified so that the diagnosis for the spectra taken was correct. This was done by 
marking the H&E slides and then finding the corresponding position on the 30 μm 
section used for spectral acquisition. The spectra were then acquired and each spectrum 
was given a corresponding pathology code. 
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5.3.2. The bladder tissue. 
 
The bladder tissue was cut into histological sections using a cryotome. The top layer 
was discarded to level out the sample, and then a 7μm section was cut for H&E 
staining, and placed on to a histology slide (Snowcoat X-tra, Surgipath). The remainder 
of the tissue was placed back into the cryovial and stored at -80°C. 
The use of the acetate paper made it possible for the tissue to be adhered to the 
cryotome chuck without the use of cutting agents. Therefore potential chemical 
contamination of the tissue was avoided. 
 
The H&E slides were viewed by a consultant histopathologist and the pathology of the 
sample was identified. Bladder tissue is usually homogenous and therefore easier than 
prostate to obtain a specific pathological diagnosis. 
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5.4. Raman spectroscopy. 
 
5.4.1. Instrumentation – The Raman spectrometer. 
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Fig 5.4: The Renishaw diode laser spectrometer. Reproduced from Crow (2004). 
 
Figure 5.4 shows the Raman spectrometer (Renishaw plc, New Mills, Wotton under 
Edge, Gloucestershire, GL12 8JR.) used to obtain spectra from the tissue samples and 
the constituents. The system has been optimised for use on human tissue through the 
work of Dr Nick Stone (2001). 
The laser used is a Renishaw high power near infrared diode laser, which supplies the 
excitation light at a wavelength of 830nm and generates 300mw of power. This is then 
focused through the microscope lens onto the tissue sample or the constituent. The 
spectrometer then collects the scattered light from the tissue/constituent and detects it. 
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The detected spectrum is recorded on the p.c. Figure 5.5 below shows the components 
of the Renishaw spectrometer in greater detail.  
 
 
Fig 5.5: The components of the Renishaw spectrometer. 
A – Diode laser, B/C – Steering mirrors, D/F – Laser line rejection apparatus, E – 
Microscope, G – Focusing lens, H – monochromator entry slit, I – Beam expanding 
lens, J – Prism mirror, K – Grating, L – CCD focusing lens, M – CCD detector. 
 
When a spectrum is measured from some tissue or a constituent the following occurs. 
The diode laser (A) acts as the excitation light source. This is directed to the laser line 
rejection apparatus by the steering mirrors (B/C). The laser line rejection apparatus, 
reflects light at the laser’s wavelength, but allows other wavelengths to pass through. D 
reflects the incident laser light via the Leica DML polarised light microscope (E) onto 
the sample. Due to the power density and signal to noise ratio achieved, as well as 
Raman and fluorescence signals from the microscope lens a x80 MIRPLAN ultra-long 
working distance (Olympus) lens was used for the prostate a x20 MIRPLAN ultra-long 
working distance (Olympus) lens was used for the bladder and a x50 MIRPLAN ultra-
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long working distance (Olympus) lens was used for the constituents. These were 
actually selected to provide the sampling volume we wanted in the tissue. Following 
interaction with the sample, the light passes back, via the collection optics, to the laser 
line rejection apparatus (F). Light at the laser wavelength (Rayleigh scattering which is 
elastic) is reflected away, whereas the remainder of the scattered light, including the 
Raman scattering, passes through and is focused onto the monochromator entry slit (H) 
by the focusing lens (G). The slit (H) is used to reject scattered light from the out-of-
focus sample volume, this acts to improve spatial resolution and reduce fluorescence. 
The monochromator has a 300 line / mm grating which had been previously selected by 
Dr Stone (2001) to give the best compromise between range and resolution. The light 
then passes via the beam expanding lens (I) to the prism mirror (J). The prism mirror 
deflects the light so that it passes to the grating (K), which separates the light into its 
constituent wavelengths, (The grating can be adjusted to allow a variable range of 
wavelengths to be selected for detection). Following separation at the grating, the light 
is again redirected by the prism mirror, so that it passes through the CCD focusing lens 
(L). The light is thereby focused onto the CCD detector (M), this consists of pixels that 
pick up different wavelengths of light on the vertical axis. The intensity at each 
wavelength is calculated by summing the charge on the pixels in the horizontal axis, and 
a spectrum is formed. The CCD used is a deep depletion charge-coupled-device detector 
(Renishaw RenCam) that comprises an array of 576 by 384 detector elements. The area 
on the array was reduced so that background noise could be reduced. The number of 
pixels on the array ultimately used to detect the spectrum has been reduced to twenty at 
each wavelength to give the best signal to noise ratio [Stone 2001]. 
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5.4.2. Renishaw spectrometer software. 
 
The Renishaw spectrometer is controlled by means of Hewlett Packard Pentium II 
Vectra personal computer (P.C.). This P.C. runs the Renishaw WiRE software 
(Windows 98 based Raman environment, version 1.3.15). This meant that the 
experimental set up, conFiguration, calibration of the spectrometer and data acquisition 
could occur. Also the GRAMS/32 software (Galactic Industries) enabled some initial 
basic analysis to occur. The vast majority of the analysis however was done on an office 
P.C. using Matlab, which will be discussed later. 
The system also contains a motorised XYZ stage that is controlled by the software and 
allows movement of the sample in three dimensions for spectra acquisition. This 
enables spectra to be obtained from an area or volume of tissue and therefore allows for 
mapping of the tissue. 
 
 
5.4.3. Optimisation of the Raman system. 
 
As well as ensuring that the system is optimised in terms of the excitation source, edge 
filter, monochromator and objective lens, it is also necessary to be aware of potential 
causes of noise within the system and to reduce the noise as much as possible.  
To measure a Raman spectrum from a biological tissue you need to maximise the signal 
to noise ratio as much as possible. This ratio is determined by the Raman intensity 
divided by the noise intensity. If you have too much noise the Raman signal will be 
swamped and meaningless. 
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There are two types of noise within the system, these are determinant noise (inherent 
within the system) and random noise (secondary to environmental changes).  
The main determinant noises are shot noise (reduced by minimising acquisition time 
and laser intensity) and detector noise (dark current reduced by cooling the detector). 
The main random noises are from variation in temperature and ambient light as well as 
cosmic rays. To minimise fluctuations in temperature an air conditioning system is used 
to provide a constant temperature of 22° C and to minimise ambient light fluctuations 
spectra are either taken in the dark or with a standard 60W light bulb which has 
previously been shown to have no detectable effects on the spectra [Stone 2001]. 
Cosmic rays cause sharp spikes to appear in the Raman spectrum, these are very 
obvious and can be removed from the spectra using the customised analysis programme 
in Matlab. 
 
 
5.4.4. Calibration of the system. 
 
As well as minimising factors that cause noise so as to improve the signal to noise ratio 
of our spectra, we also have to ensure the reproducibility of our spectra and the ability 
to transfer the information obtained from the spectra to other systems. In this way they 
can be used for medical applications. A means of doing this is by accurately calibrating 
the system and the importance of this has been discussed in the literature in the past 
[Mann 1999]. 
The system has to be calibrated for wavenumber as well as intensity. The wavenumber 
is calibrated by obtaining spectra from a neon argon lamp source with known emission 
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lines. Day to day checks are made by taking spectra of silicon. The spectra are taken 
using the x50 Leica objective with the static scans centred at 1150 cm-1. One 
accumulation at 0.1seconds is taken. The system is then re-calibrated if the silicon peak 
was not at 520 cm-1 wavenumbers. The intensity is calibrated using a white light source 
lamp that has been calibrated against a standard by the National Physical Laboratory 
which provides the user with a spectrum of absolute intensities over wavenumbers at a 
fixed distance from the light source. The system was tested using the following 3 
objectives to collect the light – x20 MIRPlan Olympus, x50 Leica and the x80 MIRPlan 
Olympus. The spectra were obtained to give an intensity count of 500000 arbitrary 
units. 
 
 
5.4.5. Spectra acquisition. 
 
All spectra were acquired following daily calibration of the spectrometer using silicon.  
 
5.4.5.1. Spectra acquisition from the constituents. 
 
The solid constituents were placed on a calcium fluoride slide, and the liquid 
constituents were placed in a cell plate. An x50 MIRPlan ULWD Olympus microscope 
objective was then used to focus in on the substance and to measure the spectra. 
Different acquisition times were used for each constituent, but the laser was always at 
full power with the monochromator slit set to 50µm. The spectra were centred at 
1150cm-1 and stored on the system’s P.C following acquisition. All of the spectra were 
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then white light corrected, baseline corrected and truncated to 450 – 1850cm-1 as 
outlined in Stone (2001).  
 
 
5.4.5.2. Spectra acquisition from the prostate samples. 
 
The TURP chip that was cut to 30µm and placed on a calcium fluoride slide, was 
passively warmed to room temperature. Initially an x2.5 NPlan Leica objective was 
used to take a white light image of the area to be mapped. Then an x80 MIRPlan 
ULWD Olympus microscope objective was used to focus on the prostate and to record 
the prostate spectra. Once focused for the white light, the focus was moved in to the 
tissue by 10µm and the system was set up for a map. The autofocus was left off and the 
acquisition time was set to 60 seconds at full laser power, for 1 acquisition. The spectra 
were taken in a line fashion from a mark on the calcium fluoride slide with 50 steps 
between each spectral acquisition. The monochromator slit was set at 50µm, and the 
recorded spectra were centred at 1150 cm-1 and stored on the system’s P.C. All of the 
spectra were then white light corrected, baseline corrected and truncated to 450 – 
1850cm-1 as outlined in Stone (2001).  
 
 
5.4.5.3. Spectra acquisition from the bladder samples. 
 
The remaining bladder tissue (either TURBT sample or biopsy) following sectioning for 
histological grading, was removed from its backing acetate, placed on a calcium 
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fluoride slide or glass slide and passively warmed to room temperature. The bladder 
biopsy samples, which had been orientated with the epithelial surface on the side, were 
re-orientated with the urothelial/epithelial surface facing upwards. Therefore the spectra 
obtained were from the urothelium, which mimics an in vivo setting.  
An x20 MIRPlan ULWD Olympus microscope objective was used to measure bladder 
spectra, with an acquisition time of 10secs at full laser power. The monochromator slit 
was set to 50µm and spectra were centred at 1150cm-1 and stored on the system’s P.C. 
Approximately 10 spectra were taken from each sample in a random fashion.  All of the 
spectra were then white light corrected, baseline corrected and truncated to 450 – 
1850cm-1 as outlined in Stone (2001).  
 
 
 
5.5. Kerr - gated  Raman spectroscopy. 
 
Raman spectroscopy of tissue is usually limited to sampling of the first 1 – 200 microns 
from its surface. Furthermore dark tissue fluoresces in such a way that the important 
Raman information is buried within the noise of the fluorescence spectral background. 
It was thought that both these problems may be overcome by combining Raman 
spectroscopy and the Kerr - gated technique.  
 
The following experiments were performed at the Rutherford Appleton laboratory (a 
UK national science facility) and were therefore allocated limited laboratory time for 
system optimisation and measurements. This restricted much of the following studies to 
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proof of principle, with the expectation that further beam time would be gained to 
extend the study in the future. This unfortunately is beyond the time available for this 
body of work. 
 
5.5.1. Instrumentation 
 
The Kerr gating system is based on the high throughput 4 picosecond optical Kerr 
shutter that has been described in previous publications by Matousek et al (1999, 2001). 
The Kerr gate is made up of two crossed polarisers (41x 41mm, Glan Taylor polarisers) 
and a Kerr medium consisting of a 2mm optical cell that is filled with CS2.  
 
When the gate is closed, the light from the sample is blocked as the polarisers are in 
cross orientation. When the gate is open the light collected from the sample has its 
polarisation rotated to allow it to pass through the cross polariser. The gate is opened by 
a short 1 picosecond gating pulse at 800nm. This bypasses the polarisers and creates a 
transient anisotropy within the Kerr medium, this then acts to rotate the polarisation of 
the light from the sample, (Figure 5.6), this effect lasts for about 4 picoseconds. 
 
The spectra were collected using a conventional Raman spectrometer (Spex, 
Triplemate). To prevent residual elastically scattered light from the 488nm probe laser 
entering the spectrometer a Kaiser holographic notch filter was used. To also prevent 
the residual 800nm gating beam scatter from entering, a saturated copper sulphate 
solution in a 1cm thick optical cell was placed in front of the spectrometer slit. 
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The Raman scattered light was collected in 180º geometry using a lens with f-number 2. 
A liquid nitrogen cooled, back illuminated NIR CCD (Andor Technology) was used to 
record the Raman spectra from the tissue. 
The probe wavelength used was 488nm, and the pulse duration was 1 picosecond. The 
pulse energy at the sample was 5 μJ (1 kHz) corresponding to 5 mW of average power. 
The beam was focused down to 300 μm diameter spot. 
 
 
Kerr medium (CS2; 2 mm)
Raman
fluorescence Gating pulse (800 nm, 500 μJ, 1 ps)
(polarisation tilted by 45o) 
Cross polariser
Polariser
sample
laser pulse
(1 ps)
 
 
Fig 5.6: A diagram and picture showing the Kerr gating Raman system. 
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5.5.2. Spectra acquisition. 
 
All spectra were acquired following daily calibration of the spectrometer using 
acetylnitrile.  
 
 
5.5.2.1. Spectra acquisition from the prostate sample. 
 
Prostate samples were obtained by taking a chip at TURP. The samples were then snap 
frozen in liquid nitrogen and transferred to a -80°C freezer for storage.  
At the time of the experiment the tissue was passively warmed to room temperature and 
placed on a cell containing urea crystals. Urea is very strongly Raman active, and was 
chosen to allow a demonstration of probing of Raman spectra at depth through the 
prostate tissue. The spectra were obtained for 20 seconds and 5 accumulations at 
varying distances through the tissue, i.e. at various time delays following the laser probe 
excitation pulse. 
 
A simple approximation as to the distance traveled by the incident photons in the tissue 
can be made (the refractive index of the tissue was taken to be 1.4). In a time of 
1ps the photons will have traversed approximately 0.2mm of the tissue. This will not 
necessarily be in a straight line as the tissue is highly scattering.  
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By taking the scattering coefficient, µs to be 48 mm-1 and the absorption coefficient, µa 
to be 1.9 mm-1 (for epithelial tissue at 577nm) [Smithies 1995] an optical depth (OD) 
can be calculated from 
   
as
OD μμ +=
1
 
The approximate optical depth in prostate tissue for 488nm is 0.02mm. 
 
 
5.5.2.2. Spectra acquisition from the bladder sample. 
 
Bladder samples were collected at cystoscopic procedures including TURP (normal 
biopsies) and TURBT. The samples were then snap frozen in liquid nitrogen and 
transferred to a -80°C freezer for storage.  
At the time of the experiment the tissue was passively warmed to room temperature and 
placed on a cell containing uric acid. Uric acid is very strongly Raman active, and was 
chosen to allow a demonstration of probing of Raman spectra at depth through the 
bladder tissue. The spectra were obtained for 20 seconds and 5 accumulations at varying 
distances through the tissue, i.e. at various time delays following the laser probe 
excitation pulse. 
 
As calculated for the prostate gland in section 5.5.2.1, the approximate optical depth in 
bladder tissue for 488nm is 0.02mm. 
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5.5.2.3. Spectra acquisition from dark tissue (kidney and liver). 
 
Pig’s liver and kidney were purchased from a local supermarket and kept refrigerated 
until used. When needed the tissue was cut into thin slices and placed on a glass slide 
ready for sampling with the laser. Obviously human tissue would have been more 
favourable for this experiment. However this was a first line experiment to assess the 
Kerr gate technique on fluorescing tissue and with the time constraints it would have 
been difficult to get ethical approval or to recruit patients for the use of human tissue. 
The animal tissue will still exhibit similar fluorescence and Raman properties, within 
the range of those necessary to perform this specific study.  
To demonstrate the ability to obtain Raman spectra from dark tissue without 
fluorescence we performed two sets of measurements; the first involved obtaining 
spectra from the liver and kidney without the use of the Kerr gate, and the second 
involved obtaining spectra with the Kerr gate. The spectra were obtained at different 
wavelengths to assess whether different components would be resonantly enhanced.  
 
5.6. Analysis of the spectra. 
 
5.6.1. Empirical analysis (univariate / bivariate analysis). 
 
Empirical analysis was the method used by Alfano et al (1991), to analyse the 
difference between spectra taken from normal breast tissue, benign breast tumour and 
malignant breast tumour. He found that by looking at the ratio of the peak intensities at 
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1445 cm-1 and 1651 cm-1, that there was a difference between the pathological groups 
and this could be used to differentiate between them spectrally. 
This type of analysis is widely used to initially construct diagnostic algorithms. It is a 
supervised method in that it can be used to differentiate between pathological groups 
purely on spectral variance when the pathology is known. It is also useful when prior 
knowledge of the tissue is not available (in this circumstance it is an unsupervised 
method) or patterns in multiple spectra are under investigation. Empirical analysis is 
extremely good when being used for simple solutions or single constituents, as by 
comparing the ratios of relevant peak intensities, concentrations can be calculated. 
Biological tissue however is a lot more complicated. Empirical analysis can be used 
with tissue by measuring the peak intensities of selected random peaks within the tissue 
spectrum to give a peak intensity ratio. Then by comparing this with the same peak 
intensity ratios in each pathological group it may be possible to differentiate between 
the groups. Alfano et al (1991) found that the peak intensity ratios between 1445 and 
1651 cm-1 was 1.23, 0.93 and 0.87 respectively for normal breast tissue, benign breast 
tumour and malignant breast tumour. 
The disadvantage of this method of analysis is that only a small proportion of the 
measured data is being used in the analysis. As biological tissue is complex a method of 
analysis therefore that incorporates as much of the measured data as possible is more 
likely to provide a more vigorous method of detection and diagnosis of biological 
pathologies [Shim 2000]. 
Multivariate analysis is the name for analytical methods that try to achieve this by 
utilising large numbers of variables. 
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5.6.2. Multivariate analysis. 
 
Multivariate analysis allows virtually all of the data contained within a measured 
spectrum to be used in the analysis. This is much better for biological tissue due to the 
subtle changes that occur between the pathological groups being classified and the 
complexity of the tissue spectra.  
The techniques used can be either supervised or unsupervised. Unsupervised techniques 
identify natural clusters or groupings and can be used to differentiate between 
pathological groups purely on spectral variance. This is useful when prior knowledge of 
the spectra is not available or patterns in multiple spectra are under investigation. 
Supervised techniques require prior knowledge of the origins of the spectra within the 
training set, i.e. class / pathological identity. 
There are a number of software packages that are commercially available for 
multivariate analysis. PLS-toolbox® for use with Matlab® (Eigenvector Technologies, 
Manson, Washington, USA) is one of these and was adapted for use with the data in 
these studies [Stone 2001] 
 
5.6.2.1.Principal component analysis. 
 
Principal component analysis (PCA) is an orthogonal technique that is unsupervised. 
Therefore it does not take into account the pathology of the tissue measured. It involves 
the calculation of principal components (PC’s) that describe the greatest variance from 
the mean. They accurately characterise the entire range of spectral variations. 
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A PC is a product of the load and the score of the spectrum whereby the load describes 
progressively decreasing amounts of variance from the mean of the dataset being 
analysed and the score is the value by which the load must be multiplied by to 
reconstruct the original spectrum from the mean. We tend to use up to 25 PC’s in our 
analysis. 
PCA is a technique that is used as a means of data reduction / compression. Therefore 
the data to be processed is reduced without actually losing any of the functional 
information. It allows collinear spectral variations to be considered together. Many 
spectral features have the same source of variation and are therefore said to be collinear 
i.e. the same information is found at more than one peak in the spectrum.  
Constituent spectra within the tissue spectra have multiple peaks, therefore a change in 
concentration of the constituent between the pathologies will change the peaks in the 
total spectrum. This collinear variation can be picked up by PCA in the form of the 
loads. If a load reflects a significant change in the concentration we can gain some 
insight into the molecular differences between pathologies. Also the loads for all the 
spectra in a spectral dataset or pathology are the same, therefore a tissue spectrum can 
be represented by just a small set of numbers, the PC scores. In this way the amount of 
data to be processed can be reduced without actually reducing the amount of functional 
data available. 
The problems with PCA tend to be due to systematic errors within the spectra such as 
unfiltered cosmic rays, inconsistent background removal and drift in wavenumber or 
intensity axes. Diagnostically significant PC’s are those that show a significant 
difference in value between the pathological groups. These are determined by analysis 
of variance (ANOVA) which will be described later in the section. 
 109
5.6.2.2.Linear discriminant analysis. 
 
Linear discriminant analysis (LDA) is a supervised technique whereby the identity of 
the class / pathological group is required. Therefore prior knowledge about the samples 
in the training set is required. LDA selects the linear combination vectors / direction in 
spectral space that provide the maximum value for the ratio between inter group 
variance and intra group variance for the optimal separation of 2 groups. Therefore you 
get linear discriminant functions that maximise the variance in the data between the 
pathological groups and minimise the variance between the members of the same 
pathological group. If there are more than 2 groups the multivariate discriminant 
analysis is used. This is the multi-group extension of LDA using (n-1) orthogonal 
directions than best separates (n) groups. For this thesis however I will use the umbrella 
term LDA. LDA is a technique therefore that is used to accentuate the clustering of 
different pathological groups. 
The disadvantage of LDA however is that the input variable (spectral wavenumbers) in 
this technique should be less than the number of spectra in the dataset. To overcome this 
PCA led LDA is used.  
 
 
5.6.2.3. Principal component analysis led linear discriminant analysis. 
 
PCA led LDA is a technique whereby the PCA is performed first to obtain PC’s and the 
PC scores are then used as the input variables instead of the spectral wavenumbers. In 
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this way the input variable number is reduced. Like LDA, PCA led LDA is a supervised 
technique. The LDA goes through each of the PC’s to ascertain whether they are useful 
in providing the maximum value for the ratio between inter group variance and intra 
group variance for the optimal separation of the pathological groups. Each PC is given a 
weight as to its ability to discriminate. It is then used to construct diagnostic algorithms 
for different pathological groups. Once constructed the diagnostic algorithm needs to be 
tested to ascertain its accuracy in predicting the confirmed histological diagnosis for 
each spectrum. The disadvantage of this type of analysis is that if there are too many 
PCs compared to a small sample size then you can overfit the data as there is not 
enough variation described in the dataset to cover a patient population. 
Also given that the gold standard Gleason scoring system and the histopathological 
grading for bladder are subject to both inter and intra observer error therefore the 
prediction madel may be incorrectly trained which may lead to groups that are 
misclassified to a greater extent than others.  
 
 
5.6.3. Analysis of variance. 
 
Analysis of variance (ANOVA) can be used with any of the previously described 
techniques. It is a technique that is used to investigate the relationship between a  
response variable (the measurement) and one or more independent variables.  
In the case of the empirical analysis ANOVA works by compiling a matrix of all the 
possible combinations of peaks therefore all the peak intensity ratios are calculated. The 
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matrix compiled is a (n x m) matrix whereby the spectra are represented by (n) and the 
intensity value by the (m). Therefore in the case of the PCA led LDA it is used on the 
PC’s to ascertain which of the PC’s are significantly able to differentiate between the 
pathologies. 
ANOVA extends the two sample t-test to a more general null hypothesis comparing the 
equality of more than two means versus them all not being equal. The t-test is used for 
testing the equality of two population means [Kendall 2002]. 
ANOVA results in F values whereby the greater the F value the greater the difference 
between the pathological groups. When the F value is above a critical value (F-crit), 
there is a statistical difference between the groups. The F-crit value in this study is set at 
99.9% or p<0.001. Two of the high F values can be plotted against each other to show 
how efficiently the variables (PC’s / peak ratios) differentiate between the pathological 
groups. 
 
 
5.6.4. Testing the diagnostic algorithm. 
 
The diagnostic algorithms can be tested by two means. The first method is the ‘leave 
one spectrum / sample out’ cross validation method. This method involves leaving a 
spectrum or all spectra from a sample out of the test data, performing PCA led LDA on 
the test data to produce an algorithm and then testing the algorithm with the left out 
spectrum / sample. The process is then repeated using all of the spectra / samples in the 
original dataset. The ‘leave one spectrum out’ method is what was previously used in 
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urology as there was only one dataset and sample numbers were limited.  The 
disadvantage of this is that the algorithm was constructed using spectra from the same 
sample as the spectrum that was left out. This can therefore result in bias and an 
inaccurate result in terms of sensitivity and specificity of the algorithm. A more 
rigorous means of testing is by using a completely different dataset to test the diagnostic 
algorithm. However with a limited number of samples this can be an acceptable way of 
testing the data 
 
 
5.6.5. Least squares analysis. 
 
To date the spectral fingerprints have only been used for classification of pathology 
groups. However, one of the objectives of this study was to attempt a first approach at 
elucidating the biochemical origins of spectral differences seen in the signals between 
pathologies. This involved the use of ordinary least squares fitting of the spectral data 
with spectra taken from the pure standards listed in section 5.1. 
 
Regression is a process that is used to estimate the mean outcome of a population by 
analysing the relationship between variables. In this way it can help us to understand the 
relationship between the given variables. 
For example if you assume that there are two continuous variables (X and Y) measured 
on each subject and an explanation as to how changes in variable Y are predicted by 
 113
changes in variable X is required, then Y is the dependent variable and X the 
independent variable [Altman]. 
To achieve the understanding for the changes a line (which can be linear (straight) or 
non-linear (curved)) is formed between the variables whereby the line is fitted so that 
each point (variable) is as close to line as it can be. In this way a line of ‘best fit’ is 
formed. This is achieved by using a regression equation [Altman]. 
The most widely used means of ‘fitting’ a regression equation is by using a computer 
based mathematical method known as least squares. As was explained earlier the line 
fits well if it passes close to each point therefore the least squares regression line is the 
line for which the sum of the squared distances from the points to the line is minimised.  
If the variables are unrelated then the line formed will have a gradient of zero (a 
horizontal straight line) and this is known as the regression coefficient which will also 
be zero.  
 
The PLS-toolbox® (Eigenvector Technologies, Manson, Washington, USA) for use with 
Matlab® was adapted for use with the data in these studies [Stone 2001]. The mean 
spectra for the pathologies and the constituents were ascertained allowing for further 
analysis to occur. The fitting of the mean spectra of the constituents to the mean spectra 
of the different pathologies in the bladder and the prostate gland was done by using 
‘ordinary least squares’ analysis. This is explained simply below: 
 
EcSX +=  
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Where S is the matrix of spectral components, c is the matrix of concentrations to be 
predicted, and X is the measured spectra. This can be used to provide a ‘best fit’ of the 
spectral components or basis spectra found within the measured spectra. The 
assumption is made that the residual is minimised and that the spectral components 
selected are the main components of the spectra.  
 
S
EXc )( −=  
The disadvantage with this technique is that any co linearity in the components selected 
will skew the fit. An example being amino acids and the proteins containing them being 
used in the model. Observation of the residual E (E=X-cS) enables the quality of the fit 
to be observed and any remaining features of the spectra to be included in the next 
iteration of the model. 
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6. Results.    
  
6.1. Constituent spectra. 
 
The constituent spectra were obtained as was described in section 5.4.5.1. The mean of 
the spectra from each constituent was then obtained by using Matlab® which was 
adapted for use with the data in these studies [Stone 2001]. The mean spectra are shown 
below in Figures 6.1 to 6.12. 
 
 
 
Fig 6.1. The mean spectrum of actin. 
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Fig 6.2. The mean spectrum of ß carotene. 
 
 
Fig 6.3. The mean spectrum of cholesterol. 
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Fig 6.4. The mean spectrum of choline. 
 
 
Fig 6.5. The mean spectrum of collagen type 1 (col1). 
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Fig 6.6. The mean spectrum of collagen type 3 (col3). 
 
 
Fig 6.7. The mean spectrum of collagen type 4 (col4). 
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Fig 6.8. The mean spectrum of DNA. 
 
 
Fig 6.9. The mean spectrum of glycogen. 
 120
 
Fig 6.10. The mean spectrum of lycopene. 
 
 
Fig 6.11. The mean spectrum of oleic acid. 
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Fig 6.12. The mean spectrum of triolein. 
 
 
 
6.2. Analysis of tissue spectra. 
 
Prostate and bladder tissue were obtained as outlined in sections 5.2.1 and 5.2.2. Raman 
spectra were then obtained from each of the tissue samples (following procedures 
outlined in section 5.4.5) and were grouped according to the histopathology of the 
sample as determined by a consultant histopathologist. The spectra were then analysed 
as discussed later in the chapter. 
Figure 6.13 shows a mean spectrum taken from a prostate sample and Figure 6.14 one 
taken from a bladder sample. The principal peaks have been labelled and the tentative 
assignments for these peaks are shown in table 6.1. These principal peaks are used in 
the empirical analysis of the spectra. 
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 Fig 6.13. A mean spectrum taken from a prostate sample. 
 
Fig 6.14. A mean spectrum taken from a bladder sample. 
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Peak Position 
(cm-1) 
Major peak assignments 
430 Cholesterol 
455 Unassigned 
526 Disulphide (C-S-S-C gauche-gauche-gauche) 
542 Disulphide (C-S-S-C gauche-gauche-trans) 
642 Tyrosine 
716 Nucleotide peak 
750 Symmetric breathing of thymine 
853 Tyrosine 
882 Tryptophan 
932 Skeletal C-C: α -helix 
936 Hydroxyproline & C-C collagen backbone 
998 Phenylalanine 
1003 Phenylalanine 
1027 Proline 
1090 PO2-  (DNA) 
1177 Tyrosine, phenylalanine 
1239 Amide III: β- sheet 
1256 Cytosine 
1309 CH2 twist/wag (lipids) 
1318 CH2 symmetric wagging (lipids) 
1446 CH2 bending mode of proteins and lipids 
1450 C-H deformation 
1662 Nucleic acids 
 
Table 6.1. Table showing the tentative assignments for the principal peaks of the spectra [Stone 
2001]. 
 
 
6.2.1. Analysis of the prostate samples and their spectra. 
 
Table 6.2 shows the number of prostate samples obtained (section 5.2.1), their 
pathology as assessed using the technique described in section 5.3.1 and the number of 
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spectra obtained (using the technique described in section 5.4.5.2) for each pathology. 
The spectra were then analysed using the analytical methods described in section 5.6 
and the mean spectrum for each pathological group was obtained. All the prostate 
spectra measured are shown in Figure 6.15. There are a number of random cosmic ray 
events superimposed over the tissue spectra. It can be seen that these have little effect 
on the mean of all the spectra from benign prostatic hyperplasia (BPH), adenocarcinoma 
Gleason score less than 7 (GS<7) and Gleason score greater than 7 (GS>7) are shown in 
Figure 6.16. From Figure 6.16 it can be seen that the differences between the 
pathological groups are very subtle. On first glance they appear very similar with only 
subtle variations in peak height and positions noted between the groups.   
 
 
 
 BPH CaP 
(GS<7)
CaP 
(GS>7) 
No. of 
Samples 51 4 3 
No. of 
Spectra 1071 84 63 
 
 
Table 6.2. The number of prostate samples obtained for each pathology and the number of spectra 
measured for each pathology. 
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 Fig 6.15. The spectra obtained for the prostate samples. 
 
Fig 6.16. The mean spectra obtained for each prostate pathology. 
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Linear discriminant analysis was then used on the spectra to produce cross validation 
classification results. This uses a ‘leave one out’ method described in chapter 5.6.4. 
80% of cross validated grouped spectra are correctly classified using this method.  
The results of this method are shown in table 6.3. 
 
Table 6.4 shows the specificity and sensitivity of Raman spectroscopy as a diagnostic 
test to classify the pathology in the prostate. This was calculated from the cross 
validation results obtained from the linear discriminant model. This table has been 
included purely to help in understanding how well the preliminary model is working 
and also to ensure that it is comparable to work done previously in the group. The 
spectra from these samples were added to the bank of those already collected and will 
be used in future experiments. 
 
Raman Prediction 
 
 
Histology 
 BPH CaP <7 CaP >7 
BPH 558 44 91 
CaP <7 10 31 1 
CaP >7 17 0 46 
 
Table 6.3. A table showing the cross validation of the Raman prediction compared to the actual 
histology for the prostate samples. 
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 BPH CaP <7 CaP >7 
Sensitivity 81 74 73 
Specificity 74 93 87 
 
Table 6.4. A table showing the sensitivity and specificity of Raman spectroscopy as a diagnostic 
test to classify pathology in the prostate. 
 
 
6.2.2. Analysis of the bladder samples and their spectra. 
 
Table 6.5 shows the number of bladder samples obtained using the technique described 
in section 5.2.2, their pathology as assessed using the technique described in section 
5.3.2 and the number of spectra obtained using the technique described in section 
5.4.5.3 for each pathology. These were then analysed using the analytical methods 
described in section 5.6 and the mean spectrum for each pathological group was 
obtained. All the bladder spectra measured are shown in Figure 6.17 and the mean of all 
the spectra from normal, cystitis, transitional call carcinoma (TCC) grades 1, 2 and 3 
and squamous differentiation are shown in Figure 6.18. It can be seen from Figure 6.18 
that the differences between the pathological groups are very subtle. On first glance they 
appear very similar with only subtle variations in peak height and positions noted 
between the groups.   
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 Normal Cystitis 
TCC 
G1 G2 G3 Sq. Dys 
No. of 
Samples 39 61 6 18 3 6 
No. of 
Spectra 390 610 60 180 30 60 
 
 
Table 6.5. The number of bladder samples obtained for each pathology and the number of spectra 
measured for each pathology. 
 
 
Fig 6.17. The spectra obtained from the bladder samples. 
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 Fig 6.18. The mean spectra obtained for each bladder pathology. 
 
Linear discriminant analysis was then used on the spectra to produce cross validation 
classification results. This uses a ‘leave one out’ method described in chapter 5.6.4. 
72% of cross validated grouped spectra are correctly classified using this method. The 
results of this are shown in table 6.6. 
Table 6.7 shows the specificity and sensitivity of Raman spectroscopy as a diagnostic 
test to classify the pathology in the bladder. This was calculated from the cross 
validation results obtained from the linear discriminant model. As was discussed for the 
prostate gland this table has been included purely to help in understanding how well the 
preliminary model is working (ie the likely prediction mis-classification will be 
highlighted here). Furthermore these values allowed comparison with the equivalent 
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work done previously in the group. The spectra from these samples were added to the 
bank of those already collected and will be used in future experiments. 
 
 
Raman Prediction 
 
 
 
 
Histology 
 Normal Cystitis TCC Squamous 
differentiation Grade1 Grade2 Grade3 
Normal 157 54 21 0 2 7 
Cystitis 50 175 8 0 3 0 
 
TCC 
Grade1  0 0 10 0 0 0 
Grade2 0 0 1 27 2 0 
Grade3 0 1 0 0 29 0 
Squamous 
differentiation 
1 10 0 0 0 19 
 
Table 6.6. A table showing the cross validation of the Raman prediction compared to the actual 
histology for the bladder samples. 
 
 Normal Cystitis TCC 
Grade 1 
TCC 
Grade 2 
TCC 
Grade 3 
Squamous  
differentiation
Sensitivity 65 74 100 90 96 63 
Specificity 84 81 95 100 99 99 
 
Table 6.7. A table showing the sensitivity and specificity of Raman spectroscopy as a diagnostic 
test to classify pathology in the bladder. 
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6.3. Constituent analysis of the tissue spectra. 
 
6.3.1. Constituent analysis of the prostate spectra. 
 
 
Over 1000 spectra were obtained from the prostate samples and these were analysed to 
give mean spectra for each of the following pathologies, Adenocarcinoma (Gleason 
score <7, 7 and >7, prostatitis, and normal prostate tissue. As the bank of spectra 
collected by the research group obtained a greater mix of pathology, this was used 
rather than just the spectra from the prostate samples collected by the author. The 
constituent spectra were fitted to the mean spectra measured (Fig 6.19) and an 
approximate value for the constituent concentration was obtained (Fig 6.20). In this way 
the biochemical basis for each pathology within the prostate was elucidated. Table 6.8 
shows the relative percentages of each constituent present in each of the pathologies. 
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Fig 6.19. The mean spectra obtained for each prostate pathology. 
 
Fig 6.20. A bar graph showing the relative concentration of each constituent for each prostate 
pathology (the pathology relating to the groups are specified in the table 6.8). 
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Pathology No Actin 
(%) 
Col1  
(%) 
Col4 
(%) 
Glycogen 
(%) 
DNA 
(%) 
Oleic 
acid 
(%) 
Triolein 
(%) 
Cholestero
l (%) 
BPH 1 52.6 21.9  2.7 -0.4 2.6 18.1 2.0 0.4 
Prostatitis 2 53.7 25.1   1.2  0.6 1.8 15.5 1.4 0.7 
Gleason 
<7 
3 52.1 19.1  0.9 -0.7 4.1 19.6 3.8 1.1 
Gleason 7 4 51.4 22.1 -1.2 -1.2 5.3 18.3 4.2 1.2 
Gleason 
>7 
5 52.1 20.1 -0.4 -1.1 4.6 17.5 6.1 1.2 
 
Table 6.8. The relative percentages of each constituent present in each prostate pathology. 
Normalised to a total of unity.  
 
 
 
6.3.2. Constituent analysis of the bladder spectra. 
 
Over 1000 spectra were obtained from the bladder samples and these were analysed to 
give mean spectra for each of the following pathologies, TCC grades 1 to 3, cystitis, 
CIS, adenocarcinoma (adenoCa) and normal urothelium. As the bank of spectra 
collected by the group obtained a greater mix of pathology, this was used rather than 
just the spectra from the bladder samples collected by the author. The constituent 
spectra were then fitted to the mean spectra measured (Fig 6.21) and an approximate 
value for the constituent concentration was obtained (Fig 6.22). In this way the 
biochemical basis of each pathology within the bladder was elucidated. Table 6.9 shows 
the relative percentages of each constituent present in each of the pathologies. 
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 Fig 6.21. The mean spectra obtained for each bladder pathology. 
Fig 6.22. A bar graph showing the relative concentration of each constituent for each 
bladder pathology. Normalised to a total of unity. (the pathology relating to the 
groups are specified in the table 6.9). 
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 Pathology No Actin 
(%) 
Col1 
 (%) 
Col4 
 (%) 
Glycogen 
(%) 
DNA 
(%) 
Oleic acid 
(%) 
Triolein 
(%) 
Cholesterol 
(%) 
Normal 1 42.2 17.9  5.4  0.8 11.1 19.0 3.9 -0.2 
Cystitis 2 52.5 6.1  2.3  0.4 15.8 17.4 5.6 -0.0 
CIS 3 42.6 14.2  2.6  0.1 17.4 18.3 4.7  0.1 
G1 TCC 4 53.7 1.2  0.7  1.9 15.8 20.3 6.7 -0.2 
G2 TCC 5 53.8 3.4  0.6  1.5 15.9 18.3 6.6  0.0 
G3 TCC 6 57.4 4.4  0.3 -2.0 14.5 19.5 5.7  0.3 
AdenoCa 7 58.0 8.2  0.7 -0.7 16.4 14.6 4.2  0.0 
 
Table 6.9: The relative percentages of each constituent present in each bladder pathology. 
 
 
 
6.4. The Kerr gated Raman spectroscopy. 
 
 
6.4.1 Depth profiling of the prostate. 
 
 
Figure 6.23 shows the spectra obtained as we go through the prostate gland tissue and 
on to the urea cell. As you can see the peak intensities change as the temporal position 
of the Kerr gate is varied. This relates to increasing depth with longer time delays and 
hence suggests that you are moving through the prostate. You can see the first 3 spectra 
are clearly tissue spectra with peaks at 1240 cmˉ¹, 1445 cmˉ¹ and 1650 cmˉ¹ consistent 
with protein peaks. The 4th spectrum has lost a lot of the signal and then the following 
spectra yield the urea peaks clearly seen at 1003 cmˉ¹ and 1170 cmˉ¹. 
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Figure 6.24 shows the spectra obtained from the urea cell to highlight the peaks. The 
peaks in Figure 6.23 at 662 cmˉ¹ and 803 cmˉ¹ are consistent with the CS2, and peaks at 
1079 cmˉ¹, 1339 cmˉ¹ and 1533 cm¯¹ are consistent with hot pixels from the detector 
and are consistent throughout all of the spectra. 
 
Fig 6.23.  Raman spectra taken from different depths (by adjusting the delay in opening the Kerr-
gate) through a sample of prostate gland on a quartz cell containing urea. See text for 
explanation of peak contributions from the experimental system. 
 
6.4.2. Depth profiling of the bladder. 
 
Figure 6.25 shows the Raman spectra measured from the bladder on top of the cell 
containing uric acid. As you can see the peak intensities change as the temporal position 
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of the Kerr gate is varied. This relates to increasing depth with longer time delays and 
hence suggests that you are moving through the urothelium and into the basement 
membrane and then on into the muscle layer. Eventually the signal from the tissue is 
lost, with peaks coming up at ~1400 cmˉ¹ and 1650 cmˉ¹ which are consistent with the 
main uric acid peaks as shown in Figure 6.26. The peaks in Figure 6.25 at 662 cmˉ¹ and 
803 cmˉ¹ are consistent with the CS2 of the Kerr-gate, and peaks at 1079 cmˉ¹, 1339 
cmˉ¹ and 1533 cmˉ¹ are caused by hot pixels from the CCD detector. 
 
 
Fig 6.24.  Raman spectra, at a wavelength of 488nm, taken from a quartz cell containing urea. 
 138
 Fig 6.25.  Raman spectra taken from different depths (by adjusting the delay in opening the Kerr-
gate) through a sample of bladder on a quartz cell containing uric acid. See text for 
explanation of peak contributions from the experimental system. 
 
 
Fig 6.26.  A Raman spectrum, at a wavelength of 488nm, taken a quartz cell containing uric acid. 
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6.4.3. Suppression of fluorescence and resonant enhancement of dark tissue. 
 
Figures 6.27, 6.29 and 6.31 show the significant improvement in the obtained spectral 
quality from kidney and liver when using the Kerr-gate. As you can see there is a 
marked difference in the overall intensities of the spectra as well as the relative quality 
of the Raman components of the spectra. This is more enhanced between the spectra 
measured from the kidney medulla. The difference in the intensities has caused the 
remaining Raman tissue spectrum to be flattened in Figures 6.27 and 6.31. This 
demonstrates the significant affect of the Kerr-gate in suppressing the fluorescence. The 
true quality of the resonant Raman spectra at both wavelengths with the Kerr-gate on 
can be seen in Figures 6.28, 6.30 and 6.32. These Figures also show that you get 
improved enhancement of the haemoglobin and carotenoids at a wavelength of 488nm 
when compared to a wavelength of 532nm. The peaks for the haemoglobin are at 
approximately 1356 cmˉ¹, 1547 cmˉ¹ and 1605 cmˉ¹, whereas the main peak from the 
carotenoids is at 1003 cmˉ¹. 
The peaks in Figures 6.27, 6.28, 6.29, 6.30, 6.31, and 6.32 at 665 cmˉ¹ and 795 cmˉ¹ are 
consistent with the CS2, and the peaks in Figures 6.28, 6.29, 6.30, and 6.32 at 915 cmˉ¹, 
974 cmˉ¹, 1250 cmˉ¹, 1318 cmˉ¹, 1410 cmˉ¹, 1510 cmˉ¹, 1612 cmˉ¹ are caused by hot 
pixels from the detector.  
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 Fig 6.27. Spectra from the cortex of a pig’s kidney at a wavelength of 488nm with the Kerr-gate 
on (20s x 30 accumulations) and off (5s x 30 accumulations). 
 
 
Fig 6.28. Spectra from the cortex of a pig’s kidney at wavelengths of 488nm (20s x 30 
accumulations) and 532nm (30s x 60 accumulations) with the Kerr-gate on. 
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 Fig 6.29. Spectra from the medulla of a pig’s kidney at a wavelength of 488nm with the Kerr-
gate on (20s x 30 accumulations) and off (5s x 30 accumulations). 
 
Fig 6.30. Spectra from the medulla of a pig’s kidney at wavelengths of 488nm (20s x 30 
accumulations) and 532nm (30s x 60 accumulations) with the Kerr-gate on. 
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 Fig 6.31. Spectra from pig’s liver at a wavelength of 488nm with the Kerr-gate on (10s x 30 
accumulations) and off (5s x 30 accumulations). 
 
Fig 6.32. Spectra from pig’s liver at wavelengths of 488nm (10s x 30 accumulations) and 532nm 
(20s x 30 accumulations) with the Kerr-gate on. 
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7. Discussion of results. 
 
7.1. Raman spectroscopy of the bladder and the prostate gland. 
 
Raman spectroscopy has been shown to be of use in distinguishing between pathologies 
within the bladder and the prostate [Crow 2003, 2004, 2005, Hart Prieto 2004]. This 
study has not only reiterated this but also shown that it is possible using slightly 
different techniques by sectioning the prostate tissue and carefully localising glands 
within the tissue as opposed to sampling a whole TURP chip (section 5.4.5.2). 
Unfortunately the histology mix collected solely by the author was not diverse enough 
for the determination of the biochemical basis of pathologies within each of the tissues, 
however they could be added to the bank of spectra collected by the group. 
The sensitivities and specificities that were calculated following cross validation (leave 
one spectrum out) for each of the pathologies measured showed ranges of 63% - 100% 
and 81% - 93% for bladder and prostate respectively and were equivalent to not only 
those obtained by Crow (2003) but also to sensitivities and specificities obtained by 
Gazi et al (2006) using FTIR spectroscopy on prostate cancer biopsies (70%-78% and 
81%-89% repectively), and De Dominicis et al (2001) using fluorescence spectroscopy 
in the bladder (87% and 63% respectively).  
The sensitivities and specificities were included purely to help in understanding how 
well the preliminary model was working and also to ensure that it was comparable to 
work done previously in the group. The spectra from these samples were added to the 
bank of those already collected and will be used in future experiments.  
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The sensitivities and specificities enabled an indication of the system performance in 
terms of correlation with the gold standard histopathology. The numbers of samples 
however were small even though large numbers of spectra were measured, therefore the 
‘leave one spectrum out method’ is potentially flawed as 9 – 21 spectra (depending on 
the tissue) within the diagnostic algorithm would be from the same tissue as the test 
spectrum. Therefore spectra from the same patient remain in the model when it is 
testing the left out spectrum. Unfortunately given the low number of samples in the 
malignant pathological groups we were unable to use a ‘leave one sample out’ method 
which would have ensured a more robust model.  
 
Using PCA led LDA in the analysis of the spectra has the disadvantage that if there are 
too many PCs compared to a small sample size then you can overfit the data as there 
may not be enough variation described in the dataset to cover a patient population. 
Also given that the gold standard Gleason scoring system and the histopathological 
grading for bladder are subject to both inter and intra observer errors [Allsbrook 2001] 
then there may be groups that are misclassified to a greater extent than others.  
 
The numbers for both the adenocarcinoma of the prostate gland and the transitional cell 
carcinoma of the bladder were small due to a number of factors. These included the fact 
that Gloucestershire Royal Hospital is not a large cancer centre, fresh tissue collection 
was required to represent repeatable biochemical changes likely to be found in vivo  (we 
are working towards the development of an in vivo probe) and there isn’t the facility 
available to us to use retrospective specimens held in a large bank of snap frozen tissue. 
Time constraints for the thesis and a single person doing the tissue collection limited the 
 145
number of samples collected. Furthermore the pathologists preferred samples not to be 
taken from whole prostate and bladder specimens as it was felt that the pathology would 
be distorted. Prostate biopsies were taken at a neighbouring hospital and due to logistics 
and time constraints the author was unable to collect these samples. Also unfortunately 
a few of the samples had diathermy artefacts and could not be utilised. 
For these reasons the spectra measured were added to the bank of spectra already 
obtained by the group to try to alleviate any bias from the small numbers. This is 
something the group will continue to improve upon over time. 
Another source potentially skewing the results could have come from there only being 
one consultant histopathologist to view the histology, with the potential intra – observer 
variation with the subjective Gleason scoring system and the identification of bladder 
histology. Ideally more than one histopathologist should have viewed the samples, a 
number of attempts were made to recruit others, but this proved difficult. Therefore only 
one urology histopathologist available to help with this work.  
 
Table 6.3 showing the cross validation (leave one spectrum out) of the Raman 
prediction compared to the actual histology for the prostate samples does have a 
reasonably high number of both false positives and false negatives. This is possibly a 
consequence of the heterogeneity of the prostate samples. Although the samples were 
checked and the areas for spectra acquisition were noted, some sampling errors may 
have occurred within the BPH section of the tissue. If this occurred then the algorithm 
would have been trained with some inaccurate data. The other theory for the false 
negatives and positives is that there are biochemical changes within the tissue that could 
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not have been seen by the method of histopathology used but that were picked up by 
Raman spectroscopy which is molecularly specific. 
 
Table 6.4 showing the cross validation (leave one spectrum out) of the Raman 
prediction compared to the actual histology for the bladder samples also has a few false 
negatives and false positives. Given the homogenous nature of the tissue samples these 
could not be secondary to spectra sampling error but are more likely due to biochemical 
or field changes that were not visible to the histopathologist. More samples were falsely 
predicted as cancer which would reinforce this hypothesis. The normal bladder samples 
were taken from cystoscopy or TURP procedures and not from TURBT procedures. 
 
To conclude we have shown that we are able to obtain usable spectra by using 
previously described techniques (section 5.4.5.2). This has enabled spectra obtained 
from tissue collected at a later date to be added to a bank of spectra. In this way our 
group will be able to achieve a bank of spectra for future analysis and to build a more 
robust model.  
As was discussed above the diagnostic algorithm contained spectra from the same tissue 
as the test spectrum therefore reducing the power of the test. The aim would be for the 
group to obtain a bank of spectra large enough that a ‘leave on sample out’ cross 
validation test could be done thereby making the model more robust. 
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7.2. The biochemical basis of pathologies within the bladder and the prostate 
gland. 
 
Raman spectroscopy has been in use for chemical analysis in industry for many years 
now. It wasn’t however until recently due to advances in technology that we have been 
able to apply it to biological tissues.  
Shafer – Peltier et al (2002a/b) have been the only other group in the literature to have 
looked at the chemical basis of disease. However this was done in breast tissue, not 
always with pure standards and has never been done before in urology. 
This study was performed to determine the biochemical basis of pathologies within the 
bladder and the prostate gland in order to attain a better understanding of pathogenesis 
and disease progression. 
 
Firstly the main building blocks or constituents of biological tissue were considered. 
This was done by reviewing those collected by Shafer – Peltier et al (2002a/b) and on 
discussion with histopathologists in both the Gloucestershire Royal Hospital and the 
Bristol Royal hospital. This unfortunately was limited to building blocks that were 
thought to be in concentrations that could be measured by Raman spectroscopy, i.e. 
gross molecules that change with pathology as opposed to subtle genetic changes such 
as p53. Also unfortunately this thesis was unable to completely validate the composition 
of tissue due to it’s molecular complexity. Other methods that could potentially help 
with this would be the use high pressure liquid chromotography (HPLC) or gas 
chromotography mass spectroscopy (GCMS). However these are expensive and would 
be very time consuming, leading to results that would still likely be a best guess. 
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Spectra were obtained from these constituents and the mean spectrum for each one was 
derived using empirical analysis. The first derivatives of these were used with ‘ordinary 
least squares’ analysis to formulate a biochemical spectral model (a full explanation of 
the analysis is given in chapter 5.6). In formulating a spectral model containing the 
main biochemical building blocks (constituents) for tissue we were able to apply it to 
the mean spectra of different pathologies within the bladder and the prostate gland. In 
doing so we were able to extract information about the microscopic composition of 
tissue in different pathologies. Note that the resulting concentrations have been 
calculated with ordinary least squares, which can be subject to some errors if 
significantly collinear constituent spectra are used or if the data is of poor quality, i.e. 
noisy. Great care was taken to minimise these possible issues. 
 
Also as ‘ordinary least squares’ analysis was used, we obtained negative percentages 
with some constituents. The ‘ordinary least squares’ analysis was used so that we were 
left with a residual spectrum and ensured that the author didn’t over fit the data. A way 
to overcome the negative values would be to use ‘non negative least squares’ analysis 
[Sowa 2006]. This is a similar method, but with the constraint that only positive 
concentrations can be obtained. Using this methodology it is feasible to overfit the data 
by still fitting the residual of the fit with the basis spectra. When ‘ordinary least squares’ 
is used, it is easier to see when things go wrong with the fit, by picking up the 
occurrence of big negative concentrations and large residuals. 
 
The results have shown that for pathologies within the bladder and the prostate gland, 
the DNA content increases as the tissue progresses from normal to malignant, and the 
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collagen content decreases. This is as expected as the nuclear to cytoplasm (actin) ratio 
increases from normal to malignant tissue and DNA is abundant in the nucleus. Also the 
cells become more abundant and therefore the extracellular matrix is reduced which is 
abundant in collagen. Until the tumour becomes larger and then you would usually 
expect more collagen. We found that using collagen types 1 and 4 gave a better spectral 
fit than by including collagen type 3 suggesting that types 1 and 4 are more abundant in 
the bladder and prostate tissue. Cholesterol was used in the model as a potential 
component of necrosis. As a tumour becomes bigger there tends to be necrotic areas 
within it where it is too big for its blood supply. Interestingly there is no cholesterol in 
the bladder spectra but it is increased in that of the prostate tissue that is malignant. This 
may be because a lot of the tumours in the bladder undergoing TURBT are papillary 
and very vascular; therefore they do not show necrotic areas. The glycogen content 
appears to increase with malignancy suggesting a higher metabolic rate in malignant 
tissue which is understandable, although different to that found in some other epithelial 
tissues such as the oesophagus. The actin level however increases in the bladder but 
decreases in the prostate gland. This may be because the bladder tumours tend to be 
papillary and therefore have a larger surface area, however the actin represents the 
cytoplasm and as the nuclear to cytoplasm ratio increase with malignancy you would 
expect the relative actin level to decrease. 
Both lycopene and β carotene were thought to be decreased in malignant tissue [Hata 
2000, Toniolo 2001, Czeczuga-Seminiuk 2003], however we found that there was none 
detected using our spectral analysis. This may be because they are in such small 
concentrations that the other spectra hide them. Also we were unable to measure the 
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PSA for our model as the only samples we could obtain were in such small quantities 
that we were unable to measure a usable spectrum. 
 
To conclude we have shown for the first time that we are able to utilise Raman 
spectroscopy in determining the biochemical basis, to a first approximation, to the 
different pathologies within the bladder and prostate gland. In this way we may achieve 
a better understanding of disease process and carcinogenesis. This could have major 
implications in the future of the diagnosis of pathologies within the bladder and the 
prostate gland. Histopathology is at present the ‘gold standard’ for diagnosis, by 
utilising Raman spectroscopy and the knowledge we have gleaned from the biochemical 
studies performed, we potentially will be able to eliminate the intra and inter – observer 
error that is seen in histopathology. Further to this it is likely that biochemical 
signatures once understood will lead to readily available prognostic information. 
 
 
7.3. Depth profiling of bladder and prostate tissue. 
 
In view of previous studies, Raman spectroscopy is thought to have the potential for 
minimally invasive detection of malignancies and pre-malignancies within the bladder 
and the prostate gland. A problem with this is the inability to obtain spectra from 
significantly beneath the surface (more than of the order of 100µm) [Caspers 2001]. 
This is needed to ascertain whether there has been any local invasion of the disease in 
the case of the bladder, or to find a focus of adenocarcinoma in an otherwise benign 
prostate gland. 
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There have been studies utilising the Kerr-gating technique to improve upon Raman 
spectra obtained from bone interiors [Morris 2004] as well as test experiments 
demonstrating the depth resolving power of the Raman Kerr gating concept on 
artificially prepared samples [Matousek 2005]. This study was designed to expand on 
this work by studying the facility of Kerr-gated Raman spectroscopy to measure 
biochemical data from depths of a few millimetres in soft tissue. To make certain that 
signal has been detected from beneath the tissue layer; specimens with strong and 
distinct Raman signals have been used. These were also selected for their relevance in 
urology. 
 
As can be seen from the results, the Raman spectra measured from the bladder on top of 
the cell containing uric acid, show how the peak intensities change as the temporal 
position of the Kerr gate is varied. This relates to increasing depth with longer time 
delays and hence suggests that you are moving through the urothelium and into the 
basement membrane and then on into the muscle layer. Eventually the signal from the 
tissue is lost, with peaks coming up at ~1400 cm-1 and 1650 cm-1 which are consistent 
with the main uric acid peaks.  
The Raman spectra obtained as we go through the prostate gland tissue and on to the 
urea cell show that the first 3 spectra are clearly tissue spectra with peaks at 1240 cm-1, 
1445 cm-1 and 1650 cm-1 consistent with protein peaks. The 4th spectrum has lost a lot of 
the signal and then the following spectra yield the urea peaks clearly seen at 1003 cm-1 
and 1170 cm-1. 
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To summarise we have shown for the first time that we are able to obtain spectra from 
different depths through prostate and bladder tissues, by utilising Kerr-gated Raman 
spectroscopy. Modeling of the time-dependent photon pathway would provide an 
enhanced understanding of the depth profiling process. This could have major 
implications in the future of Raman spectroscopy as a tool for diagnosis. Up until now 
we have been able to distinguish between different pathologies within the bladder and 
the prostate gland by sampling the tissue in vitro. This has involved looking at only the 
surface of the sample. 
 
The prostate gland is usually biopsied via the rectum. This is a painful procedure and 
can give false negatives. With the help of Raman spectroscopy and Kerr gating we 
would potentially be able to pick up the spectral differences from a small focus of 
adenocarcinoma of the prostate gland in an otherwise benign gland. 
 
The bladder would also potentially benefit from Raman spectroscopy combined with 
Kerr-gating. We would not only be able to diagnose the presence of a transitional cell 
carcinoma but would also be able to assess the stage of the tumour in terms of its 
extension through the basement membrane and beyond (i.e. greater than a few hundred 
microns below the surface). 
 
We have demonstrated the first principals for the use of Kerr-gated Raman spectroscopy 
in the diagnosis of biological pathologies. Presently however the instrumentation at the 
Rutherford Appleton Laboratory (RAL) fills two rooms. Therefore, the use of this 
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technique will require technical evolution and advancement before it will be ready for 
use in vivo. 
 
Further studies are planned to demonstrate the facility of the technique to discriminate 
between normal and diseased tissue at depths of a millimetre or more. 
 
 
7.4. Suppression of fluorescence and resonant enhancement of dark tissue. 
 
Dark tissues such as kidney and liver have always caused problems for Raman 
spectroscopy because they are highly absorbing and fluorescent at most visible and NIR 
wavelengths. Therefore it has proved difficult to obtain spectra with anything more than 
the most significant peaks. Because of this the use of Raman spectroscopy in the 
diagnosis of renal and liver disease has been largely ignored. There has been some work 
however on near infrared Fourier transform Raman spectroscopy and the liver [Keller 
1994, Crupi 2004]. These showed characteristic differences between the spectra from 
different pathological tissues but analysis was not performed to evaluate the extent of 
these differences.  
Hawi et al (1996) also looked at hepatocytes and liver tissue at an excitation wavelength 
of 632nm and they concluded that there were spectral differences between the 
pathologies but that also at 632nm there was enhancement of the haem component of 
the tissue that resulted in marked spectral difference between the tissue and the 
hepatocytes.  
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One way to try and overcome the problem with fluorescence is by using picosecond 
Kerr-gating. This technique utilises impulsive excitation with a picosecond pulsed laser 
and fast temporal gating of instantaneous Raman scattered light. In this way the signal 
to noise ratio is increased and the slow emitting fluorescence is minimised. 
There have been studies utilising the Kerr-gating technique to improve upon Raman 
spectra obtained from bone interiors [Morris 2004] but there is no published work on 
utilising this technique to obtain spectra from dark biological tissues. 
This study was performed to as a first principals study to investigate the use of Kerr-
gating for fluorescence suppression at different wavelengths in the kidney and the liver. 
Obviously it would have been better to use human tissue however we were limited with 
our time in Rutherford Appleton Laboratories and we were unable to get ethical 
approval at such short notice fresh tissue was used.  
As can be seen from the results we have shown that by utilising the Kerr - gated 
technique on the liver and kidney samples, we have been able to obtain useable Raman 
spectra from dark tissue. 
Given our positive results the group will be able to apply for more time at the 
Rutherford Appleton Laboratories to take these experiments forward. As this is done on 
a yearly basis I was unable to take this forward myself. Further work may enable the use 
of Raman for disease diagnosis in these fluorescent dark tissues, furthermore resonance 
Raman can be utilised and the accompanying fluorescence suppressed using this 
technique. Resonance Raman can be utilised to specifically enhance molecular 
constituents, such as carotenoids, nucleic acids or amino acids, depending on the 
wavelength of illumination used. As can be seen in Figures 6.28, 6.30 and 6.32 there is 
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improved enhancement of the haemoglobin and carotenoids at a wavelength of 488nm 
when compared to a wavelength of 532nm. 
 
To conclude due to the fluorescence of tissues that are extremely vascular, and therefore 
dark, we have traditionally been unable to obtain good quality spectra. We have shown 
for the first time, that by incorporating the Kerr-gating technique into the spectral 
analysis of tissue using Raman spectroscopy, we have been able to suppress the 
fluorescence and obtain spectra of adequate quality to enable further studies on 
biological tissue.  
 
Other excitation wavelengths can be used, and by tuning these to specific electronic 
absorption bands, particular species can be resonantly enhanced. With the use of Kerr-
gated fluorescence suppression there is the potential for the detection of subtle changes 
in resonance Raman spectra likely to accompany pathological changes in tissue. 
 
Raman spectroscopy is already being used to distinguish between different pathologies 
in other tissues such as the bladder [Crow 2004, Hart Prieto 2004]), prostate [Crow 
2003, 2004], cervix [Liu 1992, Mahadevan – Jansen 1996], breast [Alfano 1991] and 
oesophagus [Shim 2000, Stone 2001, Kendall 2003]. Now we will be able to potentially 
distinguish between different pathologies in more vascular tissue such as the liver and 
kidney by utilising Kerr-gated Raman spectroscopy. 
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8. Future research prospects of Raman spectroscopy in urology. 
 
The future of Raman spectroscopy in urology holds no bounds.  
 
It has already been shown that in vitro diagnosis of pathologies within the bladder and 
the prostate gland is possible with good sensitivity and specificity when compared to the 
gold standard method of diagnosis – histopathology [Crow 2003, 2004]. Using this 
technique a histopathology tool can be produced. This has implications not only for the 
patient in terms of an objective diagnosis of the tissue but also for the workload of the 
histopathologist who will not need to look down a microscope to obtain a diagnosis. 
 The next step is to show that these results are reproducible when diagnosing 
pathologies in vivo.  
Our group is in the process of perfecting a probe that will be able to go down an 
endoscope. This probe will potentially be able to take real time spectra from suspicious 
areas within the bladder. The first step however will be to form a diagnostic algorithm 
with the probe by taking spectra using the probe in an in vitro setting. This will involve 
an experimental technique similar to those used for the studies in this thesis and that of 
Crow (2004). Once a diagnostic algorithm has been formulated it will then need to be 
tested in vivo.  
To test a probe in vivo, real time spectra will be taken of specific areas within the 
bladder and then that area will be biopsied. The spectroscopic diagnosis will then need 
to be compared to the histopathology of that sample. In this way the diagnostic 
algorithm will also be tested. 
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Once vigorous testing of the probe in vivo has been undertaken, the need for biopsy will 
potentially be obviated. This will not only improve the time to diagnosis in patients with 
suspected cancer of the bladder but will reduce the risks associated with diagnosis (the 
spectral test will be able to be done under a local anaesthetic with a smaller diameter 
cystoscope, whereas to take a biopsy, a general anaesthetic is needed with a larger 
diameter cystoscope) and the time to definitive treatment.  
Not only will this be advantageous to the patient but also to the surgeon who will be 
able to diagnose more patients in a specific period of time, and the histopathologist who 
will not need to be assessing as many biopsies.  
A probe is already being used experimentally with the cervix and in the oesophagus and 
therefore is a very real potential for the bladder [Boere 2003, Mahadevan-Jansen 1998 
Motz 2004, Shim 2000,Utzinger 2003,]  
 
The use of the Kerr gating technique in conjunction with Raman spectroscopy has 
widened our potential prospects even further. The studies in the thesis have shown the 
potential to depth profile through prostate and bladder samples in vitro. If this can be 
combined with the probe it will be possible not only to assess the stage of a tumour by 
seeing how deeply through the bladder tissue it goes but also to assess surgical margins 
following resection of a tumour. When a tumour in the bladder is resected 
endoscopically it is done so using essentially a hot wire that cuts through the tissue. 
This has the effect of diathermising or burning the tissue that is left behind. When a 
Raman spectrum is taken of this diathermised area, all you get is fluorescence and no 
tissue spectrum. In utilising the Kerr gating technique a spectrum can be obtained from 
below the diathermised area and potentially will be able to be identified as normal tissue 
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or tumour. If tumour is still seen then the surgeon will know that more tissue needs to 
be taken and if the tissue beneath is normal then the surgeon will know that the surgical 
margins are clear of tumour. This has the potential to improve cure rates in patients with 
bladder cancer.  
The same can be applied to the prostate gland. In utilising the Kerr gating technique in 
conjunction with Raman spectroscopy and a probe, a small focus of adenocarcinoma 
within a large benign prostate gland can be localised using depth profiling. This initially 
will lead to more accurate biopsying of the prostate gland and ultimately to guided 
ablation of the tumour. In this case the probe will need to be tested in vivo by taking 
guided biopsies and comparing the spectral diagnosis to the histopathology of that 
sample. This will act to test the in vitro diagnostic algorithm that will have needed to 
have been formulated. 
The potential with this will not only obviate the need for biopsy and therefore have 
implications to the patient, surgeon and histopathologist as was mentioned with the 
bladder but will also potentially lead to spectroscopic guided ablation of the tumour and 
then surveillance resulting in reduced numbers of patients undergoing major operations 
such as a radical prostatectomy. 
As with the bladder this combination will also potentially result in the ability to assess 
surgical margins following a radical prostatectomy. A spectrum can be obtained from 
the surgical site or below the diathermised area if diathermy has been used and 
potentially will be able to be identified as normal tissue or tumour. If tumour is still seen 
then the surgeon will know that more tissue needs to be taken and if the tissue is normal 
then the surgeon will know that the surgical margins are clear of tumour. This has the 
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potential to improve cure rates in patients with prostate cancer post radical 
prostatectomy.  
Studies in this thesis have also shown the ability for Kerr-gated Raman spectroscopy to 
suppress fluorescence and resonantly enhance spectra from dark tissue such as the liver 
and the kidney. In urology there are a few dark tissues that have been neglected in terms 
of Raman spectroscopy because they fluoresce. These are the kidney and the testes. In 
utilising the Kerr-gated Raman spectroscopy to analyse these tissues we have the 
potential to diagnose pathologies within the kidney and the testes both in vitro and in 
vivo. The studies that have been carried out so far (as well as the potential future 
studies) on bladder and prostate tissue will be able to be performed on kidney and 
testicular tissue. This has major implications for the future of diagnosis in urology. The 
histopathologists workload will potentially be reduced and patients will be diagnosed 
and treated quickly with less invasive techniques.  
The use of Kerr – gated Raman spectroscopy will need further development and 
research. At present the instrumentation takes up a room in the Rutherford Appleton 
Laboratory, however given how far Raman spectroscopy has come since the Raman 
effect was first described in Nature by Chandrasekhara Venkata Raman [Raman 1928] 
this is a very real prospect. 
 
As was said at the beginning of this chapter ‘The future of Raman spectroscopy in 
urology holds no bounds’. Urology has the potential to move into a spectroscopic era 
that will improve upon our knowledge of pathogenesis, will provide a streamlined 
pathway to diagnosis and treatment and will improve the lives of surgeons, 
histopathologists and patients in terms of workload and quality of care.  
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You are being invited to take part in a research project. Here is some information to help you 
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Background 
The staff of Gloucestershire Royal Hospital and the Biophotonics research group are working 
together to find new ways of diagnosing and treating disease. Recent advances in laser 
technology has enabled us to develop new methods of detecting disease using light. By shinning 
light on tissue and studying the light given off we can measure the chemical makeup of the tissue 
using a technique called Raman spectroscopy. This technique should allow us to study changes 
that occur as part of the disease process. Future prospects include the measurement of the state of 
the prostate and / or bladder in the patient without the need for tissue removal. This may allow us 
to detect bladder and prostate disease earlier. 
Initially in the laboratory we will study the changes that occur in the prostate and bladder during 
disease development. To do this we need a small amount of the prostate tissue that will be 
removed during a routine operation. We also ask if you would be willing to let us take a small 
sample from your bladder, if you are undergoing a trans-urethral resection of your prostate. This 
would not ordinarily be done as part of your operation, but as only a small sample is taken it 
should make no difference to your recovery. Once we have finished studying the tissue you have 
donated, it will be destroyed, and will not be used for any other research projects. 
Your surgeon or doctor will discuss the clinical procedure with you. Being asked to be a part of 
this study does not mean you have an abnormal bladder or prostate. For involvement in this 
study we need bladder and prostate tissue ranging from normal to cancerous. 
Thank you for your help and co-operation. Please read the additional information over the other 
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You doctor will not be upset if you decide not to take part. 
3. All the information collected about you during the course of the research will be kept strictly 
confidential. Only the researcher collecting the tissue from you will know your identity. 
4. Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You’. This leaflet gives more information about medical research and looks at some 
questions you may want to ask. A copy may be obtained from CERES, PO Box 1365, 
London N16 0BW. 
5. This study has been approved by the Gloucestershire Local Research Ethics Committee. 
They may be contacted at the following address: Gloucestershire Local Research Ethics 
Committee, Gloucestershire Health Authority, Pullman Court, Great Western Road, 
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6. Further information about this research study can be obtained from: 
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you do not understand or if you would like more information. Take time to decide whether or not 
you wish to take part. Thank you for reading this sheet.  
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The staff of Gloucestershire Royal Hospital and the Biophotonics research group are working 
together to find new ways of diagnosing and treating disease. Recent advances in laser 
technology has enabled us to develop new methods of detecting disease using light. By shinning 
light on tissue and studying the light given off we can measure the chemical makeup of the tissue 
using a technique called Raman spectroscopy. This technique should allow us to study changes 
that occur as part of the disease process. Future prospects include the measurement of the state of 
the prostate and / or bladder in the patient without the need for tissue removal. This may allow us 
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Abstract 
 
Advances in technologies have brought us closer to routine spectroscopic diagnosis of early malignant disease. 
However, there is still a poor understanding of the carcinogenesis process. For example it is not known whether 
many cancers follow a logical sequence from dysplasia, to carcinoma in situ, to invasion. Biochemical tissue 
changes precede morphological and structural changes. These can be probed using Raman or FTIR 
microspectroscopy and the spectra analysed for biochemical constituents. Local microscopic distribution of various 
constituents can then be visualised. 
 
Raman mapping has been performed on a number of tissues including oesophagus, breast, bladder and prostate. The 
biochemical constituents have been calculated at each point using basis spectra and least squares analysis. The 
residual of the least squares fit indicates any unfit spectral components. The biochemical distribution will be 
compared with the defined histopathological boundaries. The distribution of nucleic acids, glycogen, actin, collagen 
I, III, IV, lipids and others appear to follow expected patterns. 
 
1. Background 
 
To date Raman spectroscopy has been demonstrated for distinguishing between tissue pathologies by utilising 
the fingerprint of the spectra. This has usually involved the use of multivariate techniques to develop a discriminant 
model. However useful this may be, it gives a feeling of missed opportunity, considering that the fingerprint is based 
exclusively on the molecular constituents of the tissue probed. This paper outlines a first attempt at elucidation of 
the biochemical variation between and across oesophageal tissue specimens, ie microscopic biochemical 
distribution.  
 
2. Methods 
 
Epithelial specimens 
 
Specimens were collected at routine endoscopy following informed written consent. They were mounted on 
acetate paper to and snap frozen in liquid nitrogen. Frozen sections were taken, one stained with haematoxylin and 
eosin, one mounted on calcium fluoride for Raman mapping and the rest of the biopsy block retained for study.  The 
full pathological range from the oesophagus was included, following consensus histopathological opinion from three 
GI-registry pathologists. Specimens for point measurements were homogeneous to be certain of the pathology 
present, and for the mapping heterogeneous specimens were selected to enable distinct differences in spectral 
biochemistry between the pathologies to be visualised. 
 
Point Raman spectra 
 
Spectroscopy was performed using a customised Renishaw System 1000 Raman microspectrometer with 
electronic stage and control software. The laser used was a Renishaw high power near infrared diode laser, which 
supplies the excitation light at a wavelength of 830nm and generates 300mw of power. This is focused through the 
microscope lens onto the tissue sample or the constituent. The lens then collects the scattered light from the 
tissue/constituent which is then passed through the spectrometer. An 80x ultra-long working distance objective was 
used (Olympus MIRPLAN NA 0.75). 
Raman tissue spectra were measured from the epithelial surface of the defrosted biopsy block. Each specimen 
had approximately 10 spectra taken from different positions, randomly determined. The time of acquisition was 30s. 
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Raman mapping 
 
Raman spectral imaging was performed on 7 μm sections of snap frozen tissue. These were placed on calcium 
fluoride slides. Spectra were collected using an automated mapping function including autofocus steps, based upon 
maximising the Raman signal from the tissue at 1450cm-1. Spectra were integrated for 60 seconds at each position, 
stepping 10-100μm between each position (depending on the map). Therefore each map can be thought of as a 
hyperspectral image, with each pixel representing the full Raman spectrum. Images of each section can be generated 
using false colour weighting of the principal component scores of the spectra acquired for the map. Further data 
analysis was performed to elucidate the microscopic biochemical variation across the samples.  
 
Measurement of  biochemical constituents 
 
The aim of measuring likely constituents was to assess the biochemical properties of pathologies from a number 
of organs to enable some quantification of the differences between the pathologies. In addition the variation of the 
biochemistry across the sample and its relation to histopathological boundaries has been studied. 
 
The following constituents were purchased from Sigma – Aldrich; Actin-from bovine muscle, (A3653). β-
carotene- type 1, synthetic, approx 95%, (C9750). Cholesterol sigma grade, 99%+, (C8667). Choline- base, approx 
50% (w/w) aqueous solution, (C9154). Collagen- type 1, from human placenta, acid soluble, (C7774), type 3, from 
human placenta, acid soluble, (C4407), type 4, from human placenta, acid soluble, (C7521). DNA- from human 
placenta, (D7011). Glycogen- from bovine liver, (G0885). Lycopene-from tomato, (L9879). Oleic Acid- water 
soluble, (O1257). Triolein (C18:1,(cis)-9)- sigma grade, approx 95%, (T7140). 
  
The above constituents were picked to as they were thought to be representative of different areas within a cell. 
DNA is representative of the cell nucleus with the other constituents of the nucleus having previously been shown to 
have a small contribution on the spectrum from the nucleus (in the form of some protein signals). The other 
constituents and the region of the cell or sample that they represent is listed here: Actin- cell cytoplasm, β-carotene- 
thought to be decreased in malignant tissue,1,2,3 cholesterol-necrosis,4 choline- thought to be abundant in malignant 
tissue,5 collagen- extracellular matrix/ basement membrane, glycogen- reduced in rapidly dividing cells such as 
malignant tissue. Only mature cells store glycogen. Lycopene- thought to be decreased in malignant tissue, oleic 
acid- abundant in epithelium and triolein- fat. 
 
The same spectrometer configuration was used for the measurement of both the constituents and tissue spectra. 
The solid constituents were placed on a calcium fluoride slide, and the liquid constituents were placed in a well 
plate. A 20x (MIRPlan ULWD Olympus) microscope objective was then used to focus in on the substance and to 
measure the spectra. Different acquisition times were used for each constituent to optimise the signal and minimise 
the noise contribution. All the constituent spectra were corrected for time of acquisition, energy sensitivity of the 
spectrometer and concentration of substance measured. The spectra from the tissue and the constituents were pre-
processed with a Savitsky-Golay 1st derivative filter to remove basic spectral offset values. 
 
Biochemical evaluation 
 
PLS-toolbox® for use with Matlab® (Eigenvector Technologies, Manson, Washington, USA) was adapted for 
use with the data in these studies. The 1st derivative mean spectra for the tissue and the constituents were ascertained 
facilitating further analysis. The fitting of the mean spectra of the constituents to the mean spectra of the different 
pathologies in the epithelial tissues was performed with ordinary least squares analysis.  
This is explained simply below. 
 
EcSX = +  
 
Where S is the matrix of spectral components, c is the matrix of concentrations to be predicted, and X is the 
measured spectra. This can be used to provide a ‘best fit’ of the spectral components or basis spectra found within 
the measured spectra. The assumption is made that the residual is minimised (ie least square of the residual) and that 
the spectral components selected are the main constituents of the spectra.  
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The disadvantage with this technique is that any co linearity in the components selected will skew the fit.  
An example being amino acids and the proteins containing them being used in the model. Observation of the 
residual E (E=X-cS) enables the quality of the fit to be observed and any remaining features of the spectra to be 
included in the next iteration of the model.  
 
3. Results and discussion 
 
Biochemical fit of single tissue spectra 
 
Figure 1 shows mean Raman spectra from nine pathology groups in the oesophagus, all measured from snap-
frozen biopsy specimens. Previously linear discriminant models have been constructed demonstrating high levels of 
agreement with histopathology.6,7 Further study of the data has been possible by fitting the mean spectra with 
constituent spectra using ordinary least squares, as explained above. Figure 2 shows some example spectra from the 
constituents measured.  Note the many complex peaks that are often superimposed upon one another when the 
constituents are combined to form cells and tissues. One issue which must be bourn in mind is the fact that Raman 
spectra from pure chemicals can often be subtly different from those found within tissues, due to the local 
environment they are found in, i.e. the presence of other biomolecules. This is usually manifest in small shifts in 
spectral peaks.  
Figure 3 demonstrates the relative concentrations of the constituents following the basis spectral fit of the mean 
oesophagus spectra. These were adjusted to provide a total concentration of unity (ignoring water contribution). The 
quality of the fit is demonstrated by the spectra in Figure 4. This displays the mean 1st derivative spectrum from 
normal oesophageal tissue and the residual, or spectral component not fit by the basis model. It can be seen that the 
fit is a good approximation, although not perfect. This is likely to be due to the need for further standard spectra to 
be included in the model, but may also be due to subtle shifts in the basis spectra due to microscopic environmental 
effects. The resulting relative concentrations for each pathology group, in Figure 3, follow changes expected during 
the carcinogenesis process. For example reducing glycogen from normal tissue onwards, increasing DNA to actin 
ratio as neoplasia progresses. This is one of the measures histopathologists use to grade the tissue.  Varying levels of 
free fatty acids and triglycerides also appear to change with progression. 
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Figure 1: Mean spectra from snap-frozen oesophageal tissue.6  
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Figure 2: Example of basis spectra measured from pure chemical standards (Sigma). 
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Figure 3: Biochemical fit for the mean spectra (1. Normal, 2. Fundic metaplasia, 3. Cardiac metaplasia, 4. 
Intestinal metaplasia, 6. Dysplasia, 7. Adenocarcinoma.). 
 
 
Figure 4: First derivative spectrum of mean normal oesophagus data (bold) with residual of fit (light). 
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Biochemical map of tissue sections 
 
Mapping of tissue sections can identify the distribution of specific molecular constituents. This can be achieved 
with a spatial resolution using the Raman microprobe of around 3μm. The correlation between the biochemistry and 
boundaries between pathologies as defined by histology can be evaluated. Examples of Haematoxylin and Eosin 
stained sections from frozen sections measured for this study are shown in Figures 5 and 6. 
The example shown in Figure 7 shows an oesophageal section with pre-cancerous Barrett’s dysplasia at the top 
of the section and normal squamous tissue around the lower border. Note the raised nucleic acid to cytoplasmic ratio 
(DNA/actin) and choline in dysplasia and the high glycogen and triolein in normal squamous areas. 
The example shown in Figure 8 shows an oesophageal section with adenocarcinoma around the left, right and 
top borders and at the bottom and middle of the section normal squamous epithelium. Note the raised nucleic acid to 
cytoplasmic ratio (DNA/actin) and oleic acid in adenocarcinoma and the high glycogen in normal squamous areas. 
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Figure 5: Haematoxylin and Eosin stained section of the oesophagus 1. HGD, 2. Normal Squamous, 3. 
Non dysplastic cardiac mucosa, 4. Submucosa / lamina propria / muscle. 
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Figure 6: Haematoxylin and Eosin stained section of the oesophagus 1. Adenocarcinoma, 2. Normal 
Squamous. 
 
 
Figure 7: Normal squamous & high-grade dysplasia (HGD) oesophagus. 
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Figure 8: Normal squamous & adenocarcinoma oesophagus. 
 
4. Conclusions 
 
We have shown for the first time that we are able to utilise Raman spectroscopy to provide some biochemical basis 
for the different pathologies within the oesophagus. In this way we can achieve a better understanding of 
cacinogenesis and other disease processes. This could have major implications in the future of the diagnosis of 
pathologies within the oesophagus and other organs. Histopathology is at present the ‘gold standard’ for diagnosis, 
however, by utilising Raman spectroscopy and the knowledge we have gleaned from the biochemical studies 
performed, we may be able to provide analytical biochemical support. Thus working towards the objective of 
eliminating the intra and inter – observer error that is seen in histopathology. 
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Abstract. Raman spectroscopy is an optical technique able to inter-
rogate biological tissues, giving us an understanding of the changes in
molecular structure that are associated with disease development. The
Kerr-gated Raman spectroscopy technique uses a picosecond pulsed
laser as well as fast temporal gating of collected Raman scattered
light. Prostate samples for this study were obtained by taking a chip at
the transurethral resection of the prostate TURP, and bladder
samples from a biopsy taken at transurethral resection of bladder tu-
mor TURBT and TURP. Spectra obtained through the bladder and
prostate gland tissue, at different time delays after the laser pulse,
clearly show change in the spectra as depth profiling occurs, eventu-
ally showing signals from the uric acid cell and urea cell, respectively.
We show for the first time, using this novel technique, that we are able
to obtain spectra from different depths through both the prostate gland
and the bladder. This has major implications in the future of Raman
spectroscopy as a tool for diagnosis. With the help of Raman spectros-
copy and Kerr gating, it may be possible to pick up the spectral dif-
ferences from a small focus of adenocarcinoma of the prostate gland
in an otherwise benign gland, and also stage the bladder cancers by
assessing the base of the tumor post resection. © 2005 Society of Photo-
Optical Instrumentation Engineers. DOI: 10.1117/1.1991848
Keywords: Raman spectroscopy; Kerr gating; prostate; bladder.
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1.1 Bladder
Each year there are 9000 cases of bladder cancer diagnosed in
men and 3600 diagnosed in women in the United Kingdom. It
is the fourth most common cancer in men and the eighth most
common in women the incidence is 8% in men and 3% in
women1. There has, however, been a reduction in the age
standardized incidence since the 1980s. This is thought to be
due to the reduction in smoking and the banning of aromatic
amines in the 1980s, both of which are known risk factors for
the development of bladder cancer.
The vast majority of bladder cancers are transitional cell
carcinomas of the bladder, and the majority of these are su-
perficial. Bladder cancer is usually diagnosed by means of a
Address all correspondence to Nicholas Stone, Gloucestershire Hospitals NHS
Trust, Cranfield Postgrad Medical School-Great Western Rd., Gloucester, Glouc-
estershire GL1 3NN, Great Britain. Tel: 44 1452 395712; Fax: 44 1452 395713;
E-mail: n.stone@medical-research-centre.com
Journal of Biomedical Optics 044006-cystoscopy and biopsy under general anaesthetic. Once diag-
nosed, patients are then staged using the tumor-nodes-
metastases TNM classification and entered into a surveil-
lance program, if no further treatment is required. The
surveillance program involves six monthly to yearly cys-
toscopies for at least ten years.
Unfortunately, some of the bladder tumors, especially car-
cinoma in situ and flat superficial tumors, can look just like
cystitis, or normal bladder.
1.2 Prostate Gland
The majority of men will suffer with symptoms related to
diseases of the prostate gland at some point in their lives, with
prostate cancer being the one of main concern. Adenocarci-
noma of the prostate gland CaP is the most frequently diag-
nosed noncutaneous cancer affecting Western men.2 Most
95% of the cancers affecting the prostate gland are adeno-1083-3668/2005/104/044006/6/$22.00 © 2005 SPIE
July/August 2005  Vol. 1041
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sitional cell carcinoma, neuroendocrine carcinoma, sarcoma,
and lymphoma. 40% of men aged between 60 and 70 years
have microscopic foci of well-differentiated CaP. It is the sec-
ond leading cause of cancer-related death in men in Western
Europe and North America,2 with 3 to 5% of men dying of
CaP. It is also a major cause of morbidity and healthcare-
related costs with 10% of men diagnosed with CaP develop-
ing clinical disease.2
CaP is diagnosed by means of an abnormal digital rectal
examination DRE and/or a raised level of serum prostate-
specific antigen PSA. Either of these will lead onto transrec-
tal ultrasonography TRUS and biopsy. The biopsies are
taken randomly, with targeting if a lesion is suspected on
TRUS. Unfortunately, the biopsies have a high number of
false negatives, and therefore a cancer can remain undiag-
nosed. These false negatives are mainly due to sampling error
CaP is present as a small focus within the prostate gland and
the biopsy has missed it. It has been shown that even if a man
has two sets of negative biopsies with a persistently raised
PSA, he has a 10% risk of having a cancer found on the third
biopsy.
PSA measurement also comes with its own problems, in
that although it is highly sensitive, it is not very specific. PSA
can also be raised in the following: benign prostate hyperpla-
sia BPH, prostatitis, acute urinary retention AUR, and uri-
nary tract infection UTI, as well as following recent urethral
instrumentation, catheterization, prostatic biopsy, and DRE.
The ideal would be to diagnose CaP at an early stage when
the PSA is within the range of 2.5 to 10 ng/ml; this would
increase the chances of cure with radical treatment. The real-
ity, given the low specificity of both the PSA, and the TRUS
and biopsy, is that many of the cancers are diagnosed when a
cure is not possible.
1.3 Raman Spectroscopy
Raman spectroscopy is an optical technique that can act to
interrogate biological tissues with chemical specificity. In do-
ing so, it gives us an understanding of the changes in the
molecular structure that is associated with disease. With this
in mind, it was felt that Raman spectroscopy could be used to
distinguish between pathologies within the bladder and the
prostate gland. By the start of the 1990s, various groups were
using Raman spectroscopy to distinguish between normal and
neoplastic tissue. The first studies looked at differentiating
between normal tissue and advanced cancers in the breast3
and gynecological organs.4,5 As techniques were refined, in-
terest moved to diagnosing neoplastic change at progressively
earlier stages. To date, in vitro studies have also been under-
taken to differentiate between different pathologies in a num-
ber of other tissues including colon,6,7 esophagus,8–10 brain,11
skin,12,13 lung,14 and larynx.15
It has already been shown that Raman spectroscopy can be
used to distinguish between different pathologies within the
bladder and the prostate gland. This, however, has been ex-
clusively in vitro.16,17
In view of previous studies, Raman spectroscopy is
thought to have the potential for minimally invasive detection
of malignancies and premalignancies within the bladder and
the prostate gland. A problem with this is the inability to
Journal of Biomedical Optics 044006-obtain spectra from significantly beneath the surface more
than of the order of 100 m.18 This is needed to ascertain
whether there has been any local invasion of the disease in the
case of the bladder, or to find a focus of adenocarcinoma in an
otherwise benign prostate gland.
1.4 Kerr Gating
A Raman signal from depths within tissues tends to be dimin-
ished by elastic scattering, and therefore the surface signal is
usually significantly stronger. A possible way to overcome
this is by temporal gating techniques such as picosecond Kerr
gating. The Kerr-gating technique uses excitation with a pico-
second pulsed laser, in combination with a fast temporal gat-
ing of the Raman scattered light. The scattered light is col-
lected at various time delays following the laser pulse.
The ability of depth probing using Raman is determined by
two stages: 1. the laser photons have to be able to migrate to
a given depth within the tissue; and 2. the Raman photons that
have been produced have to migrate back to the surface.
In this way Raman spectra from differing depths within the
tissue will emerge at different times, thereby making their
separation feasible.19
There have been studies utilizing the Kerr-gating technique
to improve on Raman spectra obtained from bone interiors,20
as well as test experiments demonstrating the depth resolving
power of the Raman Kerr-gating concept on artificially pre-
pared samples.19 This study is designed to expand on this
work by studying the facility of Kerr-gated Raman spectros-
copy to measure biochemical data from depths of a few mil-
limeters in soft tissue. To make certain that a signal has been
detected from beneath the tissue layer, specimens with strong
and distinct Raman signals have been used. These were also
selected for their relevance in urology.
2 Materials and Methods
2.1 Subjects
We obtained approval from the Gloucestershire Research Eth-
ics Committee to obtain samples for experimentation using
Raman spectroscopy. The samples used for this study were
taken following fully informed consent.
2.2 Tissue Collection and Preparation
Prostate samples were obtained by taking an extra core at
prostate biopsy procedures, or a chip at trans-urethral resec-
tion of the prostate TURP. The prostate sample used in this
study was assessed histopathologically to be benign prostatic
hyperplasia. Bladder samples were collected at cystoscopic
procedures including TURP normal biopsies and during
trans-urethral resection of bladder tumor TURBT. The blad-
der sample used was histologically normal and included the
urothelial and subsurface layers. The samples were then snap-
frozen in liquid nitrogen and transferred to an −80 °C freezer
for storage.
At the time of the experiment, the tissue was passively
warmed to room temperature and placed either on a cell con-
taining urea, or on one containing uric acid. Urea and uric
acid were chosen because they can be found within the blad-
der and prostate gland, and may also form crystals. Urea and
July/August 2005  Vol. 1042
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sen to allow a demonstration of probing of Raman spectra at
depths through the tissue samples.
2.3 Instrumentation
The Kerr-gating system is based on the high throughput
4-ps optical Kerr shutter that has been described in previous
publications by Matousek et al.21,22 The Kerr gate is made up
of two crossed polarizers 4141 mm, Glan Taylor polariz-
ers and a Kerr medium consisting of a 2-mm optical cell that
is filled with CS2 see Fig. 1.
When the gate is closed, the light from the sample is
blocked as the polarizers are in cross orientation. When the
gate is open, the light collected from the sample has its polar-
ization rotated to allow it to pass through the cross polarizer.
The gate is opened by a short 1-ps gating pulse at 800 nm.
This bypasses the polarizers and creates a transient anisotropy
within the Kerr medium, this then acts to polarize the light
from the sample.
The spectra were collected using a conventional Raman
spectrometer Spex, Triplemate. To prevent residual elasti-
cally scattered light from the 488-nm probe laser entering the
spectrometer, a Kaiser holographic notch filter was used. To
also prevent the residual 800-nm gating beam scatter from
entering, a saturated copper sulphate solution in a 1-cm-thick
optical cell was placed in front of the spectrometer slit.
The Raman scattered light was collected in 180-deg geom-
etry using a lens with f number of 2. A water heat-exchanger
cooled, deep depletion near-infrared NIR CCD Andor
Technology, Belfast, UK, DU420BR-DD was used to record
the Raman spectra from the tissue.
The probe wavelength used was 488 nm, and the pulse
duration was 1 ps. The pulse energy at the sample was 5 J
1 kHz corresponding to 5 mW of average power. The beam
was focused down to a 300-m-diam spot.
To demonstrate the ability to obtain Raman spectra from
deep layers, we performed two experiments: the first involved
placing a bladder sample urothelium upward onto a uric acid
cell, and the second involved placing the prostate sample onto
a urea cell. Both tissue samples were 1 to 2 mm thick. The
Fig. 1 A schematic diagram and photograph showing the Kerr-gated
Raman system at the Rutherford Appleton Laboratory RAL.cells were made from UV-grade quartz 100 m thick. The
Journal of Biomedical Optics 044006-spectra were obtained for 20 s and 5 accumulations at varying
distances through the tissue, i.e., at various time delays fol-
lowing the laser probe excitation pulse.
A simple approximation as to the distance traveled by the
incident photons in the tissue can be made the refractive
index of the tissue was taken to be 1.4. In a time of 1 ps, the
photons will have traversed approximately 0.2 mm of the tis-
sue. This will not necessarily be in a straight line, as the tissue
is highly scattering. By taking the scattering coefficient s to
be 48 mm−1 and the absorption coefficient a to be 1.9 mm−1
for epithelial tissue at 577 nm,23 an optical depth OD can
be calculated from
OD =
1
s + a
.
The approximate optical depth in bladder tissue for 488 nm is
0.02 mm.
3 Results
Figure 2 shows the Raman spectra measured from the bladder
on top of the cell containing uric acid. As you can see, the
peak intensities change as the temporal position of the Kerr
gate is varied. This relates to increasing depth with longer
time delays, and hence suggests moving through the urothe-
lium and into the basement membrane and then on into the
muscle layer. Eventually, the signal from the tissue is lost,
with peaks coming up at approximately 1400 and 1650 cm−1,
which are consistent with the main uric acid peaks, as shown
in Fig. 3. The peaks in Fig. 2 at 662 and 803 cm−1 are con-
sistent with the CS2 of the Kerr gate, and peaks at 1079,
1339, and 1533 cm−1 are caused by hot pixels from the CCD
detector.
Figure 4 shows the spectra obtained going through the
prostate gland tissue and on to the urea cell. As can be seen,
the first three spectra are clearly tissue spectra with peaks at
1240, 1445, and 1650 cm−1 consistent with protein peaks.
The fourth spectrum has lost a lot of the signal, and the fol-
lowing spectra yield the urea peaks clearly seen at 1003 and
1170 cm−1.
Figure 5 shows the spectra obtained from the urea cell to
highlight the peaks. The peaks in Fig. 4 at 662 and 803 cm−1
are consistent with the CS2, and peaks at 1079, 1339, and
1533 cm−1 are consistent with hot pixels from the detector
and are consistent throughout all of the spectra.
4 Conclusions
We show for the first time that we are able to obtain spectra
from different depths through prostate and bladder tissues by
utilizing Kerr-gated Raman spectroscopy. Modeling of the
time-dependent photon pathway would provide an enhanced
understanding of the depth profiling process. This could have
major implications in the future of Raman spectroscopy as a
tool for diagnosis. Up until now, we have been able to distin-
guish between different pathologies within the bladder and the
prostate gland by sampling the tissue in vitro. This has in-
volved looking at only the surface of the sample.
The prostate gland is usually biopsied via the rectum. This
is a painful procedure and can give false negatives. With the
help of Raman spectroscopy and Kerr gating, we would po-
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containing uric acid. See text for explanation of peak contributions from the experimental system.Fig. 3 A Raman spectrum, at a wavelength of 488 nm, taken from a quartz cell containing uric acid.
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Prieto et al.: Use of picosecond Kerr-gated Raman spectroscopy…tentially be able to pick up the spectral differences from a
small focus of adenocarcinoma of the prostate gland in an
otherwise benign gland.
The bladder would also potentially benefit from Raman
spectroscopy combined with Kerr gating. We would not only
be able to diagnose the presence of a transitional cell carci-
noma, but would also be able to assess the stage of the tumor
in terms of its extension through the basement membrane and
beyond i.e., greater than a few hundred microns below the
surface.
We demonstrate the first principals for the use of Kerr-
gated Raman spectroscopy in the diagnosis of biological pa-
thologies. Presently, however, the instrumentation at the Ru-
therford Appleton Laboratory RAL fills two rooms.
Therefore, the use of this technique will require technical evo-
lution and advancement before it will be ready for use in vivo.
Further studies are planned to demonstrate the facility of
the technique to discriminate between normal and diseased
tissue at depths of a millimeter or more.
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ABSTRACT 
 
The incidence of both prostate and bladder cancer is high; prostate cancer being the most frequently diagnosed non-
cutaneous cancer affecting Western men. At present the gold standard for diagnosis of pathologies within the bladder 
and the prostate gland is by means of histological examination of biopsies. This is a subjective means of examining 
tissue and has an element of both inter and intra-observer variability. 
 
A large number of specimens have been collected and analysed using both a NIR-Raman spectrometer and 
histopathology with H&E staining. Multivariate spectral prediction models have been constructed and tested. An 
evaluation of misclassification cost models and the use of cancer staging data to train the models has been made.  
 
Keywords: Raman, bladder, prostate, cancer, prostatic intraepithelial neoplasia, carcinoma in situ, dysplasia.   
 
1. INTRODUCTION 
 
1.1 The bladder. 
 
The incidence of bladder cancer in the UK is 8% in men and 3% in women.1 It is the fourth most common cancer in men 
and the eighth in women. Each year there are 9000 cases diagnosed in men and 3600 diagnosed in women, but although 
the figures are high there has been a reduction in the age standardised incidence since the 1980’s. It is thought that the 
reason for this is the reduction in smoking and the banning of aromatic amines in the 1980’s, both of which are known 
risk factors for the development of bladder cancer. 
 
The majority of bladder cancers are transitional cell carcinomas of the bladder, and most of these are superficial. The 
standard method for the diagnosis of bladder cancer is by means of a cystoscopy and biopsy, which ordinarily involves a 
general anaesthetic. Once diagnosed patients are staged by means of the TNM (tumour-nodes-metastases), classification 
and entered into a surveillance scheme, if no further treatment is required. The surveillance program involves 6 monthly 
– yearly cystoscopies for at least 10 years. 
 
Unfortunately some of the bladder tumours, especially carcinoma in situ and flat superficial tumours can look just like 
cystitis, or normal bladder.  
 
The gold standard, non-invasive test is urine cytology. This is stained with a Papanicolaou stain and has a 95% 
specificity. However the test is only 40 – 60% sensitive, (the sensitivity increases with the grade of the tumour). This is 
because of the significant inter and intra-observer variability.2 
 
1.2 The prostate gland. 
 
Recently the profile of the prostate gland has been raised in the media. This is because the vast majority of men will 
suffer with symptoms related to disease of the prostate at some point in their lives. The main concern however is of 
prostate cancer. Adenocarcinoma of the prostate gland, (CaP), is the most frequently diagnosed non-cutaneous cancer 
affecting Western men.3 It represents 95% of the cancers affecting the prostate gland, with the other 5% being made up 
of the following; transitional cell carcinoma, neuroendocrine carcinoma, sarcoma and lymphoma. As many as 40% of 
men aged between 60 and 70 years, have microscopic foci of well differentiated adenocarcinoma of the prostate gland, 
(CaP).  It is the second leading cause of cancer related death in men in Western Europe and North America,3 with 3-5% 
of men dying of CaP. It is also a major cause of morbidity and health care related costs with 10% of men diagnosed with 
CaP developing clinical disease.3  
 
The diagnosis of CaP is dependent on an abnormal digital rectal examination, (DRE), and / or a raised level of serum 
prostate specific antigen (PSA). A finding of either of these in men will lead onto transrectal ultrasonography (TRUS) 
and biopsy. The biopsies are currently taken using a sextant sampling method, with targeting if a lesion is suspected on 
TRUS. Unfortunately the biopsies have a high number of false negatives, and therefore a cancer can remain 
undiagnosed. These false negative results are mainly due to sampling error, (in that the CaP may be present as a small 
focus within the prostate gland and the biopsy may have missed this).3 It has been shown that even if a man has two sets 
of negative biopsies with a persistently raised PSA, he has a 10% risk of having a cancer found on the third biopsy. 
 
Measuring the PSA comes with its own problems, in that although it is highly sensitive, it is not very specific. The other 
diseases in which the PSA can be raised are: BPH, prostatitis, acute urinary retention, (AUR), and urinary tract infection, 
(UTI). The PSA will also be raised with recent urethral instrumentation, catheterisation, prostatic biopsy and DRE. 
 
CaP is graded using the Gleason system. This system recognises 5 grades representing a continuum of architectural 
patterns of CaP, with grade 1 being well differentiated and grade 5, poorly differentiated. The Gleason score is the 
primary and secondary growth pattern noted in the tissue, (i.e. 3+4). It has been noted that biopsy results may show inter 
and intra-observer error as they are subjective, and limit classification given the size of the sample. 
 
The ideal would be to diagnose CaP at an early stage when the PSA is in the range of 2.5-10 ng/ml, as this would 
increase the chances of cure with radical treatment. The reality, given the low specificity of both the PSA, and the TRUS 
and biopsy, is that many of the cancers are diagnosed when a cure is not possible. 
 
1.3 Raman Spectroscopy. 
 
Raman spectroscopy is an optical technique that can act to interrogate biological tissues. In doing so it gives us an 
understanding of the changes in the molecular structure that is associated with disease. With this in mind it was felt that 
Raman spectroscopy could be used to distinguish between pathologies within the bladder and the prostate gland. By the 
start of the 1990s various groups were using Raman spectroscopy to distinguish between normal and neoplastic tissue. 
The first studies looked at differentiating between normal tissue and advanced cancers in the breast,4 and gynaecological 
organs.5,6 As techniques were refined, interest moved to diagnosing neoplastic change at progressively earlier stages. To 
date, in vitro studies have also been undertaken to differentiate between different pathologies in a number of other tissues 
including colon,7,8oesophagus, 9,10,11 brain,12 skin,13,14 larynx.15 Raman spectroscopy is therefore thought to have the 
potential for minimally invasive detection of malignancies and pre-malignancies within the bladder and the prostate 
gland. 
 
2. MATERIALS AND METHODS. 
  
2.1 Subjects. 
 
The protocol for this study was approved by the Gloucestershire Research Ethics Committee. All samples were taken 
following fully informed consent. 
 
2.2 Tissue collection and preparation. 
 
Prostate samples were obtained by taking an extra core at prostate biopsy procedures, or a chip at TURP. Bladder 
samples were collected at cystoscopic procedures including TURP (normal biopsies) and TURBT. The samples were 
then snap frozen in liquid nitrogen and transferred to a -80°C freezer for storage. A frozen section was then taken from 
each sample and processed for standard histological examination. They were stained with haematoxylin and eosin, 
(H&E), and the remainder of the sample was retained at -80°C. The sections were then separately examined by two 
Consultant Pathologists and only included in the study where an agreement on histological diagnosis was reached. The 
area of interest on each section, was carefully mapped by the Pathologist, so that the region could subsequently be 
accurately targeted on the Raman system. Bladder samples were classified as normal, cystitis, carcinoma in situ, (CIS), 
transitional cell carcinoma, (TCC), and squamous cell carcinoma, (SCC). The TCCs were subdivided into grade 1, 2 or 
3. Prostate biopsies were classified as Benign Prostatic Hyperplasia (BPH), prostatitis or adenocarcinoma, with the 
adenocarcinoma group further split into sub-groups depending on Gleason score The remainder of each sample, (from 
which the frozen section had been taken), was then passively warmed to room temperature and rinsed with a buffered 
normal saline solution. 
 
2.3 Instrumentation. 
 
The tissue samples were scanned on an Optimised Raman System (Renishaw System 1000), to obtain in vitro Raman 
spectra. The system employs a diode laser producing near infra-red light at 830nm, which is accurately targeted onto the 
tissue sample via a microscope objective lens. Bladder samples were orientated to mimic their in vivo orientation, (the 
epithelium was upward facing). Each Raman spectrum was then recorded on the spectrometer using an acquisition time 
of ten seconds for bladder (x20 objective) and twenty seconds for prostate (x80 objective). 10 to 20 spectra were 
acquired from random positions on each sample. 
 
2.4 Analysis. 
 
Raman spectra have been corrected for the energy sensitivity of the spectrometer by utilising a National Physical 
Laboratory calibrated tungsten filament lamp. Cosmic rays have been removed using a filter, otherwise spectra have not 
been baseline corrected or smoothed. 
 
Spectral prediction models were constructed using the consensus histopathological data to provide the information for 
supervised classification using linear discriminant analysis following principal component analysis. The various 
histopathological groupings have been combined to produce models with differing clinical applications. Recent 
publications by the group have demonstrated excellent separation between the groups.16,17 This analysis extends to 
studying the effects of misclassification costs and assesses whether the stage of cancer invasion can be detected in 
addition to the histological grade. 
 
All models have been tested using leave one out cross-validation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. RESULTS 
 
3.1 Bladder. 
 
A total of 1525 spectra were recorded from 75 bladder samples. Table 1 shows the breakdown of samples and spectra 
measured. Mean Raman spectra from each of the groups are shown in Figure 1. 
 
 Normal Cystitis CIS 
TCC 
Adeno- 
carcinoma G1 G2 G3 Sq. Dys 
No. of 
Samples 22 10 2 9 21 9 1 1 
No. of 
Spectra 266 206 49 
257 452 215 
30 50 
924 
 
Table 1:  Number of spectra measured and sample breakdown. 
 
 
Figure 1:  Mean Raman spectra from bladder tissue used in the spectral predictive models. 
 
By combining the spectra into three groups that would be useful for biopsy selection, the model was constructed using 
two-linear discriminant functions. The resulting predictions following leave-one-out cross validation are shown in Table 
2 and the outcome measures are shown in Table 3. Other models demonstrating discrimination between many more 
groups have been published elsewhere.16  
 
Normal Cystitis TCC +CIS
Normal 254 12 0
Cystitis 10 186 10
TCC + CIS 29 54 890
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Table 2: The cross-validated results of the three group diagnostic algorithm. 
 
Normal Cystitis TCC + CIS
Sensitivity 95% 90% 91%
Specificity 97% 95% 98%  
 
Table 3: The sensitivities and specificities achieved by the three group diagnostic algorithm. 
 
The spectral data described above was combined into two groups, benign and malignant. An evaluation of the use of 
misclassification costs was made to study the effects of changing these costs when constructing the model. Prior 
probabilities and misclassification costs can be included to better represent sampling populations and the impact of test 
outcome on patient care, i.e. radical treatment for a false positive measurement, versus death from non-treatment from a 
false negative outcome.18 Figure 2 shows the distribution of the linear discriminant scores for the two-group model.  
Variation of the costs will in effect shift the decision line along the x-axis of the plot. A receiver operator curve (ROC) 
has been plotted to show the overall effect on the outcome of the model prediction when the costs of misclassification 
are varied from 1 to 491 for each group (Figure 3). 
 
A comparison has been made between the outcome from using equal misclassification costs of unity and an optimum 
level defined by that achieving the maximum combined sensitivity and specificity for malignancy. This was achieved 
with misclassification costs of 71 and 141 for groups 1 and 2 respectively.  Table 4 demonstrates these changes between 
the two models.  The positive predictive values from the original to the optimised model change from 97% to 98%. 
 
A further extension of previous work has been achieved by constructing a spectral predictive model of all the malignant 
spectra and training it with stage data, rather than histology grade data. See Figure 4 for a visual representation of this. 
The prediction results are shown in Table 5 and the outcome measures are shown in Table 5. 
 
Figure 2: Histogram of linear discriminant scores for malignant versus benign bladder model. Malignant data are plotted in black, 
benign in grey. 
 
Figure 3: ROC of sensitivity versus 1-specificity for malignant group in the two-group bladder model. This has been achieved by 
varying the relative misclassification costs of the two groups. 
                  
 
Raman Prediction Total 
Benign Neoplastic 
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(1
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Benign 442 (92%)  30 472 
Neoplastic  46 1007 (96%) 1053 
O
pt
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um
 
(1
41
:7
1)
 Benign 447 (95%) 25 472 
Neoplastic 70 983 (94%) 1053 
 
Table 4: Table of results of Raman prediction of specimens defined by consensus, blinded histopathology. Changing of the 
misclassification costs has enabled adjustment of the outcome measures. The first model has equal misclassification costs of unity, the 
next has been modified to produce the maximum combined sensitivity and specificity to malignancy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Schematic diagram of the relationship between stage of bladder carcinoma and depth of invasion. (modified from TNM 
classification of malignant tumours: Urinary bladder, 6th ed. Eds Sobin L.H, Wittekind C.H: John Wiley and Sons Inc.; 2002.) 
 pTa pT1 pT2
pTa 481 23 1
PT1 13 266 14
pT2 0 12 49
Raman Prediction
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Table 5: The cross-validated results of the three stage diagnostic algorithm. 
 
pTa pT1 pT2
Sensitivity 95% 91% 80%
Specificity 96% 94% 98%  
 
Table 6: Outcome measures from bladder stage model. 
 
3.2 Prostate. 
 
A total of 871 spectra were recorded from 56 prostate specimens. The breakdown is shown in Table 7. Mean spectra 
from each pathology group are shown in Figure 5. 
 
 BPH Prostatitis CaP 
(GS<7)
CaP 
(GS=7) 
CaP 
(GS>7) 
Totals 
No. of 
Samples 
33 2 11 5 5 56 
No. of 
Spectra 
381 34 231 111 114 871 
 
Table 7: The numbers of prostate biopsies and spectra for each pathological group studied. 
 
A three-group model was constructed to demonstrate (with leave-one out cross validation) the ability of Raman 
spectroscopy to discriminate between clinically significant pathology groups. The prediction results and outcome 
measures are shown in Tables 8 and 9 respectively. There have been other models constructed to demonstrate 
discrimination between more pathological groups. These have been published by our group.17 
 
The spectral data described above was combined into two groups, benign and malignant. An evaluation of the use of 
misclassification costs was made to study the effects of changing these costs when constructing the model. Figure 6 
shows the distribution of the linear discriminant scores for the two-group model.  Variation of the costs will in effect 
shift the decision line along the x-axis of the plot. A receiver operator curve (ROC) has been plotted to show the overall 
effect on the outcome of the model prediction (Figure 7). 
 
A comparison has been made between the outcome from using equal misclassification costs of unity and an optimum 
level defined by that achieving the maximum combined sensitivity and specificity for malignancy. This was achieved 
with misclassification costs of 51 and 111 for groups 1 and 2 respectively.  Table 10 demonstrates these changes 
between the two models.  The positive predictive values from the original to the optimised model change from 95% to 
92%. 
 
 
Figure 5: The mean Raman spectra measured from each of the pathological groups. 
 
BPH Prostatitis Carcinoma
BPH 350 21 10
Prostatitis 0 34 0
Carcinoma 34 33 389
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Table 8: The cross-validated results of the three group diagnostic algorithm. 
 BPH Prostatitis Carcinoma 
Sensitivity 92% 100% 85% 
Specificity 94% 94% 98% 
 
Table 9: The sensitivities and specificities achieved by the three group algorithm. 
 
Figure 6: Histogram of linear discriminant scores for malignant versus benign bladder model. Malignant data are plotted in black, 
benign in grey. 
 
Figure 7: ROC of sensitivity versus 1-specificity for malignant group in the two-group prostate model. This has been achieved by 
varying the relative misclassification costs of the two groups. 
 
                 
 
Raman Prediction Total 
Benign Neoplastic 
Eq
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(1
:1
) 
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Benign 393 (95%) 22 415 
Neoplastic 57 420 (88%) 477 
O
pt
im
um
 
(5
1:
11
1)
 Benign 376 (91%) 39 415 
Neoplastic 24 453 (95%) 477 
 
Table 10: Table of results of Raman prediction of specimens defined by consensus blinded histopathology. Adjustment of the 
misclassification costs has enabled adjustment of the outcome measures. The first model has equal misclassification costs of unity, the 
next has been modified to produce a higher sensitivity to malignancy, but without a significant increase in false positives. 
 
4. DISCUSSIONS 
 
Three group classification models have been constructed and exhibit good discrimination between pathology groups for 
the prostate and bladder. The use of misclassification costs has demonstrated that the prediction models could be 
adjusted to improve outcomes for a required application such as biopsy targeting, tumour margin detection, or in vivo 
diagnosis for immediate treatment. Each of these would require a different optimum model, either with low false 
negatives or low false positives. 
 
For the first time Raman spectral models have been used to distinguish between stages of cancer in addition to grade, 
thereby demonstrating the potential to enhance the clinical decision process for optimum treatment. This may imply that 
the molecular constituents at the surface of the organ contain some biochemical marker of that occurring deeper in the 
lesion. 
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Abstract. 
Kerr-gated Raman spectroscopy was used at wavelengths of 488nm and 532nm to 
demonstrate both suppression of fluorescence and resonant enhancement of Raman 
spectra from liver and kidney. These highly absorbing tissues (at visible and NIR 
wavelengths) prove difficult to measure without the fluorescence significantly 
swamping the Raman signal. We have shown that we are able to obtain Raman 
spectra of reasonable quality from dark tissues, by coupling the Kerr-gate with a 
Raman spectrometer. It is felt that by utilising this technique we will potentially be 
able to distinguish the subtle changes in Raman spectra that occur between different 
pathologies within tissues such as the kidney and liver.  
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Introduction. 
 
Raman spectroscopy is an optical technique that can be used to interrogate biological 
tissues to help us to understand the changes in molecular structure that occur with 
disease. By the beginning of the 1990s groups were utilising Raman spectroscopy to 
distinguish between normal and neoplastic tissue. The first studies looked at 
differentiating between normal breast tissue and advanced cancers in the breast,1 as 
well as diseases of the gynaecological organs.2,3 As techniques have advanced, the 
interest has moved to assessing its ability to diagnose cancers at much earlier stages. 
In this way more cancers could potentially be detected early, and therefore increase 
the chance of survival from the disease. So far in vitro studies have been performed to 
differentiate between different pathologies in a number of tissues including colon,4,5 
oesophagus,6,7,8 brain,9 skin,10,11 larynx,12 bladder,13,14 and the prostate gland,13,15   
 
Dark tissues such as kidney and liver have always caused problems for Raman 
spectroscopy because they are highly absorbing and fluorescent at most visible and 
NIR wavelengths. Therefore it has proved difficult to obtain spectra with anything 
more than the most significant peaks. Because of this the use of Raman spectroscopy 
in the diagnosis of renal and liver disease has been largely overlooked. There has been 
some work, however, on near infrared Fourier transform Raman spectroscopy in the 
liver.16 These showed characteristic differences between the spectra from different 
pathological tissues, i.e. normal and cirrhotic liver, but analysis was not performed to 
evaluate the extent of these differences. Furthermore, acquisition times of 90 to 150 
minutes were required to achieve an acceptable signal-to-noise ratio.  
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Hawi et al also looked at hepatocytes from liver tissue at an excitation wavelength of 
632nm and they concluded that there were spectral differences between the cells 
exhibiting different pathologies, but that also at 632nm there was enhancement of the 
haem component of the tissue that resulted in marked spectral difference between the 
tissue and the hepatocytes.17 
 
The difficulty of utilising Raman spectroscopy in these darker tissues has held up 
potential progress in exploring its use for improved diagnostics. If the fluorescence 
accompanying the Raman spectra of these tissues could be suppressed then the 
biochemical changes accompanying disease processes can be elucidated. Furthermore, 
by changing the wavelength of excitation it is possible to obtain resonance Raman 
signals of specific molecular species. This is usually accompanied by an increased 
fluorescence signal. 
 
One method to overcome the problem with fluorescence to use picosecond Kerr-
gating. This technique utilises impulsive excitation with a picosecond pulsed laser and 
fast temporal gating of instantaneous Raman scattered light. In this way the signal to 
noise ratio is increased and the slow emitting fluorescence is minimised. 
 
There have been studies utilising the Kerr-gating technique to improve upon tissue 
Raman spectra measured at depth, by suppressing the surface signal,18,19 but there is 
no published work on utilising this technique to obtain spectra from dark biological 
tissues. This study has been performed to investigate the use of Kerr gating for 
fluorescence suppression at different wavelengths in the kidney and the liver. This 
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will show the potential of the technique to provide wavelength dependent resonance 
signals with suppressed fluorescence.  
 
Materials and methods. 
 
Tissue collection and preparation. 
 
Pig’s liver and kidney were purchased from a local supermarket and kept refrigerated 
until required. The tissue was cut into thin slices and placed on a glass slide ready for 
sampling. Samples from the medulla and the cortex of the kidney were both studied. 
 
Instrumentation. 
 
The Kerr-gating system is based on the high throughput 4 picosecond optical Kerr 
shutter that was described in previous publications by Matousek et al.20,21 The Kerr-
gate is made up of two crossed polarisers (41x 41mm, Glan Taylor polarisers) and a 
Kerr medium consisting of a 2mm optical cell that is filled with CS2 (see Figure 1). 
When the gate is closed, the light collected from the sample is blocked. When the gate 
is open the polarisation of the collected light is rotated to allow it to pass through the 
cross polarisers. The gate is opened by a short 1 picosecond gating pulse at 800nm. 
This bypasses the polarisers and creates a transient anisotropy within the Kerr 
medium, this then acts to rotate the polarisation of the light from the sample, (Figure 
1). 
 
 5
The Raman scattered light was collected in 130º geometry using a lens with an f-
number of 2. The spectra were analysed using a dispersive Raman spectrometer (Spex 
Triplemate) mounted after the Kerr-gate. To prevent residual elastically scattered light 
from the probe laser from entering the spectrometer a Kaiser holographic notch filter 
was used. To also prevent the residual 800nm gating beam scatter from entering, a 
saturated copper sulphate solution in a 1cm thick optical cell was placed in front of 
the spectrometer slit. A water-heat-exchanger cooled, deep depletion NIR CCD 
(Andor Technology DU420BR-DD) was used to record the Raman spectra from the 
tissue.  
 
The probe source (with wavelengths 488 and 532 nm used) was provided by a 
femtosecond mode-locked Ti:sapphire laser, producing a 1 kHz pulse train, which 
was then amplified with a  Nd:YLF-pumped regenerative amplifier system to produce 
1 ps, 800 nm pulses at 2 mJ at 1 kHz. The pulse energy at the sample was around 5 μJ 
(1 kHz) corresponding to 5 mW of average power. The beam was focused down to 
300 μm diameter spot. 
 
To demonstrate the ability to obtain Raman spectra from dark tissue we performed 
two sets of measurements; the first involved obtaining spectra from the liver and 
kidney without the use of the Kerr-gate, and the second involved obtaining spectra 
with the Kerr-gate opening for approximately 4ps a short period after the excitation 
pulse. The spectra were obtained at two wavelengths to assess whether different 
components would be resonantly enhanced. Acquisition times varied depending on 
the strength of the signal measured. These are shown in the result figure captions. 
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The liver and kidney samples were also measured using a Renishaw System 1000 
microspectrometer optimised for tissue measurements at 830nm.7 This was performed 
to demonstrate the difficulty of obtaining Raman spectra, even at NIR wavelengths. A 
x20 0.4 NA ultra long working distance objective was used to illuminate the tissue 
ands collect the scattered light. Laser power at the sample was approximately 
100mW. The spectra were acquired in 1 second for the kidney and 5 seconds for the 
liver.  
 
Results. 
Figure 2 shows the Raman spectra of liver and kidney tissues at 830 nm. The sharp 
rise seen at around 150cm-1 and the ripples at higher wavenumbers are caused by the 
edge filter used to reject the elastically scattered light. At higher wavenumbers, 
900cm-1 and above, Raman signal can be seen superimposed on the fluorescence 
background. Very little of the Raman signal is strong enough to be obtained over the 
shot noise (±√N, where N is number of counts). 
 
The spectra obtained using the Kerr-gate have peaks at 665 cm-1 and 795 cm-1, these 
are consistent with Raman peaks of the CS2 Kerr-medium. The spectra have been 
truncated to remove these from obscuring the information relevant to this study. There 
are other peaks labelled with ‘*’ in Figures 4, 6, and 7. These are caused by hot pixels 
from the detector and are observed to increase in intensity linearly with time and not 
with signal strength (note they cannot be seen in the Kerr-gate off spectra with a high 
fluorescence signal).  
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Figures 3 and 5 show the strength of the fluorescence suppression at 488nm for 
kidney cortex and liver respectively. In the examples shown the fluorescence signal 
levels are between 6 and 24 times less (taking into account the time of acquisition as 
well as the signal on the plot) with the Kerr-gate on.  
 
Figures 4 and 6 show the typical Raman spectral quality from kidney and liver tissues 
when using the Kerr-gate. There is much fine detail visible, slightly tarnished by the 
CCD hotpixels. This demonstrates the possibility of utilising Raman spectroscopy in 
these dark tissues to provides a biochemical information on the tissue state. The true 
quality of the resonant Raman spectra at both wavelengths with the Kerr-gate on can 
be seen in Figures 4, 6 and 7. These figures also show that an enhancement of the 
haemoglobin and carotenoids is obtained at a wavelength of 488nm when compared 
to a wavelength of 532nm. The peaks for the haemoglobin are at approximately 1356 
cm-1, 1547 cm-1 and 1605 cm-1,22 whereas the main peak from the carotenoids is at 
1003 cm-1 (each are labelled h and c respectively in the Figures).  
 
Figure 7 demonstrates that the resonance Raman spectra obtained at 488nm showed a 
visible difference between tissues from the liver and kidney. The greatest differences 
appear to be the fatty features found in the liver spectra. This is a first attempt and 
many further spectra would need to be acquired to provide the relevant statistical 
confidence for reproducible tissue discrimination using this method.   
 
Conclusion. 
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Due to the fluorescence of tissues that are extremely vascular and dark, we have 
historically been unable to obtain good quality spectra. We have shown for the first 
time, that by incorporating the Kerr-gating technique into the spectral analysis of 
tissue using Raman spectroscopy, we have been able to suppress the fluorescence and 
obtain spectra of adequate quality to enable further studies on biological tissue.  
 
The system used has not been optimised for tissue work. Laser pulse repetition rate 
could be enhanced to raise signal without tissue damage. The spectrometer was not 
optimised for throughput with the collection optics and geometry and the CCD 
detector had a number of hot pixels, which blemished the spectra. Improvements in all 
these areas could see the signal increase between 10 and 100 times, thus facilitating 
shorter detector integration times.  
 
Other excitation wavelengths can be used, and by tuning these to specific electronic 
absorption bands, particular species can be resonantly enhanced. With the use of Kerr-
gated fluorescence suppression there is the potential for the detection of subtle 
changes in resonance Raman spectra likely to accompany pathological changes in 
tissue. 
 
Raman spectroscopy is already being used to distinguish between different 
pathologies in other tissues such as the bladder,13,14 prostate,13,15 cervix,3 breast,1 and 
oesophagus.6,7,8 Now we will be able to potentially distinguish between different 
pathologies in more vascular tissue such as the liver and kidney by utilising Kerr-
gated Raman spectroscopy. 
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Further work is planned to compare tissue pathologies in vascular tissues at various 
wavelengths to evaluate the capacity of Kerr-gated Raman spectroscopy to enhance 
the ability of RS to distinguish between normal and diseased states. 
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 Legends: 
Fig 1: A schematic diagram and photograph showing the Kerr-gating Raman system 
at the Rutherford Appleton Laboratory. 
Fig 2: Spectra from the cortex of a pig’s kidney and liver at a wavelength of 830nm. 
 
Fig 3: Spectra from the cortex of a pig’s kidney at a wavelength of 488nm with the 
Kerr-gate on (20s x 30 accumulations) and off (5s x 30 accumulations). 
 
Fig 4: Spectra from the cortex of a pig’s kidney at wavelengths of 488nm (20s x 30 
accumulations) and 532nm (30s x 60 accumulations) with the Kerr-gate on. 
 
Fig 5: Spectra from pig’s liver at a wavelength of 488nm with the Kerr-gate on (10s 
x 30 accumulations) and off (5s x 30 accumulations). 
 
Fig 6: Spectra from pig’s liver at wavelengths of 488nm (10s x 30 accumulations) 
and 532nm (20s x 30 accumulations) with the Kerr-gate on. 
 
Fig 7: Spectra from pig’s liver (10s x 30 accumulations) and kidney (20s x 30 
accumulations) at 488nm with the Kerr-gate on.  
 
 
 
 
 
 14
  
Figures: 
Fig 1. 
 
Kerr medium (CS 2; 2 mm) 
Raman 
fluorescence Gating pulse (800 nm, 500  μ J, 1  ps)
(polarisation tilted by 45 o )  
Cross  polariser 
Polariser
sample 
laser pulse 
(1  ps ) 
 
 
 
 
 
 
 
 
 
 
 
 
 15
 16
Fig 2. 
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Abstract.  
Raman spectroscopy is an optical technique that is able to interrogate biological tissues. 
Prostate samples for this study were obtained by taking a chip at TURP, and bladder 
samples from a biopsy taken at TURBT and TURP, following ethical approval. 
Constituents were purchased from  Sigma – Aldrich. 
Spectra were taken from the constituents and different pathologies within the bladder and 
the prostate. We were then able to determine the biochemical basis to these pathologies. 
We have shown for the first time that we are able to utilise Raman spectroscopy in 
determining the biochemical basis to the different pathologies within the bladder and 
prostate gland. In this way we can achieve a better understanding of disease process and 
carcinogenesis. This could have major implications in the future of the diagnosis of 
pathologies within the bladder and the prostate gland.  
 
Keywords: Raman spectroscopy, Prostate, Bladder. 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
 
Raman Spectroscopy: 
 
Raman spectroscopy is an optical technique that can be used to interrogate biological 
tissues with chemical specificity. In doing so it gives us an understanding of the changes 
in the molecular structure that are associated with disease. With this in mind it was felt 
that Raman spectroscopy could be used to determine the biochemical basis to pathologies 
in the bladder and the prostate gland. 
By the start of the 1990s various groups were using Raman spectroscopy to distinguish 
between normal and neoplastic tissue. The first studies looked at differentiating between 
normal tissue and advanced cancers in the breast1 and gynaecological organs.2,3 As 
techniques were refined, interest moved towards diagnosing neoplastic change at 
progressively earlier stages. To date, in vitro studies have also been undertaken to 
differentiate between different pathologies in a number of other tissues including colon,4,5 
oesophagus,6,7,8 brain,9 skin,10,11 and larynx.12 
There has been a lot of research work done on the bladder and the prostate gland in the 
past, with the aim to provide a specific and sensitive means of distinguishing between the 
pathologies associated with these organs. It has already been shown that Raman 
spectroscopy can be used to achieve this however the studies have been exclusively in 
vitro.13,14. 
The research to date on the bladder and prostate gland has looked at diagnosis of 
pathologies rather than at the biochemical basis of the pathologies in question. The 
biochemical changes that occur are thought to be a gradual continuum from normal to 
malignant, therefore a means of detecting pre-malignancies within these tissues would be 
by detecting the biochemical changes that are associated with disease progression before 
the actual progression has occurred. Raman spectroscopy has the potential to do this 
through a minimally invasive technique however, the biochemical basis of each of the 
pathologies within the bladder and the prostate gland must first be ascertained. 
To date this has only been done in breast tissue15. 
 
 
The Bladder: 
 
The incidence of bladder cancer in the UK is 8% in men and 3% in women. It is the 
fourth most common cancer in men and the eighth in women. Each year there are 9000 
cases diagnosed in men and 3600 diagnosed in women in the UK but although the figures 
are high there has been a reduction in the age standardised incidence since the 1980’s. It 
is thought that the reason for this is the reduction in smoking and the banning of aromatic 
amines in the 1980’s. Both of these are known risk factors for the development of bladder 
cancer.16 
Ninety percent of bladder cancers are transitional cell carcinomas of the bladder, and the 
majority of these are superficial. They tend to be found in the over 65 year olds. 
 
The Prostate Gland: 
 
27,000 men were diagnosed in the year 2000 in England and Wales with prostate 
cancer17. It is the second leading cause of cancer related death in men in Western Europe 
and North America,17,18 and the leading cause of cancer related death in the United 
States19. As many as 40% of men aged between 60 and 70 years, have microscopic foci 
of well differentiated adenocarcinoma of the prostate gland (CaP). It is also a major cause 
of morbidity and health care related costs. 3-5% of men will die of CaP and 10% of men 
diagnosed with CaP will develop clinical disease18. The diagnosis of CaP is dependent on 
an abnormal digital rectal examination (DRE), and / or a raised level of serum prostate 
specific antigen (PSA). A finding of either of these in men will lead onto transrectal 
ultrasonography (TRUS), and biopsy. The biopsies tend to be sextant sampling with 
targeting if a lesion is suspected on TRUS. Unfortunately the biopsies have a high 
number of false negatives, and therefore a cancer can remain undiagnosed. These false 
negative results are mainly due to sampling error (in that the CaP may be present as a 
small focus within the prostate gland and the biopsy may have missed this).20 It has been 
shown that even if a man has two sets of negative biopsies with a persistently raised PSA, 
he has a 10% risk of having a cancer found on the third biopsy.20 
 
 
 
 
 
Materials and methods: 
 
We obtained approval from the Gloucestershire Research Ethics Committee, to obtain 
samples for experimentation using Raman spectroscopy. The samples used for this study 
were taken following fully informed consent. 
 
Tissue collection and preparation: 
 
Bladder samples were collected at cystoscopic procedures including transurethral 
resection of the prostate (normal biopsies) and transurethral resection of bladder tumour. 
Prostate samples were obtained by taking an extra core from prostate biopsy procedures, 
or a chip of prostate during transurethral resection of the prostate. The samples were then 
snap-frozen in liquid nitrogen and transferred to an -80°C freezer for storage. 
At the time of the experiment the tissue was passively warmed to room temperature. 
 
Constituents: 
 
The aim of measuring constituents was to assess the biochemical properties of each of the 
pathologies within the bladder and the prostate gland. In this way it was hoped that it 
would be possible to quantify the differences between the pathologies. 
The following constituents were purchased from Sigma – Aldrich; Actin-from bovine 
muscle, (A3653). β-carotene-  type 1, synthetic, approx 95%, (C9750). Cholesterol sigma 
grade, 99%+, (C8667). Choline- base, approx 50% (w/w) aqueous solution, (C9154). 
Collagen- type 1, from human placenta, acid soluble, (C7774), type 3, from human 
placenta, acid soluble, (C4407), type 4, from human placenta, acid soluble, (C7521). 
DNA- from human placenta, (D7011). Glycogen- from bovine liver, (G0885). 
Lycopene-from tomato, (L9879). Oleic Acid- water soluble, (O1257). Prostate Specific 
Antigen- from human seminal fluid, minimum 95%, (P3338). Triolein (C18:1,(cis)-9)- 
sigma grade, approx 95%, (T7140). 
  
The above constituents were picked to as they were thought to be representative of 
different areas within a cell15. DNA is representative of the cell nucleus as the other 
constituents of the nucleus (ribosomes, RNA) have previously been shown to have a 
minor effect on the spectrum from the nucleus15. The other constituents and the region of 
the cell or sample that they represent is shown below: 
Actin- cell cytoplasm, β-carotene- thought to be decreased in malignant tissue21,22,23, 
cholesterol-necrosis15, choline- thought to be abundant in malignant tissue 24, collagen- 
extracellular matrix/ basement membrane, glycogen- reduced in rapidly dividing cells 
such as malignant tissue. Only mature cells store glycogen. Lycopene- thought to be 
decreased in malignant tissue, oleic acid- abundant in urothelium, PSA (prostate specific 
antigen)- produced by the prostate gland,  and triolein- fat.  
 
 
  
Raman spectroscopy of the tissue samples and the constituents: 
 
The same system was used for the measurement of both the constituent and tissue 
spectra. The laser used was a Renishaw high power near infrared diode laser, which 
supplies the excitation light at a wavelength of 830nm and generates 300mw of power. 
This is focused through the microscope lens onto the tissue sample or the constituent. The 
spectrometer then collects the scattered light from the tissue/constituent and detects it. 
The detected spectrum is recorded on the p.c.  
 
The acquisition of spectra for the tissue samples was performed as follows. A x20 
MIRPlan ULWD Olympus microscope objective was used to measure bladder spectra, 
with an acquisition time of 10secs at full laser power. Approximately 10 spectra were 
taken from each sample in a random fashion. 
For the prostate tissue, an x80 MIRPlan ULWD Olympus microscope objective was used 
to focus on the prostate and to record the prostate spectra. Once focused for the white 
light, the focus was moved in to the tissue by 10µm and the acquisition time was set to 60 
seconds at full laser power, for 1 acquisition. The spectra were taken randomly with 
approximately 10 spectra taken per sample.  
The solid constituents were placed on a calcium fluoride slide, and the liquid constituents 
were placed in a cell plate. An x20 MIRPlan ULWD Olympus microscope objective was 
then used to focus in on the substance and to measure the spectra. Different acquisition 
times were used for each constituent.  
The laser was always at full power with the monochromator slit set to 50µm for all 
spectra obtained, and they were centred at 1150cm-1 and stored on the system’s P.C 
following acquisition. 
 
The PLS-toolbox® (Eigenvector Technologies, Manson, Washington, USA) for use with 
Matlab® was adapted for use with the data in these studies7. The mean spectra for the 
pathologies and the constituents were ascertained allowing for further analysis to occur. 
The fitting of the mean spectra of the constituents to the mean spectra of the different 
pathologies in the bladder and the prostate gland was done by using ‘ordinary least 
squares’ analysis. This is explained simply below: 
 
EcSX +=  
Where S is the matrix of spectral components, c is the matrix of concentrations to be 
predicted, and X is the measured spectra. This can be used to provide a ‘best fit’ of the 
spectral components or basis spectra found within the measured spectra. The assumption 
is made that the residual is minimised and that the spectral components selected are the 
main components of the spectra.  
S
EXc )( −=  
The disadvantage with this technique is that any co linearity in the components selected 
will skew the fit. An example being amino acids and the proteins containing them being 
used in the model. Observation of the residual E (E=X-cS) enables the quality of the fit to 
be observed and any remaining features of the spectra to be included in the next iteration 
of the model. 
 
Results: 
 
Constituent spectra: 
 
The constituent spectra were obtained as described above. The mean of the spectra from 
each constituent was then obtained by using Matlab® and are shown below in figures 1 to 
12. 
 
Constituent analysis of the tissue spectra: 
 
Over 1000 spectra were obtained from both the bladder and the prostate samples and 
these were analysed to give mean spectra for each of the following pathologies, TCC 
grades 1 to 3, cystitis, CIS, adenocarcinoma (adenoCa) and normal urothelium, for the 
bladder and Adenocarcinoma (Gleason score <7, 7 and >7), prostatitis, and normal 
prostate tissue for the prostate. The constituent spectra were fitted to the mean spectra 
measured (figs 13 and 15) and an approximate value for the relative constituent 
concentration (excepting water) was obtained (figs 14 and 16). In this way the 
biochemical basis for each pathology within the bladder and the prostate was elucidated. 
Tables 1 and 2 show the relative percentages of each constituent present in each of the 
pathologies. 
Discussion: 
 
Raman spectroscopy has been in use for chemical analysis in industry for many years 
now. It wasn’t however until recently due to advances in technology that we have been 
able to apply it to biological tissues.  
Shafer – Peltier et al25,26, have been the only other group in the literature to have looked 
at the chemical basis of disease using Raman spectroscopy. However this was done in 
breast tissue, not always with pure standards and has never been done before in urology. 
This study was performed to determine the biochemical basis of pathologies within the 
bladder and the prostate gland in order to attain a better understanding of pathogenesis 
and disease progression. 
Firstly the main building blocks or constituents of biological tissue were considered. 
Spectra were obtained from these constituents and the mean spectrum for each one was 
derived using empirical analysis. The first derivatives of these were used with ‘ordinary 
least squares’ analysis to formulate a biochemical spectral model. In formulating a 
spectral model containing the main biochemical building blocks (constituents) for tissue 
we were able to apply it to the mean spectra of different pathologies within the bladder 
and the prostate gland. In doing so we were able to extract information about the 
microscopic composition of tissue in different pathologies. Note that the resulting 
concentrations have been calculated with ordinary least squares, which can be subject to 
some errors if significantly collinear constituent spectra are used or if the data is of poor 
quality, i.e. noisy. Great care was taken to minimise these possible issues. 
The results have shown that for pathologies within the bladder and the prostate gland, the 
DNA content increases as the tissue progresses from normal to malignant, and in the 
bladder the collagen content decreases. This is as expected as the nuclear to cytoplasm 
(actin) ratio increases from normal to malignant tissue and DNA is abundant in the 
nucleus. Also the cells become more abundant and therefore the extracellular matrix is 
reduced which is abundant in collagen. Until the tumour becomes larger and then you 
would usually expect more collagen. We found that using collagen types 1 and 4 gave a 
better spectral fit than by including collagen type 3 suggesting that types 1 and 4 are more 
abundant in the bladder and prostate tissue. Cholesterol was used in the model as a 
potential component of necrosis. As a tumour becomes bigger there tends to be necrotic 
areas within it where it is too big for its blood supply. Interestingly there is no cholesterol 
in the bladder spectra but it is increased in that of the prostate tissue that is malignant. 
This may be because a lot of the tumours in the bladder undergoing TURBT are papillary 
and very vascular; therefore they do not show necrotic areas. The glycogen content 
appears to increase with malignancy suggesting a higher metabolic rate in malignant 
tissue which is understandable, although different to that found in some other epithelial 
tissues such as the oesophagus. The actin level however increases in the bladder but 
decreases in the prostate gland. This may be because the bladder tumours tend to be 
papillary and therefore have a larger surface area, however the actin represents the 
cytoplasm and as the nuclear to cytoplasm ratio increase with malignancy you would 
expect the actin level to decrease.  
Both lycopene and β carotene were thought to be decreased in malignant tissue21,22,23, 
however we found that there was none detected using our spectral analysis. This may be 
because they are in such small concentrations that the other spectra hide them. Also we 
were unable to measure the PSA for our model as the only samples we could obtain were 
in such small quantities that we were unable to obtain a usable spectrum. 
 
Conclusion: 
 
We have shown for the first time that we are able to utilise Raman spectroscopy in 
determining the biochemical basis to the different pathologies within the bladder and 
prostate gland. In this way we can achieve a better understanding of disease process and 
carcinogenesis. This could have major implications in the future of the diagnosis of 
pathologies within the bladder and the prostate gland. Histopathology is at present the 
‘gold standard’ for diagnosis, by utilising Raman spectroscopy and the knowledge we 
have gleaned from the biochemical studies performed, we potentially will be able to 
eliminate the intra and inter – observer error that is seen in histopathology. 
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Legends: 
 
 
Fig 1. The mean spectrum of actin. 
 
Fig 2. The mean spectrum of ß carotene. 
 
Fig 3. The mean spectrum of cholesterol. 
 
Fig 4. The mean spectrum of choline. 
 
Fig 5. The mean spectrum of collagen type 1 (col1). 
 
Fig 6. The mean spectrum of collagen type 3 (col3). 
 
Fig 7. The mean spectrum of collagen type 4 (col4). 
 
Fig 8. The mean spectrum of DNA. 
 
Fig 9. The mean spectrum of glycogen. 
 
Fig 10. The mean spectrum of lycopene. 
 
Fig 11. The mean spectrum of oleic acid. 
 
Fig 12. The mean spectrum of triolein. 
 
Fig 13. The mean spectra obtained for each bladder pathology. 
 
Fig 14. A bar graph showing the relative concentration of each constituent for each 
bladder pathology. Normalised to a total of unity, (the pathology relating to the 
groups are specified in the table below). 
 
Fig 15. The mean spectra obtained for each prostate pathology. 
 
Fig 16. A bar graph showing the relative concentration of each constituent for each 
prostate pathology. Normalised to a total of unity. (the pathology relating to the 
groups are specified in the table below). 
Table 1. The relative percentages of each constituent present in each bladder pathology. 
 
Table 2.The relative percentages of each constituent present in each prostate pathology. 
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Tables: 
 
 
Table 1.  
 
Pathology No Actin 
(%) 
Col1 
 (%) 
Col4 
 (%) 
Glycogen 
(%) 
DNA 
(%) 
Oleic acid 
(%) 
Triolein 
(%) 
Cholesterol 
(%) 
Normal 1 42.2 17.9  5.4  0.8 11.1 19.0 3.9 -0.2 
Cystitis 2 52.5 6.1  2.3  0.4 15.8 17.4 5.6 -0.0 
CIS 3 42.6 14.2  2.6  0.1 17.4 18.3 4.7  0.1 
G1 TCC 4 53.7 1.2  0.7  1.9 15.8 20.3 6.7 -0.2 
G2 TCC 5 53.8 3.4  0.6  1.5 15.9 18.3 6.6  0.0 
G3 TCC 6 57.4 4.4  0.3 -2.0 14.5 19.5 5.7  0.3 
AdenoCa 7 58.0 8.2  0.7 -0.7 16.4 14.6 4.2  0.0 
 
 
 
 
 
Table 2 
Pathology No Actin 
(%) 
Col1  
(%) 
Col4 
(%) 
Glycogen 
(%) 
DNA 
(%) 
Oleic 
acid 
(%) 
Triolein 
(%) 
Cholesterol 
(%) 
BPH 1 52.6 21.9  2.7 -0.4 2.6 18.1 2.0 0.4 
Prostatitis 2 53.7 25.1   1.2  0.6 1.8 15.5 1.4 0.7 
Gleason 
<7 
3 52.1 19.1  0.9 -0.7 4.1 19.6 3.8 1.1 
Gleason 7 4 51.4 22.1 -1.2 -1.2 5.3 18.3 4.2 1.2 
Gleason 
>7 
5 52.1 20.1 -0.4 -1.1 4.6 17.5 6.1 1.2 
 
 
 
 
